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The Fontan procedure is the current intervention for single ventricle congenital heart defect 
patients. Eventually, all Fontan patients suffer long-term complications. These 
comorbidities are associated with blood fluid dynamics (hemodynamics) within the Fontan 
surgical connection. Numerous in vitro studies explore the effects of different patient 
conditions (breath-held, free-breathing, exercise, etc.) on Fontan hemodynamics. However, 
none of these studies are conducted with a flexible wall Fontan connection model. The 
purpose of this study was to develop a flexible Fontan connection model and examine the 
effect of patient condition on Fontan connection hemodynamics. 
 The study employed model verification, bulk hemodynamic measurement, particle 
image velocimetry, and computational methods to explore the effects of respiration, 
exercise, and pulsatility on Fontan hemodynamics. Development resulted in a patient-
specific compliance-verified in vitro Fontan circulation model. The model was then used 
to find the apparent power loss, viscous dissipation, and hepatic flow distribution of the 
Fontan connection under both physiological and derived experimental conditions. 
 The study found respiration consistently increased apparent power loss. Increasing 
exercise intensity also increased apparent power loss; the indexed viscous dissipation term 
also increased with increasing exercise intensity. Increasing pulsatility increased apparent 
power loss monotonically, but viscous dissipation showed a consistent non-monotonic 
relationship. This relationship is explained using the Womersley parameter. Power loss and 
viscous dissipation are further compared, concluding that viscous dissipation is a superior 
hemodynamic metric. Hepatic flow distribution showed no consistent trends due to 
respiration, exercise, or pulsatility effects. The time-resolved three-dimensional velocity 
 xxvii 






Single ventricle congenital heart defects are a complex and costly form of congenital heart 
disease in which there is only one functional pump to move blood throughout the body. At 
diagnosis the single ventricle circulation contains a mixture of oxygenated and 
deoxygenated blood which reduces the blood-oxygen saturation throughout the circulation. 
This scenario requires intervention to prevent systemic organ oxygen starvation and 
eventual organ failure. The current intervention standard is a set of staged palliative 
surgeries first completed by Dr. Francois Fontan in 1971 [1]. The Fontan procedure results 
in the isolation of pure, oxygenated blood in the single ventricle. This restoration of pure 
oxygenated blood pumping to the systemic organs is finalized through the creation of a 
total cavopulmonary connection (TCPC), an anastomosis of the inferior vena cava (IVC), 
superior vena cava (SVC), and the left and right pulmonary arteries (LPA and RPA, 
respectively). The resulting circulatory system is fundamentally different from a 
biventricular circulation, and is commonly known as the Fontan circulation. 
The Fontan palliation provides low operative mortality and satisfactory early to 
mid-term patient outcomes, but many patients suffer long-term complications. Over the 
approximate 40 year history of Fontan procedures the single ventricle patient’s short-term 
survival outcome has risen from 10% during the pre-Fontan era [2] to 90% during the first 
decade of life [3]. By 25 years of life, though, the survival rate drops to 70% [4]. The 
factors relating to this survival drop are a complex composition of circulatory 
complications. These complications include heart arrhythmia, liver fibrosis/cirrhosis, 
protein losing enteropathy, thromboembolism, renal dysfunction, ascites, plastic 
bronchitis, pulmonary arteriovenous malformations, and decreased exercise capacity [5,6]. 
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These complications are ubiquitous, eventually appearing in almost every Fontan patient. 
In fact, studies following Fontan patient outcomes over the last several decades have led 
some experts to state, “…it is reasonable to conclude that freedom from morbidity [for 
Fontan patients] is likely close to zero.” [7] Yet another study finds that Fontan patients 
are, “doomed to a circulatory failure.” [8] To avoid this doom one must address the cause 
or causes of these complications – one of which is Fontan circulation fluid dynamics. 
  Numerous studies show association between Fontan circulation hemodynamics and 
long-term complications [9–14]. This knowledge fueled and continues to fuel 
hemodynamic studies of the Fontan circulation using computational simulations [15–21] , 
in vitro methods [9,22–28], and animal or in vivo methods [29,30]. Each study approach 
has different merits. In vivo methods provide an incomplete view of the real Fontan system: 
a full truth partially revealed, while computational methods provide a complete view of a 
modeled Fontan system: a partial truth fully revealed. In vitro methods attempt to bridge 
this difference by providing a fuller truth of key Fontan subsystems (i.e. the Fontan 
connection) while modeling the remaining circulation. Current in vitro models of the 
Fontan circulation employ rigid TCPC sections [22,23,27,28,31–35]. These models have 
provided excellent scientific insight; however, the rigid chambers of these models have 
been criticized for their physiologic approximation to the comparatively more compliant 
TCPC connections observed in-vivo. In vitro studies that have employed a compliant 
TCPC have not verified their model compliance with in vivo data [24]. By neglecting in 
vivo verification the TCPC will not deform accurately, which affects both small scale 
hemodynamics within the TCPC and global pressure waves through the Fontan circulation 
due to cardiac or respiratory sources. 
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Therefore, the following work develops and verifies compliant TCPC models for 
inclusion in a physiologically accurate in vitro Fontan circulation model. This model is 
then employed to study the effects of respiration, exercise, and general waveform 
pulsatility on Fontan hemodynamics. The work includes both hemodynamic and flow field 
analysis with the intent of providing relationships between respiration, exercise, and 
waveform pulsatility and key hemodynamic metrics related to patient complications and 
outcomes. In addition, the flow field data collected will provide validation for detailed fluid 
structure interaction computational analysis. The hypothesis of the work is that respiration, 
exercise, and waveform pulsatility affect TCPC flow field and hemodynamic metrics 
important to Fontan patient outcomes.  
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2 HYPOTHESIS AND SPECIFIC AIMS 
The proposed work intends to employ a physiologically relevant in vitro Fontan circulation 
model to explore the effects of respiration, exercise, and pulsatility on Fontan 
hemodynamics. The hypothesis of the work is that respiration, exercise, and waveform 
pulsatility affect TCPC flow field and hemodynamic metrics important to Fontan patient 
outcomes. This hypothesis will be examined through three specific aims: (1) Development 
and Verification of a Comprehensive Fontan In vitro Model, (2) Understanding the Effects 
of Respiration on Fontan Hemodynamics, and (3) Understanding the Effects of Exercise 
and Pulsatility on Fontan Hemodynamics. 
2.1 Specific Aim 1: Development and Validation of a Comprehensive Fontan In 
Vitro Model 
In vitro models of the Fontan circulation are employed in numerous studies to understand 
Fontan hemodynamics. Early models employed rigid walls and steady flow. Subsequent 
studies utilized pulsatile, and even patient-specific waveforms. Compliant test sections, 
such as the TCPC, are the latest subject of accuracy improvement, but thus far only 
arbitrary compliance values exist in these models. Proper TCPC compliance verification 
will provide transient anatomical changes observed in vivo, improving the in vitro model’s 
reflection of in vivo physiology. The increased data collectable during an in vitro study 
(versus an in vivo study) will be incrementally more trustworthy. In addition, a verified 
Fontan in vitro model can provide data for computational simulation model validation en 
route to a complete view of the Fontan system. 
 In order to verify against in vivo data, consistent TCPC compliance measurement 
methods will be developed for both in vivo datasets and the physical in vitro models. The 
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in vivo datasets provided include phase contrast magnetic resonance images (PCMRI) 
which provide the unstressed TCPC anatomy as well as the TCPC inlet and outlet flows. 
Age-matched pulse pressure data is available from the same center to provide the rest of 
the compliance calculation’s necessary requirements. With the in vivo compliance 
established from this data, a silicone in vitro test model will be constructed via spin 
molding. The test model compliance will be measured via pressure transducers during a 
fluid injection event. Any compliance value discrepancies between the in vivo data and the 
in vitro test model will be remedied through silicone composition or model wall thickness 
alterations of subsequent test models. Each test model alteration will incur subsequent 
compliance testing until the in vitro model compliance matches the patient-specific in vivo 
compliance value. The in vitro Fontan model is then considered verified. 
 The product of this aim will be an in vivo verified Fontan circulation model as 
evidenced by matching flow waveforms and TCPC compliance to the provided PCMRI 
data. 
2.2 Specific Aim 2: Understanding the Effects of Respiration on Fontan 
Hemodynamics 
One key difference between the Fontan and healthy circulations is the presence of a sub-
pulmonary pump [36]. The Fontan circulation lacks this pump and, thus, relies on passive 
pressure gradients for its blood to reach the lungs. Under these conditions, numerous 
studies have verified that intrathoracic pressure variations due to respiration affect Fontan 
patients more drastically than those with a biventricular circulation. These studies include 
in vitro [27,37,38] , in vivo [39–43], and computational approaches [15,44,45]. However, 
none of these approaches utilize an in vivo compliance verified TCPC model. Thus, this 
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aim will utilize the Fontan circulation from Aim 1 to understand the effects of respiration 
on Fontan hemodynamics, and compare to previous results. 
Respiration effects will be isolated from cardiac effects through patient-specific 
real-time phase contrast magnetic resonance images. The effect of respiration will be 
measured by changes in global pressure, flow, TCPC pressure loss, and TCPC flow 
structures both instantaneously, and on a cycle-averaged basis. 
2.3 Specific Aim 3: Understanding the Effects of Exercise and Pulsatility on 
Fontan Hemodynamics 
Several studies show a relationship between patient exercise level and flow pulsatility and 
Fontan circulation hemodynamics (global pressure and flow) [44,46–48]. To date, this 
relationship is the strongest tie between Fontan hemodynamics and patient quality of life. 
However, none of the studies used in discovering this relationship utilized an in vivo 
verified TCPC model. Additionally, no computational models exploring this issue with 
fluid structure interaction models have done so with proper experimental validation 
[45,49–51]. Hence, the in vivo verified Fontan circulation from Aim 1 will be employed to 
explore the effects of exercise and pulsatility on Fontan hemodynamics. 
 Exercise will be represented using patient-specific exercise flows and literature-
based decreases in pulmonary vascular resistance (PVR). Defining the loop conditions as 
such will automatically set the modeled pressure waveform, which will be checked against 
literature-based Fontan exercise values for verification. Heart rate and respiratory rate 
during exercise are also available from the patient-specific data set and will be assigned 




3 BACKGROUND AND SIGNIFICANCE 
3.1 The Healthy Cardiovascular System 
The human cardiovascular system serves to supply the body with nutrient-containing blood 
essential to all organ functions. The healthy cardiovascular system performs this service 
by means of two parallel pumps within the heart, the left and right ventricle. The left, and 
more dominant, ventricle circulates oxygenated, nutrient-rich blood to the systemic organs. 
The systemic organs process the oxygen and nutrients in their various tasks and passively 
return the blood to the right ventricle. The right ventricle then pumps the oxygen-poor 
blood to the lungs for oxygenation. Oxygenated blood from the lungs then flows passively 
to the heart’s left side completing the circulatory path. Figure 3-1 shows a schematic 




Figure 3-1: Healthy cardiovascular system schematic showing the separation of oxygenated and de-
oxygenated blood (courtesy aireurbano.com) 
One key aspect of the healthy circulation is the separation of oxygen-rich and 
oxygen-poor blood. This separation ensures that the systemic organs (liver, kidneys, 
stomach, etc.) and even the heart itself (via the coronary arteries) receive a full oxygen 
supply with every stroke of the left ventricle. Without this full oxygen supply these 
systemic organs can fail. 
3.2 Congenital Heart Disease 
Congenital heart disease is a general term categorizing heart anatomy anomalies present at 
birth. The severity of the defects range from small, repairable holes in the wall between the 
left and right ventricle called the septum, or septal defects, to complex combinations of 
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defects including both ventricles, heart valves, and displacement of the major blood vessels 
surrounding the heart. Approximately 0.8-1% of all births in the United States include some 
form of congenital heart disease [52]. Table 3-1 shows incidence estimates for typical 
congenital heart diseases. 
Table 3-1: Common congenital heart disease incidence with emphasis on cyanotic births [52]. The 
cyanotic lesions are denoted with italics. 
Congenital Heart Disease Incidence (per 1,000 births) 
Bicuspid Aortic Valve 13.56 
Ventricular Septal Defect 3.57 
Atrial Septal Defect 0.94 
Patent Ductus Arteriosus 0.80 
Pulmonary Stenosis 0.73 
Tetralogy of Fallot 0.42 
Hypoplastic Left Heart 0.26 
Hypoplastic Right Heart 0.22 
Double Outlet Right Ventricle 0.16 
Pulmonary Atresia 0.13 
Single Ventricle  0.11 
Tricuspid Atresia 0.08 
All Cyanotic 1.38 
 
 Some of the most time-sensitive and complex congenital heart diseases are those 
that result in patient cyanosis. Cyanosis is a blue coloring of the skin due to a lack of oxygen 
saturation in and around the region. Children born with certain congenital heart diseases 
have hearts that mix their oxygen-rich and oxygen-poor blood and result in cyanosis. These 
patients are often termed “blue babies” because of their skin hue, and regularly require 
surgery. In fact, approximately 50% of children born with a congenital heart disease will 
require at least one surgery in their lifetime. Congenital heart disease patients are living 
much longer due to recent advances in surgical techniques and patient care, providing hope 
for further improvements but new challenges in the adult physiology [53]. 
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3.3 Single Ventricle Congenital Heart Disease 
The most complex congenital heart diseases that exist are anatomies in which only one 
functional ventricle remains, and are aptly called single ventricle congenital heart diseases. 
Although single ventricle defects occur in only 7.7% of congenital heart diseases (0.077% 
of all patients), their healthcare financial burden is extremely disproportionate [54,55]. 
Single ventricle congenital heart disease are, by definition, the most cyanotic patients of 
any congenital heart disease because they include only one functional ventricle to which 
all blood eventually travels. In contrast to Figure 3-1, the single ventricle physiology mixes 
oxygen-rich and oxygen-poor blood in the single ventricle, providing less than 100% 
blood-oxygen saturation to the systemic organs. This mixing is demonstrated in Figure 3-2. 
 One objective in treating patients with single ventricle congenital heart diseases is 
to restore the separation of oxygen-rich and oxygen-poor blood flow. This objective can 
be handled through a few different procedures depending on the cause of the single 
ventricle phenomena, but the most common method is the Fontan procedure. 
Figure 3-2: Schematic of healthy circulation (left) and single ventricle circulation (right) 
showing respective separation and mixing of oxygen-rich and oxygen-poor blood. 
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3.3.1 The Staged Fontan Procedure 
The Fontan procedure is a palliative set of staged surgical interventions that shunt the 
oxygen-poor systemic venous return past the single ventricle and connect it directly into 
the pulmonary circulation (Figure 3-3). 
 
Figure 3-3: Healthy circulation (left), single ventricle congenital heart disease circulation (center), and 
repaired single ventricle congenital heart disease (right) circulation schematics. 
 Though simple in concept, the practical application of this solution to single 
ventricle congenital heart disease is actually quite complicated. Neonatal physiology 
includes relatively high pulmonary vascular resistance which prevents successful routing 
of the entire venous return to the pulmonary vasculature. So, the systemic venous return 
cannot be connected directly to the pulmonary circulation right after birth. With imminent 
mortality approaching, the patient’s best option is a systemic to pulmonary circulation 
shunt. The first to report this first stage of the Fontan palliation was Dr. William Norwood 
[56]. 
3.3.2 The Norwood Procedure 
The Norwood procedure is performed within the first days to weeks of life. The implanted 
shunt re-circulates some partially oxygenated blood exiting the ventricle directly back to 
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the lungs, attempting to double-dip in the oxygen existing there. In some cases, including 
Norwood’s original case, the patient’s aorta is underdeveloped and requires combination 
with the pulmonary arteries to maintain sufficient diameter to support adequate blood flow. 
The pulmonary artery, then, no longer exists and the Norwood shunt acts as the only source 
of pulmonary blood flow. This situation further complicates the already delicate Norwood 
procedure, which places among the highest mortality rates among congenital heart 
practices [57]. Variations on the procedure exist through changing the specific endpoints 
of the shunt. The modified Blalock-Taussig shunt connects the right subclavian artery to 
the right pulmonary artery [56]. The Sano procedure shunts directly from the right ventricle 
to the pulmonary artery bifurcation [58] (Figure 3-4).  
 
Figure 3-4: Stage 1 Fontan procedure variation schematics: Modified Blalock-Taussig Shunt and Sano 
Shunt 
No matter the variation, the shunting of systemic to pulmonary circulations 
provides sufficient stabilization until the second stage of the Fontan palliation, the Glenn 
procedure, can be performed. 
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3.3.3 The Glenn Procedure 
Between 3 to 6 months of age, the relatively high pulmonary vascular resistance to flow in 
the neonatal circulation has subsided and the patient is prepared for a Glenn procedure. 
This second stage of the Fontan palliation first removes the Norwood shunt and replaces 
its effects by rerouting superior vena cava (SVC) flow from the right atrium to the 
pulmonary arteries. Figure 3-5 illustrates the Glenn procedure. 
 
Figure 3-5: Glenn procedure illustration. RPA -- right pulmonary artery, SVC -- superior vena cava, 
LPA -- left pulmonary artery. 
 The Glenn procedure successfully separates a larger fraction of oxygen-poor and 
oxygen-rich blood between the systemic and pulmonary circulation. The procedure focuses 
on SVC flow because approximately 60% of an infant’s total cardiac output is routed to 
their brain and upper extremities. As the child grows this ratio flips to 60% of total flow 
routing to the lower extremities. To account for this change in blood flow and finalize the 




3.3.4 The Fontan Procedure 
 First reported in 1971, the Fontan procedure completes the separation of oxygen-
poor and oxygen-rich blood by re-routing the inferior vena cava (IVC) from the right 
atrium to the pulmonary arteries [1]. The original procedure by Fontan and Baudet called 
for superior vena cava (SVC) flow to be routed to the right pulmonary artery (RPA), and a 
separate routing of the IVC to the left pulmonary artery (LPA). The original procedure also 
included the placement of a valve in the IVC to maintain unidirectional flow. In 1973, 
Kreutzer et al. proposed utilizing the native right atrium as the conduit through which the 
systemic venous return connects to the pulmonary arteries [59]. This atrio-pulmonary 
connection, served as the standard for almost 20 years, but was eventually replaced because 
it caused arrhythmias and thrombus formation (blood clots) [60,61]. The atrio-pulmonary 
connection was replaced by the total cavopulmonary connection beginning in 1988 [62]. 
The total cavopulmonary connection is performed either through the right atrium (an intra-
atrial connection) or outside the heart (an extra-cardiac connection). The intra-atrial TCPC 
differs from the atrio-pulmonary connection because the intra-atrial TCPC employs a graft 
along the atrial wall that restricts the effective flow diameter. A 1991 study showed the 
decrease in arrhythmia incidence for Fontan patients with a TCPC versus an atrio-
pulmonary connection [63]. Comparison between the extra-cardiac TCPC and the intra-
atrial TCPC is more recent, and still an area of active research. The decision whether to 
employ an extra-cardiac or intra-atrial TCPC for a given patient is dependent on numerous 
factors including patient size, anatomical geometry, and surgeon preference. One argument 
for preferring one TCPC type over the other comes from the Society of Thoracic Surgeons 
which found a higher likelihood of in hospital death during Fontan patient surgical 
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revisions for extra-cardiac connection types [64]. Figure 3-6 summarizes the differences 
between the Fontan procedure types. 
 
Figure 3-6: Schematic representation of the different Fontan connection types 
3.4 Fontan Patient Outcomes 
The half-century long development process of Fontan patient care has led to relatively 
favorable short-term outcomes for Fontan patients. These patients are reaching adulthood 
at an unprecedented rate and with ever-increasing quality of life [65]. Of approximately 
200 intra-atrial Fontan patients from Boston Children’s Hospital, estimated survival at 10 
years was 91% with freedom from complications at 87% over the same period [66]. The 
more daunting prospect for Fontan patients are the seemingly unavoidable long-term 
complications they are doomed to suffer. Unfortunately the Fontan procedure is only 
considered palliative, instead of curative, because of its long-term complications [12]. 
Twenty-year survival shows a sudden drop off for these patients, with survival rates 
varying between 69 and 83% [67]. Another study of 500 extra-cardiac (EC) Fontan patients 
show a survival rate of 96.2% at 10 years and 92.8% at 15 years, but with 15 year freedom 
from morbidities at only 82.1% [68]. To further complicate matters, the short-term success 
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enjoyed by these patients only further emphasizes the impact of long-term Fontan 
complications on the healthcare industry overall [55]. Numerous researchers recognize this 
problem and are now focused on mitigating these complications, if not curing all together, 
the failing Fontan. 
3.4.1 The Failing Fontan 
The traditional failure mode from Fontan’s original surgeries were mostly related to 
arrhythmias [63]. The atrio-pulmonary connection required surgical manipulation of the 
right atrium, an essential location in cardiac electrophysiology. Formation of the atrio-
pulmonary connection often mistakenly altered the AV node on the right atrium and thus 
affected the whole cardiac rhythm. The high arrhythmia incidence of atrio-pulmonary 
Fontan connections is one reason for clinical practice shifting to total cavopulmonary 
connection (TCPC) connections [63]. Of course, the almost half-century history of 
iterations on the Fontan connection has drastically reduced the incidence of arrhythmia in 
Fontan patients. Despite these advances the Fontan circulation still fails in a variety of 
ways. Fontan failure is most easily understood through categorization into two failure 
modes: ventricular dysfunction, and chronic Fontan failure. 
3.4.1.1 Ventricular Dysfunction 
Fontan patients suffer from an underdeveloped heart leaving them with only a single 
ventricle. Unfortunately, their remaining ventricle also behaves abnormally. Whether this 
abnormal behavior is due to fetal development issues, Fontan circulation hemodynamics, 
or both is a complicated problem under active research. Regardless of the cause, the fact 
that remaining single ventricle misbehaves is important because both systolic and diastolic 
dysfunction are common among Fontan patients. A cross-sectional analysis of 546 Fontan 
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patients revealed that 27% had abnormal ventricular ejection fractions and 72% had 
diastolic dysfunction [69]. Some attribute this ventricular dysfunction to chronic 
hypoxemia (low blood oxygen concentration) and relatively early volume loading of the 
ventricle seen by all Fontan patients through the surgical staging process [36]. 
Beyond poor ejection fractions and abnormal ventricular volumes, in most cases 
the Fontan patients suffers from low exercise tolerance. The normal heart compensates for 
increased systemic blood flow needs by increasing heart rate, contractility, and filling 
volumes in order to eject more blood. In general, Fontan patients possess an ability to eject 
whatever blood fills their heart through increased contractility, but the Fontan circulation 
prevents adequate filling and heart rate increase for high intensity exercise [70–72]. 
3.4.1.2 Chronic Fontan Failure 
Even among those who have functioning single ventricles, Fontan circulatory systems 
eventually fail in time. Indeed, one study bluntly stated that the Fontan patient is “doomed 
to fail” [8]. This hopelessness comes from the fact that chronic Fontan failure is a function 
of the nature of the Fontan circulation itself.  
 The premise of the Fontan circulation is that when only one ventricle is available it 
should be used to pump to the systemic circulation. This leaves pulmonary circulation as a 
passive system. No longer supplemented by the right ventricle, the oxygen-poor blood 
returning from the systemic organs has no additional energy source to overcome the 
vascular resistance in the lungs. Therefore, in order to reach the lungs, this blood must exist 
at a higher pressure than the lungs. Figure 3-7 shows a schematic representation of the 
differences between a healthy biventricular circulation, a Fontan circulation, and a 





Figure 3-7: Schematic representation of pressure values in different circulatory systems. LV – Left 
Ventricle, AO – Aorta, SC – Systemic Circulation, RV – Right Ventricle, RA – Right Atrium, PA – 
Pulmonary Arteries, PV – Pulmonary Veins, LA – Left Atrium, SV – Single Ventricle, VC – Vena 
Cavae, SA – Single Atrium 
The lack of a right ventricle also reduces the oscillatory nature of the pulmonary 
blood flow. Pulmonary flow in a biventricular circulation is pulsatile, but is slow, steady, 
and sluggish in the Fontan patient. These effects of the Fontan circulation place the patient 
in a state equivalent to early heart failure, which almost always deteriorates and eventually 
fails [73]. 
 This chronic Fontan failure is engrossed with several systemic organ complications. 
In fact, one reviewer argues that the nature of the Fontan circulation is to blame for all 
Fontan patient long-term complications [7]. Systemic organ complications include liver 
fibrosis/cirrhosis, protein losing enteropathy, thromboembolism, renal dysfunction, 
ascites, plastic bronchitis, and pulmonary arteriovenous malformations [6]. 
 Numerous studies have examined systemic organ complications in Fontan 




due to the increased central venous pressures just downstream from the hepatic veins seen 
in the Fontan circulation [74]. Protein losing enteropathy, excessive loss of essential blood 
proteins through artery and vein side walls, is also associated with abnormally high blood 
pressures and low cardiac output [75]. Thromboembolism, the formation of blood clots 
which travel throughout the circulation and block smaller vessels, is associated with the 
numerous interventions each Fontan patient receives, especially those involving sutures 
and grafts [76]. Renal dysfunction is abnormal kidney behavior and is associated with low 
cardiac output [74]. Ascites is accumulation of fluid in the abdominal region and is 
associated with abnormally high local blood pressures [77]. Plastic bronchitis is the 
development of casts in the bronchial tree which obstruct the airway. Its cause is unknown. 
Pulmonary arteriovenous malformations are the shunting of pulmonary arterioles to 
pulmonary venues, short-circuiting the pulmonary capillary bed. This complication is 
particularly detrimental for Fontan patients because it further desaturates their already 
oxygen-poor blood. Pulmonary arteriovenous malformations are associated with an uneven 
distribution of hepatic factor (liver-based protein) to each lung [78]. In addition to the sheer 
number complications, a patient’s individual care can be further complicated by the 
interplay between complications. 
Several differences between Fontan and biventricular circulations have direct 
effects on both ventricular dysfunction and systemic organ complications. First, 
functioning on a single ventricle leaves the remaining ventricle in a compromised situation 
– maintained flow energy requirements with decreased energy budget. This can lead to 
ventricular dysfunction and decreased exercise performance. Second, in a biventricular 
physiology the cardiac atriums possess the lowest pressure environment of anywhere in the 
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circulatory system. Thus, disconnecting the superior and inferior vena cavae (SVC and 
IVC) from the atrium increases their pressure environment. This increased pressure must 
propagate upstream in order to maintain passive downstream flow, so the upstream organs 
are also exposed to higher-than-normal pressures. This can lead to numerous systemic 
organ complications: liver cirrhosis, protein-losing enteropathy, renal dysfunction, and 
ascites. Third, disconnecting the SVC and IVC from the atrium and connecting them 
directly to the pulmonary arteries also alters the velocity fields within these vessels. This 
velocity field alteration changes lumen wall shear stress and hepatic vein (just upstream of 
the IVC) flow distributions, among numerous other factors. Thrombosis and pulmonary 
arteriovenous malformations are related to lumen wall shear stress and hepatic vein flow 
distribution, respectively [76,78]. 
3.4.2 Hemodynamics and Fontan Complications 
Hemodynamics encompasses the dynamics associated with blood flow. These dynamics 
are most readily characterized by blood flow velocity, but also include the kinetic and 
potential energy (blood pressure) required to move blood. In fact, it is into these three 
hemodynamic categories that we can group the observed Fontan complications. 
 The first hemodynamic category altered by the Fontan circulation is blood velocity. 
A biventricular circulation includes the emptying of IVC and SVC blood streams into the 
right atrium. This venous return blood velocity almost reaches instantaneous stagnation in 
the atrium before it is emptied into the right ventricle and quickly ejected to the pulmonary 
arteries. This drastic velocity change imbues blood constituent mixing. In contrast, the 
Fontan circulation eschews an atrial reservoir and never experiences the acceleration and 
deceleration associated with a sub-pulmonary ventricle. This not only discourages blood 
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constituent mixing, but also alters the geometrically and anatomically relative flow 
distributions of these constituents. Both the lack of flow pulsatility and relative flow 
distributions are associated with Fontan complications [78]. 
 The kinetic energy required to move blood through the body is provided by 
ventricles within the heart. The biventricular circulation provides the blood with kinetic 
energy twice: once just before the aorta and once just before the pulmonary arteries. This 
system provides more than enough kinetic energy during rest for blood flow. Of course, 
the Fontan circulation only has one ventricle and can, therefore, only provide kinetic energy 
once. Though it only provides the kinetic energy once per cycle, the single ventricle 
actually provides the same amount of kinetic energy during rest as two ventricles from the 
biventricular circulation. This is truly remarkable evidence of the human body’s ability to 
adapt, but ultimately results in an overworked ventricle. The single ventricle is already 
providing kinetic energy at close to maximum capacity, and thus the Fontan patient suffers 
decreased exercise performance [79]. Eventually the overworked ventricle no longer 
functions adequately [80,81]. 
 Kinetic energy differences are not only important at the heart. Two recent studies 
showed an association between kinetic energy losses taking place at the total 
cavopulmonary connection (TCPC) and Fontan patient exercise performance [48,82]. 
Ultimately, this association is more readily remedied than energy losses related to a missing 
ventricle. The TCPC can, conceivably, be optimized to reduce kinetic energy losses at the 




 The final hemodynamic category is potential energy, or blood pressure. The 
biventricular circulation establishes a normal, physiological blood pressure mapping 
throughout the circulatory system. Arteries experience relatively high pressures. Veins 
experience relatively low pressures. Above all, pressure drives blood flow. So, blood 
exiting the heart has the highest pressure and blood returning to the heart has the lowest 
pressure through either the systemic or pulmonary paths. The act of combining these paths 
in the Fontan circulation replaces the low pressures normally seen by the systemic venous 
return with higher pressures seen at the pulmonary arteries. This has two major effects. 
First, the relatively thin-walled veins cannot adequately hold this pressure and they begin 
to leak. Second, the relative pressure drop between upstream and downstream of the SVC 
and IVC is decreased and sluggish flow with high upstream pressures follows. These 
phenomena are associated with a many of the systemic organ complications suffered by 
Fontan patients [74,83,84]. 
3.5 Previous Fontan Hemodynamics Studies 
The Fontan circulation originated as a clinical palliation for a dysfunctional or non-existing 
tricuspid valve (tricuspid atresia). A non-working tricuspid valve effectually reduces a bi-
ventricular heart to a single ventricle, a fatal condition if not for the ground-breaking effort 
of Fontan and Baudet [1]. Naturally, clinicians followed the outcome of these patients, 
reporting low cardiac output, low oxygen saturations, high atrial pressures, and 
calcified/stenotic conduits [85]. Despite these observations the remaining ventricle 
appeared to work well under resting conditions [86]. Short-term complications were 
relatively minor compared to fatality, and the surgical history was not deep enough to 
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observe any of the looming long-term issues. The Fontan circulation was deemed a success, 
even if rather miraculously. 
3.5.1 Previous Clinical Studies 
 The first sign of clinical Fontan circulation trouble came in the form of heart 
arrhythmias [63]. As Fontan patient follow-up continued, more and more long-term 
complications arose causing a re-evaluation of the Fontan circulation success [4,5,66,87–
91]. Altered hemodynamics was hypothesized as playing a role, and has since been 
investigated with clinical tools (magnetic resonance imaging, echocardiography, 
catheterization pressure measurements, etc.) for virtually every complication [92–101]. 
The strongest ties between Fontan circulation hemodynamics and circulatory system 
complications are between Fontan connection power loss and patient exercise tolerance 
from Khiabani et al [48], and hepatic flow distribution and pulmonary arteriovenous 
malformations from [78] Srivistava et al. Though significant strides were made to highlight 
decreased cardiac output and elevated central venous (and atrial) pressures as macro-level 
hemodynamic issues related to Fontan complications, clinical analysis technology lacks 
the spatial and temporal resolution to comprehensively understand velocity fields and other 
fundamental hemodynamic details related to patient outcomes. Beyond the incomplete 
view provided by clinical data, these in vivo studies are simply difficult. In vivo study 
parameters are widely varying requiring high patient numbers for only correlated results 
and involve numerous ethical issues. 
3.5.2 Previous Computational Studies and Lumped Parameter Modelling 
 Computational studies provide the most detailed hemodynamic view of the Fontan 
circulation of the exploration paths mentioned. Computational studies of Fontan 
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hemodynamics are the most recent path explored, and they began with lumped parameter 
modelling. Lumped parameter models, or lumped parameter networks, operate on the 
analog between fluid and electrical systems to group circulatory system regions with 
similar flow resistance, vessel compliance, and fluid inertia. This zero-dimensional model 
of the circulatory system can then be solved through a system of non-linear ordinary 
differential equations to give transient pressure and flow solutions. Optimizing the regional 
resistances, compliances, and inertias to result in patient-specific flow and pressure curves 
can then lead to parameterization studies of the system (i.e. the effect of systemic resistance 
on cardiac output). Sundareswaran et al used lumped parameter modeling in several studies 
to explore the global Fontan circulation effects of TCPC resistance [102]. Pekkan et al, 
Haggerty et al, and Di Molfetta et al used lumped parameter modeling to simulate the use 
of Fontan mechanical assist devices to reverse the failing Fontan circulation [103–105]. 
Fogel et al and Restrepo et al used lumped parameter modeling as boundary conditions for 
simulations involving pre-interventional planning [106,107]. By far, the most common use 
of lumped parameter models is to inform higher dimensional computational model 
boundary conditions [16,18,20,44,45,108–119].  
 Higher-order computational fluid dynamics (CFD) studies focus on the detailed 
flow fields within the TCPC. Early CFD studies focused on steady flow boundary 
conditions with rigid wall vessel models. Even under these simplified conditions, complex 
secondary flow features were shown [22]. Energy dissipation and TCPC flow efficiency 
soon became and emphasis. DeGroff et al showed that even simplified models produced 
instabilities and secondary flows which significantly affect energy losses [120]. Similar 
observations were made as computational simulations advanced to include patient-specific 
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geometries [121]. Though significant contributions, it is now recognized that only fully-
coupled 2-way fluid structure interaction models of the TCPC will include all of the 
physiological cardiac and respiratory pulsatility effects necessary. The current standard for 
TCPC computational modelling comes from Long et al [45,122]. Though extremely 
detailed computational studies are still models of true physics and must rely on 
experimental validation to prove effective. 
3.5.3 Previous In Vitro Studies 
 Experimental, or in vitro, investigations of Fontan hemodynamics furthered the 
research field through the ground-breaking effort of de Leval [62]. In this study, de Leval 
explored the deficiencies of the atrio-pulmonary connection and hypothesized that 
streamlining the connection would improve TCPC flow efficiencies and overall Fontan 
circulation performance. This work fueled numerous subsequent simplified TCPC studies. 
Sharma et al. experimentally demonstrated improved efficiency through the introduction 
of a caval offset [28]. Gerdes et al. showed similar effects with the introduction of baffle 
curvature [33], while Ensley et al. advocated for connection flaring [9]. These early 
experiments paved the way for employing physical lumped parameter models patterned 
after computational lumped parameter models to more realistically capture the 
physiological Fontan circulatory system. As this thesis includes in vitro model 
development, specifically, it’s detailed study history is now outlined. 
3.5.4 In Vitro Fontan Circulation Model Development 
To model the Fontan circulation in an in vitro setting the complex network of flexible 
vessels in the body is modeled as a simplified fluid network with common elements lumped 
together. The earliest Fontan circulation physical lumped parameter models employed 
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rigid, idealized TCPC geometries and steady flow conditions [22,31,33]. De Zelicourt et al 
and Chopski et al added patient specific geometries from MRI scans, but maintained rigid 
vessel walls and steady flow conditions [23,35]. Tang et al, Figliola et al, and Vukicevic et 
al conducted studies with patient-specific geometries, rigid vessel walls, and pulsatile flow 
conditions [27,32,47]. The most physiologically accurate in vitro Fontan circulation model 
studies is by Vukicevic et al [38]. Vukicevic’s mock circulatory system is modeled after a 
computational model of the circulatory fluid network [44,123]. It includes patient-specific 
flow conditions, cardiac and respiratory pulsatility, and a flexible total cavopulmonary 
connection (TCPC). Unfortunately, though the pressure and flow waveforms are verified 
against patient-specific data, the TCPC compliance is not. Without proper TCPC 
compliance, proper TCPC deformation cannot be ensured. Without proper TCPC 
deformation the fluid velocity near the TCPC wall is not the same as in the patient. Thus, 
questions remain as to the local TCPC velocity field accuracy. The local TCPC velocity 
accuracy is important in so far as it contributes to fluid power loss occurring within the 
TCPC – one of the key metrics relating TCPC hemodynamics to patient outcomes. 
3.5.5 Respiration and Fontan Hemodynamics 
Once pulsatile flow was realized in Fontan circulation in vitro models, the possibility of 
examining the effect of respiration on Fontan connection hemodynamics was realized. 
Lack of a functional right ventricle leaves Fontan patients with passive blood flow to the 
lungs. Numerous studies note this phenomena and emphasize the importance of 




In vivo studies unanimously agree that Fontan caval flows are higher during 
inspiration than during expiration. Hsia et al attributes the increased Fontan baffle flow 
entirely to increase hepatic vein flow, rather than increased flow through the sub-hepatic 
IVC [42]. Hjortdal et al used a real-time MRI sequence to examine respiration effects 
during both rest and exercise [43]. This study also found increased caval flow during 
inspiration, but added that the inspiration to mean flow ratio found during rest was 
decreased during exercise, possibly contributing to the Fontan patient’s exercise 
intolerance. Ultimately, respiration increases Fontan patient end diastolic volumes and 
stroke volumes, and is a key component in analyzing Fontan hemodynamics [41].  
Recognizing the importance of respiration effects as outlined by in vivo studies, 
both computational [15,45,124,127] and experimental studies [27,37,38] now include 
them. However, only Long et al includes fluid-structure interactions to include proper 
respiration-driven vessel wall motion [45]. No computational studies of respiration effects 
on Fontan hemodynamics are validated against any physical flow fields. Similarly, only 
one in vitro study employs a patient-specific flexible wall Fontan connection [38], while 
the others use a rigid wall model and reservoirs in series with the flow to represent vessel 
compliance. The single study employing a patient-specific flexible wall provides no 
compliance verification, and does not include any flow field measurements.  
3.5.6 Exercise and Fontan Hemodynamics 
Though deemed a success during resting conditions, clinical studies highlight the Fontan 
patient’s inability to tolerate exercise conditions [43,70–72,85,128]. Spurred by these 
findings, and the correlation of Fontan patient quality of life to exercise capacity [129], 
numerous clinical [79,130,131] and biomedical engineering studies 
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[11,15,16,41,44,48,102,117,132–135] sought to correlate and increase Fontan patient 
exercise capacity. These studies found that, unless already failing, the Fontan single 
ventricle is capable of pumping whatever volume of blood that reaches it during exercise. 
During exercise, a biventricular heart senses the need for increased oxygen to the body and 
simultaneously increases heart rate and stroke volume in both ventricles. The left ventricle 
feeds more oxygen-rich blood to the body and the right ventricle pushes more oxygen-poor 
blood to the lungs and the left ventricle. The Fontan circulation has no functioning right 
ventricle. Therefore, it cannot fill the single ventricle with a larger stroke volume. Partial 
compensation for Fontan patients comes in the form of increased exercise heart rates, but 
ultimately their exercise capacity is limited. The strongest ties between Fontan circulation 
hemodynamics and circulatory system complications are between Fontan connection 
power loss and patient exercise tolerance, highlighted by Khiabani et al [48]. 
The total cavopulmonary connection (TCPC) replaces the physiological right 
ventricle for Fontan patients. For this reason, it was the focus of many studies mentioned 
above. However, none of the in vitro studies above account for patient-specific flexible 
walls, and none of the computationally-based studies were quantitatively validated against 
patient-specific flexible wall datasets.  
3.6 Study Significance 
The work presented here is significant to both the clinical and engineering fields. From a 
clinical perspective, the work explores the relationship between respiration, exercise, and 
pulsatility flow effects on key hemodynamic metrics related to Fontan patient outcomes. 
Though these factors have been commented on in this context before, no previous studies 
employed a compliance verified patient-specific flexible Fontan connection model. Proper 
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compliance verification and flexibility at the Fontan connection will affect the flow field 
within the connection, and all hemodynamic metrics derived from the flow field [45]. If 
the effect of compliance in the Fontan connection is large enough, the relationship between 
these key hemodynamic metrics and patient outcomes may change. 
From an engineering perspective, an in vitro model bridges the gap between limited 
data available from in vivo patient specific studies (a partial view of a full truth), and 
limitless data available from computational hemodynamic models (a full view of a partial 
truth). The in vitro model developed and the conditions tested in this study provide the first 
compliant model patient-specific stereoscopic flow field with sufficiently high spatial and 





The following section provides the technical specifications and relevant information for 
the instruments used to both control the experiments and acquire data in this study.  
4.1.1 MRI Instrumentation 
The patient-specific anatomical models and flow conditions used in this study were 
acquired from MRI scans performed at the Children’s Hospital of Philadelphia. An Avanto 
Whole Body system (Siemens Medical Solutions, Malvern, PA) was used for the anatomic 
and PCMR imaging. The Avanto system magnet had a field strength of 1.5 T and a gradient 
strength of 33 mT/m at 125 T/m/s. The system was 160 cm long with a 60 cm bore. The 
specific procedure used to acquire the anatomy and flows for this study are in section 
4.2.1.1.  
4.1.2 Fontan Circulation Model Instrumentation 
The Fontan circulation model employed in this study was a physical lumped parameter 




Figure 4-1: Fontan circulation model schematic with labeled components. The large blue rectangular 
prisms represent volumetric flow rate measurement locations. The small green rectangular prisms 
represent static pressure measurement locations. 
Flow began in an elevated reservoir (1) with a pressure head representing mean 
ventricular pressures. Flow then proceeded down the piping network through a check valve 
(2) to a junction with a programmable piston pump (3). This pump was a Vivitro 
SuperPump (Model SPL 39891; Vivitro Systems Inc, Victoria, British Columbia) 
controlled by a voltage waveform output from a custom LabVIEW 13.1 virtual instrument 
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(National Instruments, Austin TX). Pulsatile flow output from the pump was split at a tee 
junction to both the IVC and SVC inlet lines, and proceeded through pressurized air 
compliance chambers (4,5) and ball valves (6,7), which modified flow waveform 
frequency and mean flow, respectively. Flow then entered the flexible TCPC model test 
section, and proceeded out through the LPA and RPA lines, passing through two more ball 
valves (8,9) that controlled mean outlet flow rate. The pulmonary artery outflow lines met 
at a reservoir representing the Fontan single atrium (10) before the flow was then pumped 
back to the elevated reservoir by a steady centrifugal pump (11, Model 12U596; Dayton 
Pumps, Lake Forest, IL). The steady centrifugal pump rotational speed was controlled by 
the DC voltage output from a Powerstat variable autotransformer (type 3PM126; The 
Superior Electric Co, Bristol CT). The variable transformer accepted 120 V 50/60 Hz AC 
electricity signal and output a 15 A DC power source signal ranging from 0-140 V. The 
procedure for the Fontan circulation model patient-specific verification is in section 4.2.1. 
4.1.2.1 Pressure and Flow Measurement 
Figure 4-1 also outlines the pressure and flow measurement within the schematic. 
Pressure relative to atmospheric pressure was measured via fluid-filled strain gauge 
pressure transducers (Model 6199; Utah Medical Products Inc., Midvale, UT). The 
pressure transducers had a measurement range of -50 to 300 mmHg and a sensitivity of 5 
µV/V/mmHg, or ± 2 %. The pressure transducer excitation voltage and signal amplification 
was provided by a custom-built signal conditioning box constructed by the Georgia Tech 
Mechanical Engineering Electronics Lab. Signal output from the conditioning box was 
read by LabVIEW. 
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Flow rates were measured with 3 in-line and 1 clamp-on ultrasonic flow probes 
(Transonic Systems, Ithaca, NY). The 3 in-line flow measurements were performed with 
model 10PXN probes. The clamp-on measurement was with a model 8PXL probe. The 
flow probes utilized the Doppler effect to measure the flow at a frequency of 1.2 MHz. The 
flow signal from each probe was sent to a TS410 tubing flow module housed within a T402 
multi-channel research console. The research console applied a low pass filter at 100 Hz to 
each signal before the signal was read by LabVIEW. All flow probes had a resolution of 
0.01 L/min. 
4.1.2.2 Data Acquisition and Control System 
Two software-coupled National Instruments data acquisition (DAQ) systems and a custom 
LabVIEW program were used to control the pulsatile piston pump, trigger imaging 
systems, and record pressure and flow measurements. The two DAQ systems were model 
USB-6251 devices, which included 8 16-bit, 1.25 MS/s BNC analog input channels and 2 
16-Bit 2.8 MS/s BNC analog output channels. One of the 4 output channels sent a piston 
position waveform to the programmable piston pump during pulsatile flow conditions. 
Another of the analog out channels was used to send trigger signals to the PIV acquisition 
system. Of the 16 total input channels, 4 recorded flow rates (IVC, SVC, LPA, and RPA), 
7 recorded pressures (IVC, SVC, LPA, RPA, atrium, before steady pump, after steady 
pump), and 2 recorded the analog output channels re-read back to the DAQ. 
 A custom LabVIEW virtual instrument controlled the system and allowed the 
investigator to acquire, calibrate, and display all 16 analog input voltage signals. 
Acquisition sampling frequency was adjustable, and the incoming signals were used in the 
real-time calculation of several important verification parameters: signal mean, signal 
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maximum, and signal minimum. The time period over which each of these parameters was 
calculated was set independent of the sampling frequency. This allowed for cyclic averages 
during pulsatile experimental conditions. These parameters could be calculated on multiple 
signals at the same time, which allowed for additional flow pulsatility and resistance 
verification. The two output signals were controlled from the custom LabVIEW virtual 
instrument as well. Each output signal was created from a time-normalized (0 to 1) and 
amplitude-normalized (0 to 1) comma-separated variables file. The custom waveform file 
was then scaled to a specifiable time period and amplitude within the LabVIEW virtual 
instrument. More information regarding the functions and utilization of the virtual 
instrument can be found in appendix 11.1. 
4.1.3 Particle Image Velocimetry Instrumentation 
A double-cavity Nd:YAG laser with 50 mJ pulse energy and 532 nm wavelength 
(LaVision GmbH, Goettingen, Germany) provided the particle image velocimetry 
illumination. The laser beam was delivered to the measurement plane via a covered beam 
path laser arm. A collimator and sheet optics were used at the end of the laser arm to 
generate a light sheet of approximately 1 mm thickness. Fluorescent Rhodamine-B 
(excitation wavelength – 535 nm and emission wavelength – 580 nm) particles with a 
diameter of 1-20𝜇𝜇𝜇𝜇 were used to seed the flow. Two LaVision PRO-X 2M cameras were 
used, each with 1600x1200 pixel resolution. The focal length of each lens system was 60 
mm, and each lens was fitted with an OD 4, 50 mm diameter, 600 ± 50 nm bandpass filter 
(Stock No. 84-797 Edmund Optics Inc., Barrington, NJ). LaVision DaVis 8.2 software was 




The instruments found in section 4.1 were used in specific procedures in order to verify 
patient-specific Fontan circulation model behavior, and assess the effects of respiration, 
exercise, and pulsatility on Fontan circulation hemodynamics. The following section 
outlines these procedures. 
4.2.1 Patient-Specific Verification 
In order to verify patient-specific hemodynamic behavior of the Fontan circulation model, 
patient-specific data was first acquired. Then, the Fontan circulation model was developed 
to match key patient-specific hemodynamic metrics. The procedures that follow were those 
used in this verification process. 
4.2.1.1 Magnetic Resonance Imaging Protocols 
Magnetic resonance imaging (MRI) was used to acquire anatomy and flow data for 2 
Fontan patients from the Children’s Hospital of Philadelphia (CHOP). The instruments 
used for this procedure are detailed in section 4.1.1. 
The imaging protocol began with an static steady state free precession anatomic 
survey. This data was then reformatted to acquire slice orientations and positions 
perpendicular to flow for both real-time Phase Contrast Magnetic Resonance (rtPCMR) 
and segmented Phase Contrast Magnetic Resonance (sPCMR) acquisitions. The rtPCMR 
was an echoplanar sequence that used shared velocity encoding, the details of which have 
been described previously [136]. It used, in general, the following variables: repetition time 
of 9.5 milliseconds, echo time of 4.1 milliseconds, flip angle of 30 degrees, field of view 
of 320 to 400 mm, slice thickness of 8 to 10 mm, and bandwidth of 2,841 Hz/pixel. The 
acquisition protocol consisted of through-plane PCMR across the superior (SVC) and 
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inferior (IVC) vena cava, AAo, and DAo aorta for at least 10 seconds (approximately 20 
frames/second). The IVC flow was acquired near the diaphragm but above the hepatic 
entrance to the IVC. The same imaging protocol was performed under the resting free-
breathing (FB) and exercise (EX) conditions. Both FB and EX flows include respiration 
(inspiration and expiration) effects. After the resting free-breathing rtPCMR acquisition, 
the patients were slid partially out from the MRI bore to perform lower leg exercise with 
the use of an MRI-compatible supine bicycle ergometer (Lode BV, Groningen, the 
Netherlands). This ergometer allows revolutions per minute-independent workload, 
ranging from 10 to 250 watts while the patient maintains his or her position by bracing 
with hand grips. The goal was to bring the patients from the resting conditions up to a 
steady work rate at their ventilatory anaerobic threshold (VAT) (as measured in a previous 
metabolic exercise test), which was a sustainable work rate for the completion of the PCMR 
data acquisition. HR was monitored continuously. Initially, the workload was set to 20 
watts and was increased progressively at a rate of 20 watts per minute to obtain a HR 
corresponding to that of the HR at VAT on their prior metabolic exercise test. Exercise was 
then suspended, their feet quickly removed from the ergometer pedals, and they were 
automatically returned to the MRI bore isocenter for imaging. Exercise imaging took place 
less than ten seconds after the patient stopped pedaling. Real-time PCMR measurements 
of the AAo, DAo, IVC, and SVC were acquired with repeated exercise performed in 
between for the patient to return to the target HR.  
Breath-held (BH) data was acquired using a more standard segmented Phase 
Contrast Magnetic Resonance (sPCMR) procedure.  
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4.2.1.2 Patient-Specific Anatomy Acquisition 
The anatomical shape of the patient-specific verified Fontan connection model was created 
by segmenting the anatomical MRI data for each patient. Segmentation was performed via 
ITK-SNAP 3.6.0 [137]. Segmentation resulted in a three-dimensional computational model 
(.stl file) that was passed to the manufacturer for mold-making. The models were 
manufactured by BDC Labs (Wheat Ridge, CO). 
4.2.1.3 Patient-Specific Flow Waveform Calculations 
The MRI protocols described in section 4.2.1.1 resulted in a Digital Imaging and 
Communications in Medicine (DICOM) standard file data set for each condition: breath-
held, free-breathing, and exercise. The flow measurement DICOM files appear as images, 
but also include fluid velocity information in the direction normal to the image. This 
velocity information was extracted and converted to a flow rate via the Segment computer 
program from Medviso (v1.9) [138]. Segment is a well-tested MRI analysis program which 
our lab has found to provide accurate flow rate estimations when compared to clinical 
reports within 5% error. Segment was operated by loading both the magnitude and phase 
DICOM files into the program and tracing the vessel of interest (Figure 4-2). The Segment 




Figure 4-2: Medviso Segment DICOM processing program screenshot showing breath-held PCMRI 
IVC vessel tracing to extract flow rate data 
 Segment flow analysis was performed for each vessel of interest (IVC, SVC, LPA, 
RPA) during each patient condition (BH, FB, EX). Table 4-1 summarizes the patient-
specific data acquired from the MRI protocols and processed in Segment. The table lists 
the mean flow rate of each vessel, which was determined over 1 cardiac cycle worth of 
data for the breath-held conditions and 3 respiration cycles for the free-breathing and 




Table 4-1: Mean flow rate values (L/min) of each patient and each condition acquired from MRI. The 
* denotes those vessel values that were calculated instead of directly acquired. 
 Patient ID CHOP11B CHOP235A 
 Fontan Type Extra-Cardiac Intra-Atrial 
Breath-Held PCMRI Mean Flow Rate (L/min) 
IVC 2.35 2.36 
SVC 0.86 0.75 
LPA 1.45 0.70 
RPA 1.76 2.41 
Free-Breathing RTMRI Mean Flow Rate (L/min) 
IVC 3.07 2.20 
SVC 0.97 2.85 
LPA 2.24* 1.14* 
RPA 1.80* 3.91* 
Exercise RTMRI Mean Flow Rate (L/min) 
IVC 6.38 3.55 
SVC 1.76 3.67 
LPA 3.71 1.94 
RPA 4.43 5.28 
 
A difference in data lengths for the different patient-specific conditions was caused 
by the difference in MRI protocols. The breath-held condition was acquired under a 
standard cardiac gated phase contrast protocol which uses data over multiple cardiac cycles 
to phase average a single cardiac period length of data. The single cardiac cycle reported 
was then an average of multiple cardiac cycles acquired over approximately one minute of 
wall time. In contrast, the free-breathing and exercise data sets were acquired with real-
time MRI protocols which resulted in only 20 secs of wall time data acquisition. These data 
sets are acquired at a higher frequency than the standard phase contrast MRI protocol used 
for the breath-held data, but are not cardiac- nor respiratory-gated. Without gating, the 
cardiac and respiratory cycles cannot be phase averaged, and an integer number of cardiac 
and respiratory cycles is not guaranteed within the 20 seconds of acquisition. 
Hemodynamic analyses and particle image velocimetry experiments (sections 4.2.2.1 and 
4.2.2.2) required periodic experimental model boundary conditions for proper phase 
averaging and experimental uncertainty reduction, so a Fourier analysis procedure was 
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implemented to generalize all patient-specific waveforms from all MRI protocols. This 
procedure is discussed in section 4.2.1.3.2. 
4.2.1.3.1 Missing Waveforms 
Some vessel waveforms (LPA and RPA during free-breathing conditions) were not 
collected clinically, as denoted by an asterisk in Table 4-1. These vessel waveforms were 
calculated by summing the IVC and SVC free-breathing waveforms, and multiplying the 
resultant waveform by the ratio of the mean outlet flow from the breath-held condition. For 
example, the free-breathing LPA waveform for CHOP11B was calculated by summing the 
CHOP11B free-breathing IVC and SVC waveforms and multiplying this waveform by the 
ratio of the mean CHOP11B breath-held LPA flow (1.45 L/min) to the CHOP11B breath-
held total outflow (3.21 L/min; 1.45/3.21 = 45.2%). This estimation assumed no change in 
frequency content between the inflows and outflows of the free-breathing data sets and that 
the LPA and RPA downstream flow resistances (the pulmonary vascular resistance) do not 
change between breath-held and free-breathing conditions. Though these assumptions are 
reported to hold true by Naeije and Chesler [139], calculations were still performed to 
assess their validity in this case. 
The validity of this estimation method for these 4 missing waveforms was tested 
by comparing the patient-specific PA waveforms to the PA waveforms calculated using 
the method described above for each patient under the breath-held condition. Figure 4-3 
shows the calculation of the CHOP11B BH LPA waveform compared to the patient-




Figure 4-3: Comparison of CHOP11B BH patient-specific and estimated waveforms as verification of 
the missing waveforms estimation method. The error bars represent a 10% assumed MRI uncertainty 
interval. 
4.2.1.3.2 Fourier Analysis – Decomposition of Respiratory and Cardiac Cycles 
All MRI-based flow waveforms were analyzed and filtered with a custom 
MATLAB (The MathWorks, Inc. Natick, MA) program via Fourier analysis. The purpose 
of the Fourier analysis was two-fold: generalize the MRI-acquired waveforms to be 
periodic solutions with an integer number of respiratory/cardiac cycles, and filter out high-
frequency flow waveform noise. The custom MATLAB program used a single row vector 
of patient-specific raw flow rate data as input, and requested the time step (in seconds) 
between flow rate data points from the user. With this information, the program executed 
MATLAB’s built-in fast Fourier transform function (FFT) 1000 times, sampling different 
amounts of the raw data signal for each FFT calculation. These 1000 FFT calculations were 






















single-sided amplitude spectra was used to eliminate the effects of sample length on the 
revealed frequency content. Figure 4-4 shows an example single-sided amplitude spectrum 
acquired from the CHOP11B FB IVC waveform. Appendix 11.3 includes the custom 
MATLAB script executed. 
 
Figure 4-4: Single-sided amplitude spectrum of IVC flow for patient CHOP11B under free-breathing 
conditions 
 The single-sided amplitude spectrum was used to extract frequency content and 
filter the raw data. Respiratory and cardiac frequencies (and their harmonics) were 
identified by peaks in the single-sided amplitude spectrum. Filtering was performed by 
identifying the 2nd harmonic of the cardiac frequency and then excluding all frequencies 
greater than this frequency, as well as all other frequencies with amplitude less than the 
amplitude of the 2nd harmonic of the cardiac frequency. This filtering algorithm was 
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Figure 4-5 shows the same single-sided amplitude spectrum with the included frequencies 
kept highlighted.  
 
Figure 4-5: Single-sided amplitude spectrum with frequencies kept highlighted 
 To verify that the filtered waveform matched well with the raw MRI data, each 
filtered waveform was reconstructed as a sum of sine and cosine functions, as in Equation 
(4-1). 
 
𝑄𝑄 = 𝐴𝐴0 + �𝐴𝐴𝑛𝑛 cos(𝜔𝜔𝑛𝑛𝑡𝑡) + 
𝑘𝑘
𝑛𝑛=1
𝐵𝐵𝑛𝑛 sin(𝜔𝜔𝑛𝑛𝑡𝑡) (4-1) 
 
where 𝑄𝑄 was the filtered waveform, 𝐴𝐴0 was the zero frequency waveform content, 𝑛𝑛 was 
the discrete frequency number determined by the MRI sampling frequency and the raw 
waveform signal length, 𝑘𝑘 was the total number of frequencies kept, and 𝜔𝜔 = 2𝜋𝜋𝜋𝜋. 
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An example comparison between the filtered waveform and the raw MRI data is shown in 
Figure 4-6. A correlation between the two curves below resulted in 𝑅𝑅2 = 0.879. 
 
Figure 4-6: Comparison of CHOP11B FB IVC flow rate raw MRI data and post filtering procedure. 
 The frequency content extracted from each MRI IVC waveform was used to 
identify characteristic frequencies for each experimental condition. These characteristic 
frequencies are listed in Table 4-2. 
Table 4-2: Characteristic respiration and cardiac frequencies acquired from each MRI IVC waveform 
for each model and condition 
Model Condition 𝒇𝒇𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓 (Hz) 𝒇𝒇𝒄𝒄𝒄𝒄𝒓𝒓𝒄𝒄 (Hz) 
CHOP11B 
BH -- 0.969 
FB 0.278 0.955 
EX 0.499 1.998 
CHOP235A 
BH -- 1.310 
FB 0.262 0.956 
EX 0.615 1.290 
 
The filtered waveforms reconstructed according to Equation (4-1) served as the 
























4.2.1.4 In Vitro Fontan Circulation Model Verification 
The in vitro Fontan circulation model was verified for BH, FB, and EX conditions using 2 
metrics: flow waveform and TCPC model compliance. 
4.2.1.4.1 Flow Waveform Verification 
The in vitro Fontan circulation model flow waveform for each vessel was verified against 
the patient-specific flow waveforms established through methods in section 4.2.1.2. The 
model flow waveform was created through a combination of steady, gravity-driven flow 
and the programmable piston pump. The programmable piston pump was controlled with 
a comma-separated variable file via a custom LabVIEW VI. The LabVIEW VI established 
a constant gain to the piston waveform, which was then manually adjusted through dials 
on the SuperPump control box. Mean flow rate was controlled by manually adjusting the 
amount of gravity-drive flow passing through the various ball valves throughout the 
circulation model; minor model flow waveform adjustments were also made manually by 
adjusting the air-fluid ratio in the compliance chambers (Figure 4-1).  
In general, the programmable piston pump was fed the condition-specific IVC 
waveform for a period of time corresponding to 4 times the lowest characteristic frequency 
shown in Table 4-2. The first 3 characteristic periods included data collection. The 
remaining characteristic cycle length was used in particle image velocimetry data 




Figure 4-7: CHOP11B FB IVC flow rate waveform showing different time scales important for flow 
waveform verification. A, B, C, and D denote different time scales within each data acquisition; see 
Table 4-3. 
Table 4-3 summarizes the different time scales used for each experimental 
condition. Note that the data collection time and total time (C and D) are rounded to the 
nearest 0.02 secs to accommodate a 50 Hz experimental data sampling rate. 
Table 4-3: Cardiac frequency, respiratory frequency, data collection time, and total characteristic time 
for each experimental condition 
Model Condition 𝒇𝒇𝒄𝒄𝒄𝒄𝒓𝒓𝒄𝒄 (Hz) (A) 𝒇𝒇𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓 (Hz) (B) 𝑻𝑻𝒄𝒄𝒄𝒄𝒅𝒅𝒄𝒄 (secs) (C) 𝑻𝑻𝒅𝒅𝒕𝒕𝒅𝒅 (secs) (D) 
CHOP11B 
BH 0.969 -- 3.10 4.10 
FB 0.955 0.278 10.80 14.40 
EX 1.998 0.499 6.02 8.02 
CHOP235A 
BH 1.310 -- 2.30 3.06 
FB 0.956 0.262 11.46 15.26 
EX 1.290 0.615 4.88 6.50 
 
The pattern of 3 data collection cycles and 1 timing cycle was repeated at least 20 























each condition to establish a condition-specific in vitro Fontan model circulation vessel 
waveform. These waveforms, with their associated measurement uncertainty, were then 
compared to the patient-specific MRI vessel waveforms (assigned a 10% uncertainty [140]) 
both qualitatively and quantitatively. Quantitative comparison utilized two metrics: a ratio 
of the average difference between the two waveforms to the time-averaged value of the 
two waveforms and a time-normalized root mean square. The first error metric is shown in 















4.2.1.4.2 TCPC Model Compliance Verification 
The patient-specific flow waveforms calculated in section 4.2.1.2 were used to determine 
a patient-specific TCPC compliance for both CHOP11B and CHOP235A. Compliance is 
a bulk material property metric relating the amount of total volume deformation an object 









In order to verify that the in vitro TCPC model matched the patient-specific 
compliance both the patient-specific compliance and the existing in vitro TCPC 
compliance were necessary to determine. Then, the in vitro TCPC compliance had to be 
altered to match patient-specific compliance in a cost-effective manner. Finally, it was 
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necessary to confirm the resulting in vitro TCPC model and patient-specific compliance 
match. This verification process took place in five stages: 
(1) The patient-specific data was analyzed to determine an in vivo target 
compliance. 
(2) An arbitrary-thickness (1mm) in vitro model was constructed and tested to 
determine its compliance. 
(3) The in vitro compliance test was reproduced computationally to determine an 
effective Young’s modulus (Eeff). 
(4) The model thickness was computationally iterated upon using the effective 
Young’s modulus to determine a target model wall thickness which would match 
the target compliance. 
(5) A new model with the computationally-derived target wall thickness was 
constructed and tested in vitro to determine if its compliance matched the target 
compliance from stage one.  
4.2.1.4.2.1 Patient-Specific Data Analysis 
Patient-specific flow waveforms were acquired from phase contrast magnetic resonance 
images according to the procedure detailed in section 4.2.1.1. The change in volume over 
the cardiac cycle was calculated by integrating the net flow in the TCPC over a cardiac 
cycle. Inferior vena cava (IVC) and superior vena cava (SVC) flow contributed to the 
TCPC volume while right pulmonary artery (RPA) and left pulmonary artery (LPA) flow 
subtracted from it. The volume change was defined as the minimum volume subtracted 
from the maximum volume. The pressure change was determined by the average pulse 
pressure in each of the IVC, SVC, LPA and RPA. 
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4.2.1.4.2.2 In Vitro TCPC Compliance Testing 
The flexible TCPC model was constructed of a shore 30A hardness silicone 
material that was dip molded to the patient-specific geometry based on anatomy acquired 
from magnetic resonance images (MRI). The MRI data was acquired according to the 
protocol in section 4.2.1.1. The patient-specific anatomy was segmented from the MRI 
images using ITK-SNAP to produce a 3D computer surface [137]. This computational 
model was then 3D printed to produce the mold for silicone model production. The flexible 
models were manufactured by Biomedical Device Consultants Laboratories (Wheat Ridge, 
CO). The compliance of the manufactured model was a function of both its material 
properties, shape, and wall thickness. Without knowing each model’s compliance a priori, 
an arbitrary thickness (1mm) model was manufactured for each patient-specific anatomy. 
In vitro compliance testing was used for stages 2 and 5 of the verification method 
(section 4.2.1.4.2). Testing consisted of suspending the model in the physiological 




Figure 4-8: In vitro TCPC model suspended in physiological orientation in preparation for compliance 
testing 
The ends of each vessel were sealed with ball valves and the TCPC was filled with 
a saline blood analog solution to 15 mmHg, the minimum TCPC pressure from the patient-
specific catheter readings. Using a 50 cc syringe and a Harvard Apparatus PHD 2000 pump 
(Harvard Apparatus, Holliston, MA), a known volume of solution was injected into the 
system and its associated pressure change was recorded. Pressure was measured by 6199 
Deltran® pressure transducers (Utah Medical Products, Inc. Midvale, UT). The injected 
volume was then removed from the TCPC and returned to the injection pump. Subsequent 
injection volumes were varied until they resulted in a 2 mmHg increase in TCPC pressure 
– the mean pulse pressure from the age-matched cohort. Once the appropriate injection 
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volume was determined, the injection/removal and pressure recording process was 
repeated additional 10 times to reduce measurement uncertainty. 
4.2.1.4.2.3 Computational Simulations 
Computational simulations were used in stages 3 and 4 of the verification method. The 
simulations utilized ANSYS Mechanical and Response Surface Optimization (RSM) 
modules (ANSYS, Inc., Canonsburg, PA). 
 Computational reproduction of the in vitro compliance testing of the arbitrary 
thickness (1mm) model TCPC used the same 3D computer surface model passed to the 
manufacturer for model production. The computational surface model was given the 
arbitrary (1mm) thickness within the ANSYS Mechanical module using shell181 elements. 
Shell181 elements were employed because of their unique ability within ANSYS 
Mechanical to couple to hydrostatic fluid elements (HSFLD 242) and reduce computational 
cost compared to a fully-coupled fluid structure interaction model. The hydrostatic fluid 
elements applied the same volume change over time as measured from the in vitro 
compliance test. The injected fluid was incompressible and had a density of 1000 kg/m3. A 
hybrid meshing approach was used; therefore, the structure mesh contained both 
tetrahedral and hexahedral mesh elements. The mesh edge size was constrained to 0.001 
m, and the final mesh included 23,741 elements. This mesh setup provided grid-
independent results. The simulation employed a linear elastic material model with an 
assumed Poisson’s ratio of 0.5. 
Material properties determination and model thickness optimization utilized the 
Response Surface Optimization module in ANSYS Workbench, which achieved the 
optimization objective with little a priori information in a cost-effective manner. Because 
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this study focused on single-objective optimizations, the Screening optimization approach 
was used.  The genetic aggregation response surface type was used because of its 
robustness for a wide range of applications. 
4.2.2 Experimental Approach 
With patient-specific verification of the in vitro Fontan circulation model complete per the 
section 4.2.1 procedures, the effect of respiration, exercise, and pulsatility on Fontan 
hemodynamics was more accurately examined. Table 4-4 summarizes the experimental 
conditions collected to study each effect for both TCPC models. 
Table 4-4: Experimental conditions summary based on available patient-specific data for each 







Respiration Breath-Held Free-Breathing 
Breath-Held 
Free-Breathing 




Waveform Pulsatility Breath-Held 
Steady Breath-Held* 
Low Pulse Breath-Held* 
Breath-Held 
High Pulse Breath-Held* 
 
 A total of 7 experimental conditions were utilized based on 3 patient-specific data 
sets (BH, FB, EX) to study the 3 independent variables (respiration, exercise intensity, and 
waveform pulsatility), for each of the 2 models (CHOP11B and CHOP235A). Each model 
was mounted in the in vitro Fontan circulation model and the circulation model was then 
tuned to one of the experimental conditions. Each experimental condition was defined by 
a verified flow waveform for each vessel (section 4.2.1.4.1) and vessel-specific literature-
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based mean pressure values. Bulk transient hemodynamic (pressure and flow) data was 
collected and particle image velocimetry was performed for each experimental condition. 
 The derived experimental conditions found in Table 4-4 were created to acquire 
more data and more fully understand the effect of each independent variable on bulk and 
local hemodynamics. The steady breath-held condition was defined as the same mean flow 
rates for each vessel (IVC, SVC, LPA, and RPA) as the patient-specific breath-held 
condition, but without any frequency content or pulsatility to the flow. This condition was 
created by turning off the programmable piston pump. The low pulse breath-held and high 
pulse breath-held conditions were defined by waveforms with the same mean value as the 
patient-specific breath-held condition, but with waveform pulsatilities that were 2 standard 
deviations less than or greater than the patient-specific waveform pulsatility, respectively. 
The cohort from which these standard deviations were derived was the 100 patients in the 
Cardiovascular Fluid Mechanics Fontan Database for which flow pulsatility effects were 
analyzed using computational fluid dynamics [10]. Pulsatility was defined as the ratio of 
the difference in waveform maxima over a cycle to the mean waveform value over the 







The half-peak exercise condition was defined as having the flow waveform shape 
and pulsatility of the patient-specific peak exercise condition, but a mean value set at the 
average between the free-breathing and peak-exercise mean flow values, for each vessel. 
A comprehensive table summarizing key metrics for each experimental condition is found 
in Appendix 11.5. 
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Having acquired the bulk and local hemodynamic data through this experimental 
approach, the following sections detail the data analysis methods. 
4.2.2.1 Hemodynamic Analysis 
Hemodynamic data included transient pressure and flow rate waveforms acquired via the 
pressure and flow instrumentation discussed in section 4.1.2.1. After proper patient-
specific flow waveform calculations (section 4.2.1.2), the Fontan circulation model 
programmable piston pump was set to the patient-specific flow waveform for each 
condition, at a period approximately equal to 4 times the lowest frequency found in Table 
4-2. The acquired data was ensemble averaged over this condition-specific period, 
summarized in Table 4-5.  
Table 4-5: Pulsatile piston pump cycling periods for each patient-specific condition; relate to Table 4-3 










 These periods were assigned in order to model 4 patient-specific hemodynamic 
cycles. Under breath-held conditions this corresponded to 4 cardiac cycles. During free-
breathing and exercise conditions this corresponded to 4 respiratory cycles (and 12-18 
cardiac cycles). 
The ensemble-averaged pressure and flow waveforms for each vessel were used to 
calculate an apparent power loss for each experimental condition. The apparent power loss 
was derived from a control volume energy analysis assuming constant velocity profiles at 




























where 𝑃𝑃 is the time-averaged vessel static pressure, 𝜌𝜌 is the fluid density (1060 𝑘𝑘𝑎𝑎
𝑚𝑚3
), 𝑄𝑄 is 
the time-averaged vessel volumetric flow rate either in or out of the TCPC, and 𝐴𝐴 is the 
vessel cross-sectional area. The TCPC inlets are the IVC and SVC, and the outlets are the 
LPA and RPA. 
 To adequately compare to previous publications [48] and compare between 










where 𝐵𝐵𝐵𝐵𝐴𝐴 is the patient’s body surface area and 𝑄𝑄 is the time-averaged flow rate into the 
TCPC (sum of IVC and SVC flow rate). 
4.2.2.2 Particle Image Velocimetry 
Particle image velocimetry (PIV) is an optical flow visualization method used to obtain 
instantaneous velocity field measurements, from which other metrics can then be obtained. 
The fluid in question is seeded with tracer particles, which are assumed to follow the fluid 
velocity field. A laser pulsation illuminates the measurement domain, and a camera is used 
to capture successive images of the particles within the fluid. The camera images are then 
analyzed with statistical algorithms to determine the distance each particle traveled 
between images. Knowing the distance traveled and the time between images allows for a 
full velocity field calculation. Capturing particles illuminated by a laser sheet results in a 
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two-dimensional velocity field with two components of velocity for each particle (2D2C). 
Acquiring the same laser-sheet-illuminated particles with two cameras results in a two-
dimensional three-component velocity field (2D3C). Spreading the laser illumination over 
a volume of fluid and using at least 4 cameras results in a three-dimensional three-
component velocity field (3D3C). 
4.2.2.2.1 Velocity Field Acquisition 
This study utilized 2D3C PIV over multiple planes for each model in an attempt to more 
completely sample the highly three-dimensional flow fields characteristic of total 
cavopulmonary connections. Table 4-6 and Figure 4-9 summarize the sampling plane 
locations for both models.  
Table 4-6: PIV sampling plane locations as measured from the base of each model's refractive index 
bath 
Plane Number CHOP11B Plane Height (mm) CHOP235A Plane Height (mm) 
1 110 67 
2 115 71 
3 120 80 
4 125 86 
5 130 89 
6 135 93 





Figure 4-9: Schematic showing location of PIV sampling planes for each model. CHOP11B is on the 
left. CHOP235A is on the right. 
 Each model was positioned according to physiological orientation within an acrylic 
box. The box also served to hold liquid water glycerin to minimize refractive index changes 
throughout the system, and thereby minimize reflections. The laser-illuminated sampling 
planes were created by delivering a 532 nm wavelength 50 mJ pulse energy double-cavity 
Nd:YAG laser beam to a collimator and sheet optics via a shielded beam path. The double-
cavity laser produced two laser sheet pulses, each lasting 3-5 ns. The separation between 
laser pulses varied from 800-2600 μs depending on the measured fluid velocity field. 
 PIV data were acquired for each model under each of the transient inlet 
experimental conditions listed in Table 4-4, as well as a steady flow inlet condition for the 




Table 4-7: Acquired PIV data set summary using IVC as representative of the changes for all TCPC 
vessels 
Model Condition Mean IVC Flow Rate (L/min) IVC Pulsatility (%) 
CHOP11B 
BH 
Steady 2.35 0 
Patient-Specific 2.35 33.4 
Low Pulsatility 2.35 12.7 
High Pulsatility 2.35 57.5 
FB Steady 3.07 0 Patient Specific 3.07 84.8 
EX 
Peak Steady 6.38 0 
Peak Patient-Specific 6.38 101.1 
Half-Peak Steady 4.70 0 
Half-Peak Pulsatile 4.70 93.4 
CHOP235A 
BH 
Steady 2.36 0 
Patient-Specific 2.36 31.9 
Low Pulsatility 2.36 22.0 
High Pulsatility 2.36 38.6 
FB Steady 2.20 0 Patient Specific 2.20 115.2 
EX 
Peak Steady 3.55 0 
Peak Patient-Specific 3.55 126.4 
Half-Peak Steady 2.88 0 
Half-Peak Pulsatile 2.88 118.4 
 
The two frame-straddling cameras and the laser (see section 4.1.3) were triggered 
for each double-pulse to occur at specific points throughout each condition waveform. For 
example, PIV acquisition during the CHOP11B FB patient-specific condition was 
triggered at 57 time points over the 10.80 sec data sampling period (see Table 4-5), as 




Figure 4-10: PIV data acquisition trigger points shown on the CHOP11B FB IVC flow curve as 
representation of PIV triggering for all conditions. A, B, C, and D denote different time scales within 
each data acquisition; see Table 4-3. 
 Though continuous triggering was synced between the Fontan circulation model 
and the PIV system via LabView, the command to begin PIV acquisition (and wait for the 
next LabView trigger) was given manually. Thus, the last ¼ of each piston pump period 
was left untriggered to provide an audio cue for the manual command. Table 4-8 is an 
extension of Table 4-3, and summarizes the PIV image triggering for each pulsatile flow 
condition. Table 4-8 supplies the period of time over which data was collected (𝑻𝑻𝒄𝒄𝒄𝒄𝒅𝒅𝒄𝒄) for 
each experimental condition, and the total number of trigger points used to sample 𝑻𝑻𝒄𝒄𝒄𝒄𝒅𝒅𝒄𝒄. 
The period of time over which data was collected is also listed in  Table 4-3 in context of 
the individual cardiac and respiratory frequencies of each experimental condition, as well 
as the total experimental condition run-time (𝑻𝑻𝒅𝒅𝒕𝒕𝒅𝒅), which includes some time during which 





























Table 4-8: PIV acquisition summary for pulsatile flow conditions; relate to Table 4-3 and Table 4-4 
Model Condition 𝑻𝑻𝒄𝒄𝒄𝒄𝒅𝒅𝒄𝒄 (sec) Trigger Points 
CHOP11B 
BH 3.10 31 
FB 10.80 57 
EX 6.02 61 
CHOP235A 
BH 2.30 27 
FB 11.46 53 
EX 4.88 22 
 
A short study was conducted to determine the number of data cycles (𝑻𝑻𝒄𝒄𝒄𝒄𝒅𝒅𝒄𝒄) 
necessary for PIV velocity values to converge. The convergence study found that 
approximately 125 ensemble-averaged image pairs were necessary for PIV data 
convergence, so 150 image pairs of each triggered time point were conservatively acquired. 
The details of the convergence study are found in Appendix 11.6.  
4.2.2.2.2 Image Calibration 
Transformation from pixel-based to physical velocity values based on the acquired images 
required camera calibration. Camera images were calibrated using a 3-dimensioanl 
calibration plate 3D printed to fit the test section housing and include 1 mm diameter dots 
spaced 4 mm apart in one plane (XY-plane). An additional plane of dots was offset from 
the original plane by 2 mm in the X direction and 1 mm in the Z direction. Figure 4-11 




Figure 4-11: Schematic rendering of CHOP11B calibration plate in transparent test section housing 
 The calibration plate was placed in in the test section housing without the flexible 
TCPC model because the flexible model was not amenable to interior calibration. Without 
an interior calibration the light ray path from the calibration plate shown in Figure 4-11 
could have been slightly different than that of an illuminated particle used for velocimetry 
calculations. Thus, a secondary self-calibration procedure was required for each data set 
collected. The self-calibration procedure is detailed in section 4.2.2.2.3. 
 LaVision DaVis software was used to acquire the calibration images for each 
model. Calibration images were not re-acquired for every plane of data collected because 
self-calibration was included as a post-image-acquisition process. Calibration images were 
taken while the laser sampling plane was aligned to the calibration plate to ensure accurate 
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laser sampling plane location. The laser sampling plane was attached to a 1-dimensional 
traverse which, once aligned, only permitted translation in the z-direction, normal to the 
test section housing baseplate.  
4.2.2.2.3 PIV Self-Calibration 
To account for differences in light ray paths between the illuminated particles imaged for 
velocimetry and the calibration plate imaged without the presence of a TCPC model, a 
post-acquisition PIV self-calibration procedure was employed. This procedure is a feature 
of the LaVision DaVis software designed to modify existing calibration settings for 
distortion and position differences present between calibration images and data images. 
The self-calibration process simply includes identification of particles or features present 
in both stereo images (each image coming from one of the two cameras) that are the same 
physical location (Figure 4-12). From this information, DaVis calculates a disparity map 
prediction between the two images and performs a subsequent image cross-correlation to 
create a complete disparity field between the two images. The calculations required to map 
the two images onto a shared physical space are then compared to the existing calibration 
parameters that perform the same function, and the existing calibration is updated with the 




Figure 4-12: PIV self-calibration screenshot showing image feature identification and initial disparity 
map 
4.2.2.2.4 PIV Image Processing 
Image spatial cross-correlation was performed on the acquired images with DaVis software 
(section 4.1.3) to compute the velocity fields. The software used subpixel peak position 
interpolation to improve the accuracy of the displacement computation. The signal-to-noise 
ratio of the correlation peak was improved by using an adaptive multi-pass iterative scheme 
with an interrogation window overlap. A 64×64 pixel interrogation window with 50% 
overlap was used for the first pass while the second pass utilized a 32×32 pixel window 
with 75% overlap. Each camera pixel represented 7.4×7.4 𝜇𝜇𝜇𝜇2of physical area. These 
settings resulted in a velocity vector resolution of around 1 mm. The raw images for a given 
time point were summed to create a time-average image which was then subtracted from 
each of the 150 images to remove background noise, as a pre-processing step. The 
background-subtracted data were then masked algorithmically based on relative spatial 
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intensities in order to capture only fluid motion inside the moving TCPC model walls. PIV 
processing was only conducted over the image remaining after masking. An applied vector 
range and a median filter were used to post-process each instantaneous image. All 150 
instantaneous images were then time-averaged to produce a single velocity vector field for 
a given time point. 
4.2.2.2.5 PIV Velocity Field Analysis 
PIV velocity field analysis was performed using a combination of custom ParaView 
(Version 5.2.0, Kitware Inc., Clifton Park, NY) state machines and custom MATLAB 
(Version 8.6.0, MathWorks Inc., Natick MA). The processed phase-averaged velocity 
fields were exported from DaVis (see Section 4.2.2.2.4) and ParaView was employed to 
align the planes in space, interpolate the experimental data in time and space, calculate 
hepatic flow distribution, and determine the fluid viscous dissipation. Custom MATLAB 
scripts were employed to reformat and prepare data sets for each of these different analyses. 
The details of these processes follow, and the state machines and scripts are found in 
Appendix 11.7. 
4.2.2.2.5.1 Plane Alignment 
The processed transient velocity fields from DaVis were all assigned a unique coordinate 
system that, though consistent within each acquired plane, was not consistent across all 
planes for a given experimental condition. Thus all planes for each experimental condition 
(CHOP11B: 7 planes, 10 conditions; CHOP235A: 6 planes) were spatially aligned both to 
each other and to a static 3D patient-specific TCPC geometry according to common 
features found in all acquired images. The imported planes existed on a rectangular domain, 
so the plane alignment state machine also applied a threshold to the data to eliminate large 
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areas of zero velocity data. The patient-specific TCPC geometry was also assigned a 0 
velocity value on its surface for future interpolation considerations. The newly-aligned 
velocity values were then exported as point-specific comma-separated variable files for 
each acquired time step. A custom MATLAB script then reformatted the planes and the 
TCPC geometry from individual data sets into a single, transient point cloud data set. 
4.2.2.2.5.2 Spatial and Temporal Interpolation 
The transient point cloud data set created by aligning the individual acquisition planes was 
imported into a separate custom ParaView state machine which interpolated the velocity 
values in both space and time. The spatial interpolation enclosed the point cloud in a 
rectangular prism volume with 0.5 mm x 0.5 mm x 0.5 mm resolution, and mapped velocity 
values from the point cloud data set to the volume with a Gaussian kernel. The Gaussian 
kernel considered 8 surrounding points from the point cloud data set for each mapped value 
in question, and points without 8 surrounding values were assigned a 0 velocity value. The 
enclosed rectangular prism volume was then resampled using a TCPC geometry 
unstructured mesh to remove all velocity values (almost entirely composed of velocity = 
0) outside the TCPC physical space. At this point, the spatially interpolated unstructured 
mesh included velocity values only for the discrete and irregular experimental time points 
at which PIV data was collected. The unstructured mesh data set was then linearly 
temporally interpolated to a regular time step size equal to 0.1 secs. Figure 4-13 provides 
a flow chart summary of the interpolation process. Verification of the interpolation process 




Figure 4-13: PIV velocity field interpolation process flow chart. The individual diagrams represent the 
aligned planes as a point cloud, the enclosed volume linear interpolation, and the final resampled data 
set (L to R). 
4.2.2.2.5.3 Hepatic Flow Distribution Calculation 
Hepatic flow distribution was determined by seeding the spatially and temporally 
interpolated velocity field with massless fluid particles using ParaViews ParticleTracer 
filter. Particle seeding took place at every data node on a cross-sectional IVC plane. 
Additional Lagrangian particles were added every 0.1 secs for either the cardiac or 
respiratory period of the experimental condition (depending on if the BH, FB, or EX 
condition were being analyzed). The Lagrangian particle identity, location, velocity, and 
time history were recorded for a total of 5 characteristic cycles (cardiac or respiratory). A 
custom MATLAB script then identified whether or not each particle passed through a 
cross-section LPA or RPA plane, or is still present in the TCPC domain yet to pass through 
either plane. The hepatic flow distribution was then calculated as the percent of particles 
passing through the LPA plane as a fraction of the total number of particles passing through 








4.2.2.2.5.4 Viscous Dissipation Term Calculation 
The fluid viscous dissipation term was calculated for each spatially and temporally 
interpolated velocity field using ParaView, according to Equation (4-9). 
  










































where 𝜑𝜑 is the viscous dissipation rate per unit volume normalized by dynamic viscosity 
and 𝑢𝑢 is the fluid velocity.  
This term was both time- and space-averaged for each condition according to the 
condition’s characteristic time scale (Table 4-8, 𝑇𝑇𝑜𝑜𝑎𝑎𝑖𝑖𝑎𝑎) to eliminate the effect of patient 
geometry size and time when comparing the effect of respiration, exercise, and pulsatility. 
Normalizing by dynamic viscosity does not affect the relationship between viscous 
dissipation term values because the experimental fluid was Newtonian. 
 For comparison between different experimental conditions, 𝜑𝜑 was also non-
dimensionalized to create an indexed viscous dissipation term, 𝑖𝑖𝜑𝜑. Equation (4-10) details 






where 𝐵𝐵𝐵𝐵𝐴𝐴 is the patient-specific body surface area and 𝑄𝑄 is the condition-specific average 
flow rate into the TCPC (sum of IVC and SVC flow). 
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4.2.2.3 Uncertainty Analysis 
Uncertainty exists in all measurement, and is possibly the most important thing to know 
about a measurement. All of the uncertainty analysis that follows is performed to produce 
a 95% confidence interval. 
4.2.2.3.1 Hemodynamic Uncertainty 
The total uncertainty in hemodynamic (pressure and flow) data collected was determined 
using the root-sum-squares (RSS) method [141]. The RSS method for uncertainty 






where 𝑢𝑢𝑚𝑚 is the combined measurement uncertainty, and 𝑢𝑢𝑘𝑘 is either the design-stage 
uncertainty, systematic uncertainty, or random uncertainty (𝐾𝐾 = 3). This measurement 
uncertainty was then propagated to other hemodynamic-based metrics (i.e. power loss) 





 𝑖𝑖 = 1, 2, … , 𝑖𝑖 (4-12) 
 









 Equation (4-12) computes a sensitivity index, 𝜃𝜃𝑚𝑚, where the hemodynamic-based 
metric, 𝑅𝑅, is a function of 𝑖𝑖 variables, 𝜕𝜕, which each have their own uncertainty, 𝑢𝑢?̅?𝑚𝑖𝑖. 
Equation (4-13) then uses the sensitivity index to weight the uncertainties of each variable 
contributing to the metric uncertainty. Note that the sensitivity index and the variable 
uncertainties are both evaluated at the variable mean value, as denoted by the over-bar. 
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 Design-stage uncertainty was assigned via the measurement device specifications 
discussed in section 4.1.2.1. Systematic uncertainty was assigned based on the presence of 
drift, if any, between control or baseline conditions within a data collection set. In general, 
no drift existed in hemodynamic measurement instruments. Random uncertainty was 
assigned a value of twice the standard deviation of repeated measurements of the value in 
question. Thus, all reported uncertainty values can be considered on a 95% confidence 
interval.  
4.2.2.3.2 Particle Image Velocimetry Uncertainty 
PIV measurement uncertainty was quantified following the method outlined by Raffel, et 
al [142]. Error measurements were taken from the steady flow versions of the patient-
specific conditions for each model. The total measurement uncertainty was divided into 3 
error forms: particle lag error, 𝜀𝜀𝑎𝑎, bias error, 𝜀𝜀𝑏𝑏, and random error, 𝜀𝜀𝑟𝑟. These individual 
error were calculated for a 95% confidence interval, and combined into a total error, 𝜀𝜀𝑇𝑇, 
using the same RSS method found in Equation (4-11). All errors were calculated for each 
velocity component (𝑉𝑉𝑚𝑚, 𝑉𝑉𝑦𝑦, and 𝑉𝑉𝑧𝑧), as both a velocity value and a percentage of the 
maximum velocity. 
CHOP11B errors were 0.022 m/s, 0.033 m/s, and 0.046 m/s in the 𝑉𝑉𝑚𝑚, 𝑉𝑉𝑦𝑦, and 𝑉𝑉𝑧𝑧 
directions, respectively. These errors correspond to a 1.08% to 11.59% velocity magnitude 
error range. CHOP235A errors were 0.05 m/s, 0.033 m/s, and 0.05 m/s in the 𝑉𝑉𝑚𝑚, 𝑉𝑉𝑦𝑦, and 
𝑉𝑉𝑧𝑧 directions, respectively. These errors correspond to a 2.44% to 14.49% velocity 




4.2.2.3.3 Hepatic Flow Distribution Uncertainty 
The uncertainty in hepatic flow distribution calculation was determined by the difference 
between the calculated hepatic flow distribution and subsequent HFD calculation with a 
modified velocity field. The modified velocity field was determined by adding or 
subtracting a random value to each velocity vector component from the original HFD field. 
The random value added or subtracted to each velocity vector component was sampled 
over an interval bounded by the positive and negative value of  the maximum uncertainty 
of that vector component from the particle image velocimetry uncertainty analysis found 
in section 4.2.2.3.2. For example, given an HFD value, x, for a given experimental 
condition with maximum PIV velocity uncertainties of UVx, UVy, and UVz, the velocity field 
which produces x, (Vx, Vy, and Vz) are changed to a new velocity field (Vx + rand(-UVx, 
UVx), Vy + rand(-UVy, UVy), Vz + rand(-UVz, UVz)). The new velocity field then produces a 
new HFD value, y, and the difference between the two HFD values (x-y) is set as the HFD 
uncertainty. 
4.2.2.3.4 Viscous Dissipation Term Uncertainty 
Viscous dissipation term confidence intervals were calculated by propagating the PIV 
uncertainties to the viscous dissipation term equations (Equation (4-9) and Equation 
(4-10)). The error propagation procedure followed was the same as that used in section 






5.1 In Vitro Fontan Circulation Model Verification 
The in vitro Fontan circulation model verification results stand to engender confidence in 
the circulation model’s ability to reproduce hemodynamics on the bench-top representative 
of in vivo values. The in vitro Fontan circulation model verification results include both 
flow waveform verification and TCPC model compliance verification. 
5.1.1 Flow Waveform Verification 
The results from comparing patient-specific and in vitro Fontan circulation model 
waveforms are summarized in Table 5-1. The table summarizes two metrics, a ratio of the 
average difference between the two waveforms to the time-averaged value of the two 
waveforms (𝜀𝜀𝑎𝑎𝑎𝑎𝑎𝑎) and a time-normalized root mean square (𝜀𝜀𝑟𝑟𝑚𝑚𝑟𝑟), for each model, 
condition, and vessel of the data collected. Details for each of these metrics are provided 
in Equation (4-2) and Equation (4-3). 
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Table 5-1: Time-averaged and RMS error metrics for each vessel waveform under each condition and 
both models tested 
Model Condition Vessel 𝜺𝜺𝒄𝒄𝒂𝒂𝒂𝒂(%) 𝜺𝜺𝒓𝒓𝒓𝒓𝒓𝒓 (mL/s2) 
CHOP11B 
BH 
IVC 10.7 20.34 
SVC 4.3 2.64 
LPA 8.2 9.45 
RPA 14.8 20.19 
FB 
IVC 11.2 7.51 
SVC 15.9 3.58 
LPA 9.8 4.53 
RPA 12.0 4.71 
EX 
IVC 5.7 28.78 
SVC 4.9 6.67 
LPA 6.6 15.73 
RPA 6.0 20.04 
CHOP235A 
BH 
IVC 7.8 15.97 
SVC 8.0 4.65 
LPA 5.2 2.96 
RPA 2.7 5.35 
FB 
IVC 5.5 4.40 
SVC 5.1 5.21 
LPA 6.4 2.82 
RPA 6.9 9.12 
EX 
IVC 9.7 19.83 
SVC 9.5 20.51 
LPA 6.3 6.17 
RPA 5.6 17.24 
 
 The greatest average difference between the patient-specific and the modeled 
curves occurred for the SVC of the CHOP11B patient-specific FB model at 15.9%. The 
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patient-specific and modelled waveforms for this vessel under this model and condition are 
shown in Figure 5-1. 
 
Figure 5-1: Flow rate verification for CHOP11B patient-specific FB SVC. The error bars represent a 
95% confidence interval. 
 Figure 5-2 shows the comparison for the vessel with the greatest time-normalized 
root mean square error – CHOP11B patient-specific EX IVC. This vessel flow rate time-
normalized root mean square value is 28.78 mL/s2, meaning that every second the 



























waveform is 28.78 mL/s (1.73 L/min). This value is 27.6% of the mean flow through the 
IVC under this experimental condition. 
 
Figure 5-2: Flow rate verification for CHOP11B patient-specific EX IVC. The error bars represent a 
95% confidence interval. 
5.1.2 TCPC Model Compliance Verification 
The results of verifying TCPC model compliance against patient-specific compliance 
values is broken into 3 categories: the result of patient-specific data analysis, the result of 
in vitro compliance testing, and the result of computational simulations. Patient-specific 
data analysis resulted in compliance target values for which the models were constructed 
to possess. In vitro compliance testing produced a pressure-volume relationship for a model 
of arbitrary wall thickness. Computational simulations resulted in an estimated model wall 
thickness to achieve patient-specific compliance, which was then verified through 



























5.1.2.1 Patient-Specific Data Analysis 
The results of the patient-specific pressure and volume data analysis described in section 
4.2.1.4.2 are summarized in Figure 5-3, Figure 5-4, and Table 5-2. 
 
Figure 5-3: CHOP11B BH patient-specific TCPC volume as a function of time 
 Figure 5-3 shows patient-specific TCPC volume over a cardiac cycle for patient 
CHOP11B during the BH condition, as found by integrating the TCPC inflow and outflow 
waveforms. The maximum change in volume over this time period is 2.11 mL with a 10% 
uncertainty assigned for all MRI measurements [140]. 
 Figure 5-4 shows the analysis result for patient CHOP235A, also during the breath-
held condition. CHOP235A’s mean volume is 109.57 mL, and CHOP11B’s mean volume 


















Figure 5-4: CHOP235A BH patient-specific TCPC volume as a function of time 
 Table 5-2 summarizes the patient-specific data analysis through displaying the 
pressure change values for an age-matched cohort, and ultimately the in vivo compliance 
targets. These in vivo compliance targets are the values for which the flexible TCPC models 
were designed. Given a material from the manufacture (BDC Labs) and a patient-specific 
geometry, the remaining variable to affect model compliance was the model wall thickness. 
Both in vitro compliance testing and computational simulation results informed this model 
wall thickness parameter. 
Table 5-2: In vivo compliance target values. The uncertainties provided are for a 95% confidence 
interval. 
Patient Number ΔV (mL) ∆P (mmHg) In Vivo Compliance (mL/mmHg) 

















5.1.2.2 In vitro Compliance Testing 
The in vitro compliance testing methods covered 2 different model tests: one of arbitrary 
thickness where the purpose of the testing was to acquire a pressure-volume relationship 
and characterize material properties (step 2, section 4.2.1.4.2); and one of a defined 
thickness where the purpose of testing was to verify if the computational simulations 
estimated the proper wall thickness (step 5, section 4.2.1.4.2). The computational 
simulation verification was performed by comparing the in vitro compliance value against 
the patient-specific in vivo compliance target found in Table 5-2. Each of these two tests 
were performed for each of the patients (CHOP11B and CHOP235A), resulting in four in 
vitro compliance test results.  
5.1.2.2.1 In vitro Compliance Testing to Characterize Material 
 In vitro compliance testing to characterize the material of a 1 ± 0.1 mm thick 
CHOP11B TCPC model found that 3.91  ± 0.08 mL (95% confidence interval) was the 
required injection that resulted in a 1.96 ± 0.01 mmHg change in pressure (P1 = 15.1 ± 0.11 
mmHg, P2 = 17.1 ± 0.11 mmHg). Repeating this injection volume 10 times resulted in a 
1.99 ± 0.1 mL/mmHg compliance. The 1 mm thick model was approximately 46% more 
compliant than the patient-specific target. 
In vitro compliance testing to characterize the material of a 1 ± 0.1 mm thick 
CHOP235A TCPC model found that 0.51 ± 0.01 mL (95% confidence interval) was the 
required injection that resulted in a 2.28 ± 0.08 mmHg change in pressure (P1 = 14.9 ± 0.14 
mmHg, P2 = 17.2 ± 0.17 mmHg). Repeating this injection volume 10 times resulted in a 
0.22 ± 0.03 mL/mmHg compliance. The 1 mm thick model was approximately 87% less 
compliant than the patient-specific target. 
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These results informed step 3 of the verification process: determining an effective 
Young’s modulus (Eeff) by reproducing the in vitro compliance test computationally. 
5.1.2.2.2 In vitro Compliance Testing to Verify Computational Wall Thickness Estimate 
In vitro compliance testing to verify the computational wall thickness of the 1.4 ± 
0.1 mm thick CHOP11B TCPC model found that 2.69 ± 0.09 mL was the required injection 
that resulted in a 1.97 ± 0.02 mm Hg change in pressure (P1 = 15.1 ± 0.21 mmHg, P2 = 
17.1 ± 0.20 mmHg). Repeating this injection volume 10 times resulted in a 1.37 ± 0.05 
mL/mmHg compliance. 
In vitro compliance testing to verify the computational wall thickness of the 0.38 ± 
0.1 mm thick CHOP235A TCPC model found that 3.61 ± 0.19 mL was the required 
injection that resulted in a 2.1 ± 0.2 mm Hg change in pressure (P1 = 15.0 ± 0.30 mmHg, 
P2 = 17.1 ± 0.17 mmHg). Repeating this injection volume 10 times resulted in a 1.70 ± 
0.12 mL/mmHg compliance. 
5.1.2.3 Computational simulations 
The first computational simulation step (step 3, section 4.2.1.4.2) sought the appropriate 
effective Young’s modulus to achieve the measured 1 mm thick in vitro TCPC compliance. 
The procedure measured the internal TCPC pressure after injecting 4 mL of fluid. Figure 






Figure 5-5: Computational analysis optimization showing effective Young's modulus as a function of 
the compliance. 
Though almost linear, the relationships between the Young’s modulus and 
compliance shown in Figure 5-5 for CHOP11B and CHOP235A are 𝐸𝐸𝑜𝑜𝑒𝑒𝑒𝑒 =  −12243𝐶𝐶 +
44866,𝑅𝑅2 = 0.9959 and 𝐸𝐸𝑜𝑜𝑒𝑒𝑒𝑒 =  −14587𝐶𝐶 + 23384,𝑅𝑅2 = 0.9969. Therefore, for 
CHOP11B to achieve a compliance of 1.99 mL/mmHg, the material’s effective Young’s 
modulus was calculated as 20500 Pa. For CHOP235A to achieve a compliance of 0.22 
mL/mmHg, its material’s effective Young’s modulus was calculated as 20100 Pa. 
With the resultant Young’s modulus, the computational simulation then targeted 
the appropriate TCPC wall thickness (δ) to match the in vivo 1.36 mL/mmHg and 1.73 
mL/mmHg target compliances from CHOP11B and CHOP235A, respectively (step 4, 
section 4.2.1.4.2; also see Table 5-2). The response curves are shown in Figure 5-6. Both 

















CHOP235A response curves are 𝛿𝛿 =  1.9𝐶𝐶−0.96,𝑅𝑅2 = 1 and 𝛿𝛿 =  0.4975𝐶𝐶−0.419,𝑅𝑅2 = 1, 
respectively. 
 
Figure 5-6: CHOP11B TCPC wall thickness vs compliance response surface 
The response curves estimate a 1.41 mm and 0.40 mm TCPC wall thickness for the 
CHOP11B and CHOP235A models in order to match their respective target in vivo 
compliance. The in vitro tests verified these as proper wall thickness estimates by matching 
an in vitro compliance test of a CHOP11B TCPC model with 1.41 mm wall thickness and 
a CHOP235A model with 0.4 mm wall thickness to the appropriate in vivo target listed in 
Table 5-2 (see section .5.1.2.2.2).  
Table 5-3 summarizes all TCPC model compliance verification results. The 
columns of the table correspond to the TCPC model compliance verification methods steps 
from section 4.2.1.4.2, which are repeated here for convenience: 























(2) An arbitrary-thickness (1mm) in vitro model was constructed and tested to 
determine its compliance. 
(3) The in vitro compliance test was reproduced computationally to determine an 
effective Young’s modulus (Eeff). 
(4) The model thickness was computationally iterated upon using the effective 
Young’s modulus to determine a target model wall thickness which would match 
the target compliance. 
(5) A new model with the computationally-derived target wall thickness was 
constructed and tested in vitro to determine if its compliance matched the target 
compliance from stage one. 
Table 5-3: TCPC model compliance verification results summary 











CHOP11B 1.36 ± 0.78 1.99 ± 0.1 20.5 1.41 1.38 ± 0.1 
CHOP235A 1.73 ± 0.99 0.22 ± 0.1 20.1 0.40 1.70 ± 0.1 
 
With the in vitro Fontan circulation model verification results established, the study 
now examines effect of respiration, exercise, and pulsatility on power loss, hepatic flow 
distribution, and energy dissipation rate in the following sections. 
5.2 Velocity Fields 
The particle image velocimetry acquisition and analysis methods (section 4.2.2.2) resulted 
in a time-resolved three-dimensional velocity field for the patient-specific, derived, and 
steady experimental conditions for each model. In all, 20 three-dimensional velocity fields 
were collected: 3 steady flow conditions, 3 patient-specific conditions, and 4 derived 
conditions for each of the two models. Each velocity field contains quantitative velocity 
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vector component data resolved for every 0.1 seconds (100 ms) on a 0.5mm x 0.5mm x 
0.5mm grid. Table 5-4 lists the experimental conditions for which three-dimensional 
velocity fields were collected. 
Table 5-4: List of experimental conditions for which three-dimensional velocity fields were collected 



























 One purpose of collecting this velocity field data is for comparison to subsequent 
computational fluid dynamics (CFD) simulations hoping to validate the use of fluid-
structure interaction (FSI) models. Any use of this study’s velocity field results to validate 
a CFD FSI methodology will use quantitative results and analyses specific to the 
computational methodology. Hence, no CFD-relevant quantitative results of the velocity 
field are presented here alone because the CFD FSI simulations have yet to be performed. 
All 20 sets of time-resolved three-dimensional velocity fields are saved on the CFM Lab 
servers for use in future CFD FSI studies.   
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 The time-resolved velocity fields are also necessary for this study because two of 
the three patient-relevant metrics (viscous dissipation and HFD) used in determining the 
effect of respiration, exercise, and pulsatility on Fontan hemodynamics are quantitative 
metrics derived directly from them. The third patient-relevant metric (power loss) is 
calculated entirely from static pressure and volumetric flow rate data. A qualitative 
assessment of each velocity field is useful in assigning reasoning for the changes in the 
power loss, viscous dissipation, and hepatic flow distribution metrics observed (sections 
6.3, 6.4, 6.5, and 6.6). Therefore, the effect of respiration, exercise, and pulsatility results 
presentations also include qualitative comparisons of the different velocity fields involved. 
 Fourteen of the 20 sets of time-resolved three-dimensional velocity fields and 
hemodynamic results are used to show the effect of respiration, exercise, and pulsatility on 
the power loss, viscous dissipation and hepatic flow distribution terms. The six velocity 
fields acquired, but not employed are: CHOP11B FB steady, CHOP11B half-peak EX 
steady, CHOP11B peak EX steady, CHOP235A FB steady, CHOP235A half-peak EX 
steady, and CHOP235A peak EX steady. These data were collected as CFD FSI validation 
data sets, but were not useful in determining trends due to respiration, exercise, or 
pulsatility. The effect of respiration comparison utilized the patient-specific BH and FB 
conditions for each model, which includes multiple changes in experimental conditions 
based on in vivo patient data. The steady BH and steady FB values only include changes in 
mean flow rate and IVC:SVC flow ratio between conditions, which would contaminate the 
findings. The steady FB, steady half-peak EX, and steady peak EX values were not 
included in the effect of exercise comparisons for similar reasons. In contrast, the effect of 
pulsatility comparisons included the steady BH condition because all 4 conditions included 
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in this comparison (steady BH, low pulsatile BH, patient-specific BH, and high pulsatile 
BH) had effectively equal condition parameters except for pulsatility (see Appendix 11.5, 
Table 11-7). Appendix 11.9 includes a comprehensive results summary of all 20 
experimental conditions, for completeness. 
5.3 Effect of Respiration 
The effect of respiration on Fontan hemodynamics is shown by comparing the BH and FB 
experimental conditions for both the CHOP11B and CHOP235A models. Patient-relevant 
metrics are derived from both the time-resolved three-dimensional velocity fields and the 
pressure and flow rate data for each model under these conditions. The CHOP11B BH 
patient-specific and FB patient-specific velocity fields are shown in Video 5-1 and Video 
5-2 for qualitative comparison, respectively. 
 
Video 5-1: CHOP11B BH patient-specific velocity fields. The black 3-component velocity vectors show 
velocity direction. The color provides the velocity magnitude. The upper right panel is a coronal view 





Video 5-2: CHOP11B FB patient-specific velocity fields. The black 3-component velocity vectors show 
velocity direction. The color provides the velocity magnitude. The upper right panel is a coronal view 
of the Fontan model with all planes present. 
Both the CHOP11B BH patient-specific and CHOP11B FB patient-specific 
velocity fields show a pulsatile nature with vector magnitude and direction changing most 
dramatically with the cardiac cycle frequency. Both exhibit peak velocity values located in 
the LPA of approximately the same magnitude (~0.6 m/s). Figure 5-7 shows the qualitative 
IVC and SVC inflow stream collision line (red) during minimum IVC flow rates for the 
CHOP11B BH and CHO11B FB cases at the 130mm plane. Observing the video shows 
this line is relatively stable for all time points between both cases. In general, the flow 




Figure 5-7: CHOP11B patient-specific BH and patient-specific FB velocity fields at the 130mm plane 
and minimum IVC flow rate time points. The black 3-component velocity vectors show velocity 
direction. The color provides the velocity magnitude. 
However, there is one significant qualitative difference between the CHOP11B BH 
and CHOP11B FB velocity fields. Unlike the CHOP11B BH condition, the CHOP11B FB 
condition experiences peak and near-peak velocities in the IVC and Fontan connection 
regions at some time points. Figure 5-8 shows the velocity field for each case during their 
respective peak IVC inflow rate time points. 
 
Figure 5-8: CHOP11B patient-specific BH and patient-specific FB velocity fields at the 130mm plane 
and peak IVC flow rate time points. The black 3-component velocity vectors show velocity direction. 
The color provides the velocity magnitude. 





Video 5-3: CHOP235A BH patient-specific velocity fields. The black 3-component velocity vectors 
show velocity direction. The color provides the velocity magnitude. The upper right panel is a coronal 
view of the Fontan model with all planes present. 
 
Video 5-4: CHOP235A FB patient-specific velocity fields. The black 3-component velocity vectors show 
velocity direction. The color provides the velocity magnitude. The upper right panel is a coronal view 
of the Fontan model with all planes present. 
Qualitative comparison of the CHOP235A BH patient-specific and CHOP235A FB 
patient-specific velocity fields show more differences between them than the CHOP11B 
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comparison case. Though both CHOP235A velocity fields show peak velocities located in 
the LPA, the most noticeable difference is the higher SVC inflow velocity in the FB case. 
The higher SVC inflow velocity magnitude raises the SVC inflow momentum in 
comparison to the IVC inflow. The differences in the collision line location and shape 
throughout time for the FB case, as shown in Figure 5-9 and Figure 5-10, is also evidence 
of the higher unsteadiness the FB flow field experiences.  
 
Figure 5-9: CHOP235A patient-specific BH and patient-specific FB velocity fields at the 89mm plane 
and minimum IVC flow rate time points. The black 3-component velocity vectors show velocity 
direction. The color provides the velocity magnitude. 
 
 
Figure 5-10: CHOP235A patient-specific BH and patient-specific FB velocity fields at the 89mm plane 
and peak IVC flow rate time points. The black 3-component velocity vectors show velocity direction. 
The color provides the velocity magnitude. 
Sections 5.3.1, 5.3.2, and 5.3.3 provide further insight on the effect of respiration 
on Fontan hemodynamics. 
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5.3.1 Effect of Respiration on Power Loss 
Section 4.2.2.1 and Equation (4-6) provide the specifics for a power loss metric which is 
related to how efficiently fluid flows through the Fontan models. Table 5-5 summarizes 
two power loss metrics, 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  and 𝑖𝑖𝑃𝑃𝑖𝑖, calculated for each model’s BH and FB 
experimental conditions. Apparent power loss and indexed power loss calculation details 
are provided by Equations (4-6) and (4-7), respectively.  
Table 5-5: Power loss values for each model at each BH and FB experimental condition 
Model Condition ?̇?𝑬𝒄𝒄𝒓𝒓𝒓𝒓 (mW) 𝒊𝒊𝑴𝑴𝒊𝒊 (x106) 
CHOP11B BH Patient-Specific 16.3 ± 5.9 290.3 ± 128.3 FB Patient-Specific 55.6 ± 9.7 418.6 ± 128.2 
CHOP235A BH Patient-Specific 18.0 ± 4.6 374.0 ± 111.1 FB Patient-Specific 33.8 ± 14.9 170.6 ± 79.6 
 
 The greatest apparent power loss appears for each model during the FB patient-
specific case at 55.6 ± 9.7 mW (CHOP11B) and 33.8 ± 14.9 mW (CHOP235A). Both 
models also show that FB apparent power losses are greater than BH apparent power losses. 
Figure 5-11 and Figure 5-12 compare the patient-specific BH and FB indexed power loss 




Figure 5-11: CHOP11B patient-specific indexed power loss values comparing BH and FB conditions. 



















Figure 5-12: CHOP235A patient-specific indexed power loss values comparing BH and FB conditions. 
* denotes the patient-specific conditions. The error bars represent a 95% confidence interval. 
5.3.2 Effect of Respiration on Viscous Dissipation 
A viscous dissipation term was calculated for each model’s BH and FB conditions, as 
outlined in section 4.2.2.2.5.4.. Table 5-6 summarizes 𝜑𝜑 and the indexed viscous 
dissipation term, 𝑖𝑖𝜑𝜑, for respiration effects. Equation (4-9) and Equation (4-10) detail the 
viscous dissipation  term and the indexed viscous dissipation term. 
Table 5-6: The effect of respiration on viscous dissipation terms 
Model Condition 𝝋𝝋 (1/s2) 𝒊𝒊𝝋𝝋 (x1012) 
CHOP11B BH Patient-Specific 6272.8 ± 280.6 10.66 ± 1.21 FB Patient-Specific 5586.53 ± 423.3 5.95 ± 0.77 


















Figure 5-13 and Figure 5-14 compare the indexed viscous dissipation  term between 
the BH and FB patient-specific conditions for each model. 
 
Figure 5-13: CHOP11B comparison between BH and FB patient-specific viscous dissipation term 




















Figure 5-14: CHOP235A comparison between BH and FB patient-specific viscous dissipation term 
values. * denotes the patient-specific conditions. The error bars represent a 95% confidence interval. 
5.3.3 Effect of Respiration on Hepatic Flow Distribution 
Hepatic flow distribution (HFD) was calculated for each model’s BH and FB conditions, 
as outlined in section4.2.2.2.5.3. Table 5-7 summarizes the effect of respiration on HFD.  
Table 5-7: Effect of respiration on hepatic flow distribution 
Model Condition HFD (%LPA) 
CHOP11B BH Patient-Specific 61.06 ± 19.6 FB Patient-Specific 49.78 ± 12.0 
CHOP235A BH Patient-Specific 54.96 ± 30.0 FB Patient-Specific 42.60 ± 35.9 
 
Figure 5-15 and Figure 5-16 compare the HFD between the BH and FB patient-






















Figure 5-15: CHOP11B comparison between BH and FB patient-specific HFD values. * denotes the 
patient-specific conditions. The error bars represent a 95% confidence interval. 
 
 
Figure 5-16: CHOP235A comparison between BH and FB patient-specific HFD values. * denotes the 

























































5.4 Effect of Exercise 
The effect of exercise on Fontan hemodynamics is shown by comparing the patient-specific 
FB, patient-specific peak EX, and pulsatile half-peak EX experimental conditions for both 
the CHOP11B and CHOP235A models. Patient-relevant metrics are derived from both the 
time-resolved three-dimensional velocity fields and the pressure and flow rate data for each 
model under these conditions. The CHOP11B velocity fields are shown in Video 5-2 
(section 5.3), Video 5-6, and Video 5-5 for qualitative comparison, respectively. 
 
Video 5-5: CHOP11B pulsatile half-peak EX velocity fields. The black 3-component velocity vectors 
show velocity direction. The color provides the velocity magnitude. The upper right panel is a coronal 




Video 5-6: CHOP11B patient-specific peak EX velocity fields. The black 3-component velocity vectors 
show velocity direction. The color provides the velocity magnitude. The upper right panel is a coronal 
view of the Fontan model with all planes present. 
 Qualitatively comparing the CHOP11B patient-specific FB, pulsatile half-peak EX, 
and patient-specific peak EX velocity fields show differences between the velocity fields. 
The collision line location comparison between Figure 5-17 and Figure 5-18 suggests an 
increase in velocity field unsteadiness from the patient-specific FB case to the pulsatile 
half-peak EX case, and a subsequent increase in unsteadiness from the pulsatile half-peak 
EX case to the patient-specific peak EX case. Video observation also appears to show more 
rapid velocity changes during the EX conditions than during the FB condition; a 
comparison also suggesting higher unsteadiness during the EX conditions. Velocity 
magnitude comparisons should be conducted carefully as the color bars differ for each 
velocity field. The patient-specific FB and pulsatile half-peak EX conditions have similar 
minimum velocity magnitudes at the inlets and at the Fontan connection (Figure 5-17), 
with higher patient-specific peak EX condition velocity values. The peak IVC flow rate 
time point reveals increasing velocity magnitude at the flow inlets and Fontan connection 
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on the 130mm plane from the patient-specific FB condition to the pulsatile half-peak EX 
condition. This velocity magnitude also increases from the pulsatile half-peak EX 
condition to the patient-specific peak EX condition. 
 
Figure 5-17: CHOP11B patient-specific FB, pulsatile half-peak EX, and patient-specific EX velocity 
fields at the 130mm plane and minimum IVC flow rate time points. Note the different color bars for 
each velocity field. The black 3-component velocity vectors show velocity direction. The color provides 





Figure 5-18: CHOP11B patient-specific FB, pulsatile half-peak EX, and patient-specific EX velocity 
fields at the 130mm plane and peak IVC flow rate time points. Note the different color bars for each 
velocity field. The black 3-component velocity vectors show velocity direction. The color provides the 
velocity magnitude. 
The CHOP235A patient-specific FB, patient-specific peak EX, and pulsatile half-
peak EX velocity fields are shown in Video 5-4 (section 5.3), Video 5-7, and Video 5-8 for 




Video 5-7: CHOP235A patient-specific peak EX velocity fields. The black 3-component velocity vectors 
show velocity direction. The color provides the velocity magnitude. The upper right panel is a coronal 
view of the Fontan model with all planes present. 
 
Video 5-8: CHOP235A pulsatile half-peak EX velocity fields. The black 3-component velocity vectors 
show velocity direction. The color provides the velocity magnitude. The upper right panel is a coronal 
view of the Fontan model with all planes present. 
Qualitatively comparing the CHOP235A patient-specific FB, pulsatile half-peak 
EX, and patient-specific peak EX velocity fields shows more similarity between the 
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velocity fields than is present in the CHOP11B cases. The collision line comparison 
between Figure 5-19 and Figure 5-20 shows only slight change in shape and location 
between the minimum and maximum IVC flow rate time points. This qualitative finding 
suggests less overall unsteadiness for the CHOP235A exercise comparison conditions 
when compared to the CHOP11B exercise conditions. Video observation, though, shows 
that pulsatility is clearly present. Comparing overall velocity magnitudes between 
conditions shows very little change. This is not surprising, as the change in some 
experimental condition parameters (mean inflow rate and IVC pulsatility) between the 
CHOP235A patient-specific FB, pulsatile half-peak EX, and patient-specific peak EX 
conditions is less than the change in the same parameters for the CHOP11B patient-specific 
FB, pulsatile half-peak EX, and patient-specific peak EX conditions. (see Table 11-7). For 
example, CHOP235A mean inflow rate changes from 4.96 L/min, to 6.20 L/min, and 7.08 
L/min from patient-specific FB, to pulsatile half-peak EX, and patient-specific peak EX. 
CHOP11B mean inflow rate changes from 4.04 L/min, to 5.95 L/min, and 7.90 L/min from 
patient-specific FB, to pulsatile half-peak EX, and patient-specific peak EX. Sections 5.4.1, 






Figure 5-19: CHOP235A patient-specific FB, pulsatile half-peak EX, and patient-specific EX velocity 
fields at the 89mm plane and minimum IVC flow rate time points. The black 3-component velocity 





Figure 5-20: CHOP235A patient-specific FB, pulsatile half-peak EX, and patient-specific EX velocity 
fields at the 89mm plane and peak IVC flow rate time points. The black 3-component velocity vectors 
show velocity direction. The color provides the velocity magnitude. 
5.4.1 Effect of Exercise on Power Loss 
Comparison of 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  and 𝑖𝑖𝑃𝑃𝑖𝑖 values for the patient-specific FB, patient-specific peak EX, 
and pulsatile half-peak EX conditions demonstrate the effect of exercise on power loss. 
Table 5-8 summarizes these values.  
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Table 5-8: Power loss values comparing FB and EX experimental conditions 
Model Condition ?̇?𝑬𝒄𝒄𝒓𝒓𝒓𝒓 (mW) 𝒊𝒊𝑴𝑴𝒊𝒊 (x106) 
CHOP11B 
FB Patient-Specific 55.6 ± 9.7 418.6 ± 128.2 
EX Half-Peak Pulsatile 96.6 ± 8.3 268.1 ± 70.9 Peak Patient-Specific 278.5 ± 5.7 329.4 ± 82.6 
CHOP235A 
FB Patient-Specific 33.8 ± 14.9 170.6 ± 79.6 
EX Half-Peak Pulsatile 71.5 ± 9.8 185.3 ± 37.8 Peak Patient-Specific 97.9 ± 17.1 170.6 ± 39.4 
 
 Consistent trends between both models include increasing apparent power loss 
from the patient-specific FB condition to the pulsatile half-peak EX condition, and a 
continued increase to the patient-specific peak EX condition. The same trend does not hold 
for indexed power loss values, which are shown further in Figure 5-21 and Figure 5-22. 
 
Figure 5-21: The effect of exercise on indexed power loss values for CHOP11B. The * denotes the 



















Figure 5-22: The effect of exercise on indexed power loss values for CHOP235A. The * denotes the 
patient-specific conditions. The error bars represent a 95% confidence interval. 
5.4.2 Effect of Exercise on Viscous Dissipation 
Table 5-9 summarizes the effect of exercise on viscous dissipation. 
Table 5-9: The effect of exercise on viscous dissipation terms 
Model Condition 𝝋𝝋 (1/s2) 𝒊𝒊𝝋𝝋 (x1012) 
CHOP11B 
FB Patient-Specific 5586.53 ± 423.3 5.95 ± 0.77 
EX Half-Peak Pulsatile 18850.3 ± 44.5 9.26 ± 0.97 Peak Patient-Specific 33359.0 ± 527.2 9.30 ± 0.98 
CHOP235A 
FB Patient-Specific 533.6 ± 9.0 0.41 ± 0.04 
EX Half-Peak Pulsatile 742.4 ± 7.9 0.37 ± 0.04 Peak Patient-Specific 807.9 ± 7.2 0.31 ± 0.03 
 
Figure 5-23 and Figure 5-24 show the effect of exercise on indexed viscous 


















Figure 5-23: The effect of exercise on indexed viscous dissipation for CHOP11B. * denotes the patient-



















Figure 5-24: The effect of exercise on indexed viscous dissipation for CHOP235A. * denotes the patient-
specific conditions. The error bars represent a 95% confidence interval. 
5.4.3 Effect of Exercise on Hepatic Flow Distribution 
Figure 5-25 and Figure 5-26 compare the HFD between the FB and EX experimental 
conditions for each model, which outlines the effect of exercise. Table 5-10 summarizes 
the effect of exercise on hepatic flow distribution. 
Table 5-10: Effect of exercise on hepatic flow distribution 
Model Condition HFD (%LPA) 
CHOP11B 
FB Patient-Specific 49.78 ± 11.9 
EX Half-Peak Pulsatile 45.45 ± 2.0 Peak Patient-Specific 58.08 ± 5.3 
CHOP235A 
FB Patient-Specific 40.60 ± 35.9 























Figure 5-25: Effect of exercise on HFD for CHOP11B. * denotes the patient-specific conditions. The 




















Figure 5-26: Effect of exercise on HFD for CHOP235A. * denotes the patient-specific conditions. The 
error bars represent a 95% confidence interval. 
5.5 Effect of Pulsatility 
The effect of pulsatility on Fontan hemodynamics is shown by comparing the BH steady, 
BH low pulsatility, BH patient-specific, and BH high pulsatility experimental conditions 
for both the CHOP11B and CHOP235A models. Metrics for each model are derived, in 
part, from the time-resolved three-dimensional velocity fields calculated from stereo PIV 
data. The CHOP11B velocity fields are shown in Figure 5-27, Video 5-9, Video 5-1 






















Figure 5-27: CHOP11B BH steady flow velocity fields denoted with velocity vectors and colored by 
velocity magnitude. The black 3-component velocity vectors show velocity direction. The color 
provides the velocity magnitude. The upper right panel is a coronal view of the Fontan model with all 
planes present. 
 
Video 5-9: CHOP11B BH low pulsatility velocity fields. The black 3-component velocity vectors show 
velocity direction. The color provides the velocity magnitude. The upper right panel is a coronal view 




Video 5-10: CHOP11B BH high pulsatility velocity fields. The black 3-component velocity vectors show 
velocity direction. The color provides the velocity magnitude. The upper right panel is a coronal view 
of the Fontan model with all planes present. 
 
Comparing the CHOP11B BH steady, CHOP11B BH low pulsatility, CHOP11B 
BH patient-specific, and CHOP11B BH high pulsatility velocity fields, little variation 
between the cases exists. The most prominent qualitative observation made is regarding 
the IVC-SVC collision line for the high pulsatility condition. Figure 5-28 and Figure 5-29 
show the change in the shape of the line between the minimum and maximum peak IVC 
flow rate time points. This observation suggests that the high pulsatility case experiences 
the most unsteadiness at the center of the Fontan connection. The velocity magnitudes of 
all the conditions are very similar, with Figure 5-28 and Figure 5-29 showing the high 
pulsatility case as having greater velocity magnitude than the other cases as the IVC flow 
progresses into the center of the Fontan connection. Video observation highlights that the 




Figure 5-28: CHOP11B steady BH, low pulsatility BH, patient-specific BH, and high pulsatility BH 
velocity fields at the 130mm plane and minimum IVC flow rate time points. The black 3-component 





Figure 5-29: CHOP11B steady BH, low pulsatility BH, patient-specific BH, and high pulsatility BH 
velocity fields at the130mm plane and peak IVC flow rate time points. The black 3-component velocity 
vectors show velocity direction. The color provides the velocity magnitude. 
 
The CHOP235A velocity fields are shown in Figure 5-30, Video 5-11, Video 5-3 





Figure 5-30: CHOP235A BH steady flow velocity fields denoted with velocity vectors and colored by 
velocity magnitude. The black 3-component velocity vectors show velocity direction. The color 
provides the velocity magnitude. The upper right panel is a coronal view of the Fontan model with all 
planes present. 
 
Video 5-11: CHOP235A BH low pulsatility velocity fields. The black 3-component velocity vectors 
show velocity direction. The color provides the velocity magnitude. The upper right panel is a coronal 




Video 5-12: CHOP235A BH high pulsatility velocity fields. The black 3-component velocity vectors 
show velocity direction. The color provides the velocity magnitude. 
There appears no discernable qualitative difference between the IVC-SVC collision 
line of the CHOP235A cases shown in Figure 5-31 and Figure 5-32. In fact, when 
comparing the CHOP235A BH steady, CHOP235A BH low pulsatility, CHOP235A BH 
patient-specific, and CHOP235A BH high pulsatility velocity fields there is very little 
difference between any of them. This is in contrast to the CHOP11B cases, which see 
significant qualitative differences in the IVC-SVC collision line. This stands to reason, as 
the CHOP235A model compliance was greater, allowing for more pulsatile fluctuations to 
be absorbed by the model wall and reducing the pulsatility effect on the flow field. Table 
11-7, a summary of the comprehensive experimental condition metrics, also shows that the 
IVC pulsatility range for the CHOP11B cases (0-57.5%) is greater than the IVC pulsatility 
range for the CHOP235A cases (0-38.6%). These differences also contribute to the lack of 
unsteadiness of the CHOP235A cases compared to the CHOP11B cases. Sections 5.5.1, 
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Figure 5-31: CHOP235A steady BH, low pulsatility BH, patient-specific BH, and high pulsatility BH 
velocity fields at the 89mm plane and minimum IVC flow rate time points. The black 3-component 





Figure 5-32: CHOP235A steady BH, low pulsatility BH, patient-specific BH, and high pulsatility BH 
velocity fields at the 89mm plane and peak IVC flow rate time points. The black 3-component velocity 
vectors show velocity direction. The color provides the velocity magnitude. 
5.5.1 Effect of Pulsatility on Power Loss 
Comparison of 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  and 𝑖𝑖𝑃𝑃𝑖𝑖 values for all of the BH experimental conditions illustrates 
the effect of pulsatility on power loss. Table 5-11 summarizes these values.  
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Table 5-11: Power loss values for all BH experimental conditions 
Model Condition ?̇?𝑬𝒄𝒄𝒓𝒓𝒓𝒓 (mW) 𝒊𝒊𝑴𝑴𝒊𝒊 (x106) 
CHOP11B BH 
Steady 6.9 ± 3.0 114.7 ± 57.3 
Low Pulsatility 7.2 ± 3.0 125.0 ± 60.8 
Patient-Specific 16.3 ± 5.9 290.3 ± 128.3 
High Pulsatility 20.6 ± 7.5 360.8 ± 159.7 
CHOP235A BH 
Steady 8.8 ± 3.2 182.2 ± 71.8 
Low Pulsatility 9.9 ± 4.9 206.2 ± 107.9 
Patient-Specific 18.0 ± 4.6 374.0 ± 111.1 
High Pulsatility 26.9 ± 7.0 501.5 ± 150.8 
 
 Apparent power loss increases with pulsatility for both models, as does indexed 
power loss. The indexed power loss values are further shown in Figure 5-33 and Figure 
5-34. 
 
Figure 5-33: The effect of pulsatility on indexed power loss values for CHOP11B. * denotes the patient-





















Figure 5-34: The effect of pulsatility on indexed power loss values for CHOP235A. * denotes the 
patient-specific condition. The error bars represent a 95% confidence interval. 
5.5.2 Effect of Pulsatility on Viscous Dissipation 
Table 5-12 summarizes the effect of pulsatility on viscous dissipation. 
Table 5-12: The effect of pulsatility on viscous dissipation terms 
Model Condition 𝝋𝝋 (1/s2) 𝒊𝒊𝝋𝝋 (x1012) 
CHOP11B BH 
Steady 7442.6 ± 143.9 12.08 ± 1.28 
Low Pulsatility 5535.3 ± 48.9 9.28 ± 0.97 
Patient-Specific 6272.8 ± 280.6 10.66 ± 1.21 
High Pulsatility 7392.0 ± 347.3 12.43 ± 1.42 
CHOP235A BH 
Steady 1225.4 ± 36.8 2.42 ± 0.26 
Low Pulsatility 743.6 ± 108.6 1.48 ± 0.26 
Patient-Specific 756.3 ± 28.4 1.49 ± 0.17 
High Pulsatility 789.0 ± 17.6 1.45 ± 0.16 
 
Figure 5-35 and Figure 5-36 show the effect of exercise on indexed viscous 





















Figure 5-35: The effect of pulsatility on indexed viscous dissipation for CHOP11B. * denotes the 























Figure 5-36: The effect of pulsatility on indexed viscous dissipation for CHOP235A. * denotes the 
patient-specific condition. The error bars represent a 95% confidence interval. 
 
5.5.3 Effect of Pulsatility on Hepatic Flow Distribution 
Figure 5-37 and Figure 5-38 compare the HFD between all BH  experimental conditions 
for CHOP11B and CHOP235A, respectively. This comparison outlines the effect of 



















Table 5-13: The effect of flow pulsatility on hepatic flow distribution 
Model Condition HFD (%LPA) 
CHOP11B BH 
Steady 53.85 ± 8.9 
Low Pulsatility 71.94 ± 12.0 
Patient-Specific 61.06 ± 19.6 
High Pulsatility 56.49 ± 6.6 
CHOP235A BH 
Steady 40.0 ± 25.7 
Low Pulsatility 58.93 ± 41.1 
Patient-Specific 54.96 ± 30.0 
High Pulsatility 63.86 ± 36.0 
 
 
Figure 5-37: The effect of pulsatility on HFD for CHOP11B. * denotes the patient-specific condition. 
























Figure 5-38: The effect of pulsatility on HFD for CHOP235A. * denotes the patient-specific condition. 





















6.1 In Vitro Fontan Circulation Model Verification 
The in vitro Fontan circulation model results presented in section 5.1 show good agreement 
between the in vivo flow rates and the modeled flow rates for each condition tested, as well 
as matching of each model’s compliance to its respective in vivo target compliance. The 
flow rate waveform agreement in section 5.1.1 is characterized using two metrics: a ratio 
of the average difference between the two waveforms to the time-averaged value of the 
two waveforms (𝜀𝜀𝑎𝑎𝑎𝑎𝑎𝑎) and a time-normalized root mean square (𝜀𝜀𝑟𝑟𝑚𝑚𝑟𝑟) only to fully 
characterize the error. The ratio of the average difference between the two waveforms to 
the time-averaged value of the two waveforms (𝜀𝜀𝑎𝑎𝑎𝑎𝑎𝑎) provides time-independent 
information that can be used to compare error between conditions, but does not characterize 
the complete set of possible differences between two waveforms. For example, consider a 
1 L/min steady flow rate waveform compared to a pulsatile flow rate waveform (i.e. sine 
curve) with a time-average value equal to 1 L/min. The average difference ratio value 
(𝜀𝜀𝑎𝑎𝑎𝑎𝑎𝑎) between the two waveforms is 0, but the two waveforms are clearly different. In 
summary, the average difference ratio value (𝜀𝜀𝑎𝑎𝑎𝑎𝑎𝑎) characterizes the bias between the two 
waveforms, and the time-normalized root mean square (𝜀𝜀𝑟𝑟𝑚𝑚𝑟𝑟) quantifies how accurately 
the in vitro Fontan circulation model mimics patient-specific flow rate waveforms. The 
time-independent nature of 𝜀𝜀𝑟𝑟𝑚𝑚𝑟𝑟 maintains its ability for cross-condition comparison. 
 No one vessel consistently demonstrated a lower average error than any other vessel 
across multiple experimental conditions, and there was no discernable pattern when 
examining the errors between conditions. In general, the EX conditions for both models 
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had higher 𝜀𝜀𝑟𝑟𝑚𝑚𝑟𝑟 values, but the highest 𝜀𝜀𝑎𝑎𝑎𝑎𝑎𝑎values are found for the CHOP11B FB 
condition. Overall, the 𝜀𝜀𝑎𝑎𝑎𝑎𝑎𝑎 values ranged from 2.7% for the CHOP235A BH RPA flow 
waveform to 15.9% for the CHOP11B FB SVC flow waveform. The 𝜀𝜀𝑟𝑟𝑚𝑚𝑟𝑟 values ranged 
from 2.64 mL/s2 for the CHOP11B BH SVC flow waveform to 28.78 mL/s2 for the 
CHOP11B EX IVC flow waveform. Comparing the two models shows slightly better flow 
waveform agreement for the CHOP235A model than for the CHOP11B model. The 
average 𝜀𝜀𝑎𝑎𝑎𝑎𝑎𝑎 and 𝜀𝜀𝑟𝑟𝑚𝑚𝑟𝑟 values for CHOP235A across all vessels at all conditions was 6.6% 
and 9.52 mL/s2, respectively. The average 𝜀𝜀𝑎𝑎𝑎𝑎𝑎𝑎 and 𝜀𝜀𝑟𝑟𝑚𝑚𝑟𝑟 values for CHOP11B across all 
vessels at all conditions was 9.2% and 11.40 mL/s2, respectively.  
Examination of the error results from the flow waveform verification suggests some 
insights. The fact that EX conditions had generally higher 𝜀𝜀𝑟𝑟𝑚𝑚𝑟𝑟 values and that the EX 
conditions also had the highest flow pulsatilities suggests that 𝜀𝜀𝑟𝑟𝑚𝑚𝑟𝑟 scales with flow 
pulsatility. However, the FB conditions had the next highest pulsatility values, but have 
generally lower 𝜀𝜀𝑟𝑟𝑚𝑚𝑟𝑟 than BH conditions, so the relationship of 𝜀𝜀𝑟𝑟𝑚𝑚𝑟𝑟 to flow condition 
must be multi-factorial. Overall, the observed errors are comparable to the 5% error 
reported for the only similar mock circulatory system reported in the literature [27]. The 
details of this system are provided in the subsequent paragraphs. 
 The TCPC model compliance verification results found in section 5.1.2 
demonstrated good agreement between the in vivo patient-specific target and in vitro model 
compliance with a computationally-derived wall thickness. The TCPC model verification 
process included numerous steps out of necessity in order to properly verify the compliance 
value. The calculated in vivo target compliance values (Table 5-2), that were subsequently 
successfully matched by the in vitro TCPC models, have substantially higher compliance 
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than the only other known in vitro flexible TCPC model from Vukicevic et al [38]. Table 
6-1 shows the compliance values for the TCPC models in this study compared to the study 
from Vukicevic et al. 
Table 6-1: Compliance value comparison between this thesis and the only other known in vitro Fontan 
study that employed a patient-specific flexible TCPC model 
Study Model Compliance (mL/mmHg) 
Thesis CHOP11B 1.36 ± 0.78 
Thesis CHOP235A 1.73 ± 0.99 
Vukicevic et al -- 0.28 
 
The only similar mock circulatory system that includes a patient-specific flexible 
TCPC model is the product of the Modeling of Congenital Hearts Alliance (MOCHA), a 
multi-institutional collaboration including experimental modeling, computational 
modeling, and clinical research experts. The system MOCHA employs is a physical 
lumped parameter model with 4 major branches of the circulatory system: the upper body, 




Figure 6-1: Schematic representation of MOCHA in vitro Fontan circulation model [38]. 
 The MOCHA in vitro Fontan circulation model employs a Berlin Heart (Berlin 
Heart GmbH, Berlin, Germany) as the driving pressure to create an aortic waveform. The 
aortic waveform is then modified via resistance (R) and compliance (C) elements to create 
the necessary patient specific waveforms at the TCPC test section. Inertance (L) is shown 
in the schematic, but is affected only by the total mass of the modeling fluid. Flow changes 
due to thoracic pressure (Pth) are supplied via a pneumatic pump to the IVC, and are 
independent of the aortic flow provided by the Berlin Heart. 
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To date, studies from the MOCHA group’s in vitro Fontan circulation model 
employed either rigid-walled TCPC models, or flexible TCPC models with arbitrary 
material properties [27,32,37,38]. The most recent study by Vukicevic et al sought to 
control retrograde flow in Fontan patients due to respiration effects with a one-way 
bioprosthetic valve [38]. The study employed a patient-specific flexible TCPC model, but 
the material properties / compliance value of the model is only stated, never justified: 
“The TCPC test section is a patient-specific geometry based on MR images 
and realized using a thin-walled (1 ± 0.2 mm), compliant (C ~ 0.28 ml/mm 
Hg) silicone phantom (Shelley Medical Imaging, London, Ontario).” 
Without proper TCPC model compliance, the MOCHA group mock circulatory 
system matches pressure and flow waveforms by adjusting compliance values at other 
locations throughout the Fontan circulation model (i.e. Clb, Cliver). This allows the study 
to maintain TCPC model inlet and outlet pressure and flow waveform accuracy (global 
metrics), but does not guarantee an accurate internal TCPC flow field. The TCPC model 
verification methods outlined in the current thesis are an effort to establish both global and 
local flow accuracy. 
 The in vivo patient-specific TCPC volume vs time curves shown in Figure 5-3 and 
Figure 5-4 help to place the importance of proper TCPC compliance modeling in context. 
Examination of these figures reveals the average TCPC volume change over one cardiac 
cycle to be 2.4 mL. Based on the two available patient geometries, the relative range of this 
volume change is between 2.5 and 3.5% of the total TCPC volume. With such small 
dynamic change over a cardiac cycle, one might not expect large variations in the metrics 
calculated between steady and pulsatile flow conditions. Yet, large variations were found 
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to exist. Table 5-11, for example, shows a 136% change in apparent power loss and a 153% 
change in indexed power loss between the CHOP11B BH steady and CHOP11B BH 
patient-specific conditions. These large changes in flow-based metrics without significant 
TCPC deformation suggests that properly modeled compliance affects TCPC fluid 
dynamics more drastically than intuitive. 
This fluid dynamic effect under different physiological and derived experimental 
conditions is the subject of discussion in sections 6.3, 6.4, and 6.5. These sections each 
show significant trends, which can only be considered as reliable as the accuracy of the in 
vitro Fontan circulation model employed. Ultimately, the addition of a compliance-verified 
flexible TCPC model to an in vitro Fontan circulation system is a novel step toward more 
accurate in vitro modeling. Though the TCPC does not deform a large percentage over a 
cardiac or respiratory cycle, the fluid dynamic effects are significant, and patient-relevant 
metrics are notably altered. 
The potential impact of properly in vitro Fontan circulation modeling on the results 
found from studying the effects of respiration, exercise, and pulsatility on Fontan 
hemodynamics cannot be understated. Any limitations or inaccuracies found in the in vitro 
Fontan circulation model will be propagated to the hemodynamic results. These limitations 
are addressed in section 7.1, and should be carefully considered when drawing general 




6.2 Experimental Conditions 
The examination of the effects of respiration, exercise, and pulsatility on Fontan 
hemodynamics used patient-specific data acquired from MRI. Table 6-2 provides a 
summary of the experimental conditions collected, for clarity. 
Table 6-2: List of experimental conditions collected during this study. Patient-specific conditions were 



























By themselves, examination of the results collected from only the patient-specific 
experimental conditions allowed for understanding the effect of respiration and exercise 
on Fontan hemodynamics. However, studying only the patient-specific experimental 
conditions limits the study’s ability to isolate flow field characteristics and assign physical 
reasoning to the changes in the calculated metrics. For example, power loss, viscous 
dissipation, and HFD changes due to respiration effects cannot be attributed to a single 
factor. The multiple factors involved include, but are not limited to: flow waveform 
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frequency content, flow waveform pulsatility, mean TCPC flow (sum of IVC and SVC 
flow), inflow ratio (ratio of IVC flow rate to SVC flow rate), and outflow ratio (ratio of 
LPA flow rate to RPA flow rate). In addition, each experimental condition is patient-
specific, meaning that the changes in each of these factors between the BH and FB 
conditions for CHOP11B were not the same as the changes seen in these factors for 
CHOP235A. 
In an effort to create more generalizable results and clarify the physical reasoning 
for the hemodynamic changes seen, several artificial physiological conditions were 
included in the study. These derived experimental conditions include both steady and 
pulsatile flow scenarios, and are also listed in Table 6-2. Adding these derived experimental 
conditions to the study allows for the isolation of pulsatility effects on Fontan 
hemodynamics, the results of which are more generalizable and have broader application. 
The effect of respiration and effect of exercise results remain patient-specific because the 
changes in flow metrics describing these physiological changes are patient-dependent. The 
additional experimental conditions, specifically the steady flow conditions, also provide a 
simpler flow field usable as a “first-step” CFD simulation validation. 
6.3 Effect of Respiration 
The effect of respiration on Fontan connection hemodynamics was evidenced by 
comparisons between the BH and FB patient-specific physiological conditions. as several 
studies exist reporting the role of respiration in Fontan hemodynamics [27,42,126,135] and 
on cardiac filling [41]. However, these studies report a global respiration effect (ratio of 
Fontan flow rates during inspiration to the expiration flow rate). In contrast, the current 
study examined the local effect of respiration physiology, and considered the cumulative 
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physiological change without separating the respiratory period into inspiration and 
expiration phases. 
 This local effect of respiration was quantified by the power loss, viscous 
dissipation, and hepatic flow distribution terms (indexed and non-indexed) described in 
section 4.2.2. All of the metrics are listed for 2 experimental conditions for each model: 
BH patient-specific and FB patient-specific. Comparing the BH and FB steady conditions 
isolates the effect of mean flow rate changes between the two physiological conditions. 
Comparisons between the BH and FB patient-specific cases include all physiological 
effects of respiration (flow rate changes, pulsatility changes, frequency content changes, 
etc.). The following paragraphs first identify the power loss, viscous dissipation, and 
hepatic flow distribution trends resulting from the effect of respiration. The results and 
trends are then compared to existing literature data. The final paragraphs give physical 
reasoning and explanation for the trends shown. 
6.3.1 Data Trends 
The apparent power loss (𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇ ) and indexed power loss (𝑖𝑖𝑃𝑃𝑖𝑖) metrics listed in 
Table 5-5 demonstrate observable an observable trend. The patient-specific FB 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  values 
are greater than the corresponding BH values for both models. However, the FB 𝑖𝑖𝑃𝑃𝑖𝑖 values 
are not always greater than the BH 𝑖𝑖𝑃𝑃𝑖𝑖 values, as CHOP235A shows a decrease in 𝑖𝑖𝑃𝑃𝑖𝑖 
from BH to FB conditions for both steady and patient-specific considerations. 
The viscous dissipation term (𝜑𝜑) and indexed viscous dissipation term (𝑖𝑖𝜑𝜑) listed 
in Table 5-6 also demonstrate trends. Both 𝜑𝜑 and 𝑖𝑖𝜑𝜑 show a consistent decrease from steady 
flow to the patient-specific condition across both models and during both BH and FB 
scenarios. Both 𝜑𝜑 and 𝑖𝑖𝜑𝜑 also show increased values during FB conditions when compared 
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to BH conditions during steady and patient-specific cases, except for the CHOP235A 
patient-specific comparison. 
The hepatic flow distribution (HFD) metric shown in Figure 5-15 and Figure 5-16 
shows a consistent decrease in percent hepatic flow to the LPA from the patient-specific 
BH condition to the patient-specific FB condition. 
6.3.2 Literature Comparison 
Of the metrics calculated in this study (power loss, viscous dissipation, and hepatic 
flow distribution), only the power loss metric has been quantified for changes dues to 
respiration to date in the literature. Liu et al report a 150% increase in apparent power loss 
when respiration is added to a single rigid-wall CFD simulation [124]. This result is 
consistent with this study’s trend. Though not peer-reviewed, the PhD dissertation by Tsz 
Ling Elaine Tang directly compared apparent power loss and indexed power loss values 
from 9 CFD simulation that used patient-specific pulsatile flow boundary conditions and 
patient-specific rigid-wall Fontan connection anatomies [143]. Tang found that free-
breathing apparent power loss values exceeded breath-held apparent power loss for each 
of the 9 patient simulated. This finding is consistent with the results from this study. Tang 
also found that indexed power loss was not consistently higher or lower when respiration 
was added; another trend consistent with the data from this study. Other contemporary 
studies include power loss calculations while simulating or modeling Fontan connection 
flows under free-breathing conditions, but do not directly compare the effect of respiration 
on power loss [15,44,45]. The order of magnitude of the apparent power loss values found 
in these studies coincides with the results from this study. Overall, the data from this study 
compares well with data from the literature. 
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6.3.3 Physical Reasoning 
Table 6-3 provides a comprehensive view of the experimental conditions used for 
this comparison, and can be used to assess reasoning behind the power loss, viscous 
dissipation, and hepatic flow distribution trends previously noted.  
Examination of the table shows an interesting comparison between the BH and FB 
conditions. Four metrics (𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇ , 𝑖𝑖𝑃𝑃𝑖𝑖, 𝜑𝜑, and 𝑖𝑖𝜑𝜑) all increasing in value from BH to FB 
conditions, except for 𝑖𝑖𝑃𝑃𝑖𝑖 and 𝑖𝑖𝜑𝜑 during the CHOP235A BH to FB transition. Examination 
of Table 6-3 shows that FB conditions have higher mean inflow rates than BH conditions, 
and consistent flow ratios (both IVC:SVC and LPA:RPA) except when comparing the 
CHOP235A BH and FB IVC:SVC flow ratio. Adding to this fact the knowledge that the 
𝑖𝑖𝑃𝑃𝑖𝑖 and 𝑖𝑖𝜑𝜑 are indexed to account for changes in mean inflow rate suggests a fundamental 
difference in the CHOP235A BH and FB flow fields. The change in IVC:SVC flow ratio 
between these conditions suggests a shift in the collision point of the inflowing flow 
streams relative to the TCPC geometry which creates less flow power lost and less energy 
dissipated due to viscosity. 
The decreasing HFD trend from the patient-specific BH to the patient-specific FB 
is counter-intuitive when the experimental conditions are considered because the 
LPA:RPA flow ratio increases under these same conditions for both models. The 
CHOP11B model increases from 45.9% to 56.4%, and the CHOP235A model LPA:RPA 
flow ratio increases less, from 23.0% to 25.3%. These model flow ratio increases may not 
be practically different when flow rate measurement uncertainties are considered. 
Regardless, with more of the total flow exiting through the LPA, one would think that a 
higher percent of the IVC flow (HFD) would traverse this path as well. However, the data 
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shows otherwise. This counterintuitive result is easily explained for the CHOP235A model 
by a drastic decrease in IVC:SVC flow ratio. The change in IVC:SVC flow ratio for 
CHOP235A from the patient-specific BH to the patient-specific FB condition is from 
76.8% to 43.8%. Using these values and the mean inflow rate for the same conditions we 
see that the mean IVC flow decreases between the BH and FB condition, even though the 
total mean inflow rate increases. At the same time, the SVC flow drastically increases, 
shifting the mass balance between the two inflow streams and causing the counterintuitive 
result. The changes between patient-specific BH and FB conditions for CHOP11B are less 
dramatic, yet it still shows the same decrease in HFD with an increase in LPA:RPA flow 
ratio. This result is not uncommon, and simply shows that HFD is a Lagrangian metric 
manifest as the accumulation of the entire velocity vector field time history [144]. Time-
averaged experimental condition parameters do not capture this time history, so using them 
to predict or understand HFD results should be done with caution. 















BH Patient-Specific 3.2 75.1 45.9 33.4 
FB Patient-Specific 4.04 76.3 56.4 84.8 
CHOP235A 
BH Patient-Specific 3.10 76.8 23.0 31.9 




6.4 Effect of Exercise 
The effect of exercise on Fontan connection hemodynamics is shown by comparison 
between the FB and EX patient-specific and derived physiological conditions. It is well 
known that Fontan patients experience lower exercise capacity than their healthy peers, 
with reasons attributed to reduced cardiorespiratory functional capacity 
[43,48,71,128,145]. Yet few studies have closely examined the local TCPC velocities 
during exercise, with the hope that improved surgical and medical techniques may improve 
Fontan patient exercise capacity. The comparison of patient-specific FB, pulsatile half-
peak EX, and patient-specific peak EX experimental conditions include all the 
physiological changes that occur during exercise. These physiological changes include, but 
are not limited to: mean flow rate, flow rate peak frequency, flow rate frequency content, 
flow rate pulsatility, IVC:SVC flow ratio, and LPA:RPA flow ratio. The following 
paragraphs first identify the power loss, viscous dissipation, and hepatic flow distribution 
trends resulting from the effect of exercise comparison conditions. The results and trends 
are then compared to existing literature data. The final paragraphs give physical reasoning 
and explanation for the trends shown. 
6.4.1 Data Trends 
The apparent power loss metric listed in Table 5-8 includes a consistent trend. The 
𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  values increased consistently from the FB patient-specific condition to the half-peak 
pulsatile EX condition, and from the half-peak pulsatile EX condition to the peak patient-
specific EX condition. However, 𝑖𝑖𝑃𝑃𝑖𝑖, which accounts for differences in mean flow and 
patient-size, did not show any consistent trend, much less the same trend as 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇ . 
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The viscous dissipation term (𝜑𝜑) listed in Table 5-9 showed the same trend as that 
seen by 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  in Table 5-8; both values increase consistently from the FB patient-specific 
condition to the half-peak pulsatile EX condition, and from the half-peak pulsatile EX 
condition to the peak patient-specific EX condition. 
The hepatic flow distribution (HFD) metric shown in Figure 5-25 and Figure 5-26 
shows no consistent trend with changes in exercise intensity. 
6.4.2 Literature Comparison 
Of the three metrics calculated in this study, only changes in power loss due to 
exercise effects is also present in the current literature. Marsden et al report the apparent 
power loss calculated for two patients whose hemodynamics are simulated using 
computational fluid dynamics with rigid wall boundary conditions [15]. The study 
simulates a resting, free-breathing condition with a mean IVC flow rate equal to 1.2 L/min, 
and then increases IVC flow rate by increments of 1.2 L/min for each of three different 
exercise levels (light exercise, moderate exercise, and heavy exercise). Cardiac and 
respiratory frequency are also increased during the exercise simulations. Table 6-4 shows 
the results from the Marsden et al study. 
Table 6-4: The effect of exercise level on apparent power loss from Marsden et al [15] 
Exercise Level Patient A ?̇?𝑬𝒄𝒄𝒓𝒓𝒓𝒓 (mw) Patient B ?̇?𝑬𝒄𝒄𝒓𝒓𝒓𝒓 (mw) 
Rest 6.7 13.9 
Light Exercise 19.5 51.6 
Moderate Exercise 44.8 87.4 




 The apparent power loss results from Marsden et al are of the same order of 
magnitude with this study’s apparent power loss values, and also agree with this study’s 
apparent power loss trends. 
 PhD thesis work by Tang compared Fontan connection anatomy metrics to apparent 
power loss and indexed power loss values calculated from steady flow rigid-wall CFD 
simulations for both rest and exercise mean flow rates. Of the two cohorts used, 11 patients 
were the same between the same between the steady FB and steady EX simulations. 
Comparing these results showed that steady FB apparent power loss was less than steady 
EX apparent power loss for each patient. Indexed power loss did not hold the same trend. 
Four of the 11 patients showed a decrease in indexed power loss the steady FB simulation 
to the steady EX simulation. These trends hold with the data shown in this study. 
 Overall, the data shown in this study compares well with data from the literature. 
6.4.3 Physical Reasoning 
Table 6-5 provides a comprehensive view of the experimental conditions used for 
the effect of exercise comparison. Examination of these experimental conditions can be 
used to assess some reasoning behind the power loss and viscous dissipation. 
The 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  trend where values increase consistently from the FB patient-specific 
condition to the half-peak pulsatile EX condition, and from the half-peak pulsatile EX 
condition to the peak patient-specific EX condition corresponds to increasing mean inflow 
rates (cardiac output) for the same conditions, across both models. Thus, the increase in 
mean inflow rate seems the most likely candidate to explain this increase in apparent power 
loss. Likewise, the 𝜑𝜑 trend, which follows the same pattern, can be attributed to changes 
in the mean inflow rate (cardiac output) as well. 
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No other power loss, viscous dissipation, or hepatic flow distribution trends hold 
with any IVC:SVC flow ratio, LPA:RPA flow ratio, or IVC pulsatility trends shown in 
Table 6-5. This suggests that the changes in power loss, viscous dissipation, and hepatic 
flow distribution functions of a single experimental condition variable. Instead, it is more 
likely that these hemodynamic metrics are results of a multi-variate cumulative effect 
which may not even be limited to the experimental condition variables listed. Other factors 
could include biological changes due to increased exercise intensity (vascular resistance 
changes, oxygen consumption levels, etc.) 
That being said, there is an interesting trend within the experimental condition 
variables alone. As the IVC:SVC flow ratio increases the LPA:RPA flow ratio decreases 
for the CHOP11B model. This same trend does not hold for CHOP235A, and suggests 
something about the CHOP11B geometry and fluid dynamics which encourages IVC flow 
to proceed down the RPA. 




















7.90 79.3 43.1 101.1 
Half-Peak 
Pulsatile 5.95 77.8 46.1 93.4 
CHOP235A 





7.08 48.2 25.3 126.4 
Half-Peak 




The power loss data shown here are in agreement with previous data from the 
Georgia Tech Cardiovascular Fluid Mechanics Lab relating power loss to Fontan patient 
exercise capacity. Figure 6-2 shows this study’s data superimposed on data from Khiabani 
et al [48]. The ratio of peak EX 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  to the patient-specific FB 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  follows the same 
relationship to the ratio of the peak EX mean inflow rate to the patient-specific FB mean 
inflow rate as the previously published data. This engenders confidence in stating that 
CHOP235A enjoys greater exercise capacity than CHOP11B, as CHOP11B has the greater 
indexed power loss values. 
Table 6-6: Superposition of this study's data on previously published data from 
Khibani et al [48] 
 


























Peak EX Mean Inflow Rate : FB Mean Inflow Rate




6.5 Effect of Pulsatility 
The effect of pulsatility on Fontan connection hemodynamics is shown by comparison 
between the patient-specific and derived BH experimental conditions. Flow pulsatility is 
established as an important parameter in Fontan patient pulmonary vasculature, as it plays 
a role in vasodilation and pulmonary vascular resistance [146]. The relationship between 
pulsatility and Fontan connection hemodynamics, though, has yet to be fully established, 
and, therefore, connections to pulmonary arteriovenous malformations and exercise 
capacity are weak. This study examines the local effect of pulsatility on Fontan 
hemodynamics in an effort to further inform the importance of restoring physiological 
pulsatility to Fontan patients. 
 The comparison of steady BH, low pulsatile BH, patient-specific BH, and high 
pulsatile BH experimental conditions does not include any true physiological changes. The 
only physiologically accurate condition is the patient-specific BH scenario. Instead, these 
conditions artificially change the flow waveform pulsatility without significantly altering 
any other flow waveform variables. This fact allows these results to be more generally 
applicable. The following paragraphs first identify the power loss, viscous dissipation, and 
hepatic flow distribution trends resulting from the effect of pulsatility comparison 
conditions. The results and trends are then compared to existing literature data. The final 
paragraphs give physical reasoning and explanation for the trends shown. 
6.5.1 Data Trends 
 The 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  and 𝑖𝑖𝑃𝑃𝑖𝑖 metrics listed in Table 5-11 show a consistent trend. Both 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  
and 𝑖𝑖𝑃𝑃𝑖𝑖 increase with increasing IVC flow waveform pulsatility. To explore this 
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relationship, a comprehensive list of the experimental condition values are listed in Table 
6-7. 















Steady 3.28 73.9 46.9 0 
Patient-
Specific 3.2 75.1 45.9 33.4 
Low 
Pulsatility 3.22 73.8 46.9 12.7 
High 
Pulsatility 3.21 74.1 45.9 57.5 
CHOP235A BH 
Steady 3.10 79.0 23.5 0 
Patient-
Specific 3.10 76.8 23.0 31.9 
Low 
Pulsatility 3.09 77.0 18.6 22.0 
High 
Pulsatility 3.21 77.3 23.1 38.6 
 
The CHOP11B 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  and 𝑖𝑖𝑃𝑃𝑖𝑖 increase with increasing IVC flow waveform 
pulsatility is more linear than the same relationship for CHOP235A, as seen in Figure 6-3 




Figure 6-3: CHOP11B relationship between power loss metrics and IVC waveform pulsatility 
 





















































Both Figure 6-3 and Figure 6-4 show that the increase in 𝑖𝑖𝑃𝑃𝑖𝑖 value with increasing 
IVC flow waveform pulsatility is greater than the increase in the 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  value. This is most 
likely due to the effect of mean flow rate on each metric’s relationship to pulsatility. 
 Table 5-12 shows an interesting trend for both 𝜑𝜑 and 𝑖𝑖𝜑𝜑. Though with different 
absolute values, both of these metrics show an increase in value with increasing pulsatility 
not including the steady flow experimental condition. The steady flow condition for both 
models possesses high 𝜑𝜑 and 𝑖𝑖𝜑𝜑 values compared to the pulsatile conditions, and is the 
maximum value in each case except for the CHOP11B 𝑖𝑖𝜑𝜑 set wherein the steady flow 
condition value is exceeded by the high pulsatility value (IVC flow pulsatility = 57.5%). 
6.5.2 Literature Comparison 
Contrary to the effect of respiration and the effect of exercise results, both power loss 
changes and hepatic flow distribution changes due to pulsatility effects are found in the 
literature for comparison. The most applicable literature comparison comes from Khiabani 
et al, who calculated apparent power loss from the computational fluid dynamics 
simulations from 24 patient-specific breath-held pulsatile and steady flow conditions using 
rigid wall anatomies [147]. This study found that the percent difference in apparent power 
loss between the pulsatile and steady flow conditions increased non-linearly with an 
increase in weighted pulsatility index, a wholistic Fontan connection pulsatility term where 
the pulsatility of each vessel (IVC, SVC, LPA, and RPA) is weighted by that vessel’s flow 
rate. Another study by Wei et al assess the usefulness of steady versus pulsatile patient-
specific breath-held conditions for use in surgical planning cases across 101 patients [148]. 
This study shows that a difference in indexed power loss between the pulsatile and steady 
conditions is statistically dependent on the flow pulsatility, and increases with increasing 
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pulsatility. The difference in hepatic flow distribution between the pulsatile and steady 
flow conditions is not statistically dependent on the pulsatility index. These findings by 
Wei et al coincide with this study’s trends. 
6.5.3 Physical Reasoning 
The trend where both 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  and 𝑖𝑖𝑃𝑃𝑖𝑖 increase with increasing pulsatility is widely attributed 
to the increase in overall fluid dynamic unsteadiness that occurs with increasing pulsatility. 
Increasing pulsatility effectively increases the instantaneous velocity gradients present in 
the TCPC flow field. High velocity gradients result in higher momentum losses, which are 
manifest as a monotonically increasing 𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎̇  and 𝑖𝑖𝑃𝑃𝑖𝑖 trend. 
The non-monotonic trend seen between 𝜑𝜑 and 𝑖𝑖𝜑𝜑 suggests there is a fundamental 
difference between steady flow and pulsatile flow as seen by the viscous dissipation term. 
Equation (4-9) reminds us that the viscous dissipation term is based on spatial velocity 
gradients. During steady flow these spatial velocity gradients do not change in time. During 
pulsatile flow the spatial velocity gradients are changing based on the transient velocity 
profile changes. It is these transient velocity profile changes that create the decreased 
spatial gradients, and hence the decreased viscous dissipation between the steady and low 
pulsatility cases. Then, as the pulsatility increases, the peak velocity in the transient 
velocity profile becomes greater, increasing the spatial velocity profiles, and causing the 
increasing viscous dissipation with pulsatility. 
 Further details of this phenomena are best explained with a simple example: the 
Womersley solution to the Navier-Stokes equations [149]. Pulsatile flow in a straight tube 




Figure 6-5: Womersley velocity profiles at different Womersley numbers, α 
 The velocity profiles during the Womersley solution change in time, as shown by 
the different rows of velocity profiles in the figure. The shape of the velocity profile is 






where 𝜔𝜔 is the angular frequency of the pulsatility, 𝑖𝑖 is a characteristic length scale (vessel 
diameter), and 𝜈𝜈 is the fluid kinematic viscosity. 
 Figure 6-5 clearly shows that the spatial gradients of a pulsatile flow are different 
(and less than) the spatial gradients of a steady, Poiseuille, flow profile. This is the cause 
of the drop in viscous dissipation from the steady BH condition to the BH low pulsatility 
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condition seen in Figure 5-35 and Figure 5-36. Increasing pulsatility then increases the 
peak velocity of each of these transient profiles without affecting 𝛼𝛼. This increases the 
magnitude of the velocity profile extremes, but does not change its shape. Increasing the 
magnitude of the velocity while maintaining shape increases the spatial velocity 
magnitude. This is the reason for the increase in viscous dissipation with increased 
pulsatility, once pulsatility is present, as seen in Figure 5-35. Figure 5-36 does not see the 
same increase because the CHOP235A pulsatility does not change much between the BH 
low pulsatility and BH high pulsatility conditions (Table 6-7), and the effect falls within 
the measurement uncertainty bounds. Table 6-8 includes the Womersley number for the 
conditions exploring pulsatility effects.  
Table 6-8: The effect of pulsatility on viscous dissipation terms, including IVC pulsatility and 
Womersley number, α 
Model Condition 𝝋𝝋 (1/s2) 𝒊𝒊𝝋𝝋 (x1012) IVC Pulsatility (%) α 
CHOP11B BH 
Steady 7442.6 ± 143.9 12.08 ± 1.28 0 - 
Patient-Specific 6272.8 ± 280.6 10.66 ± 1.21 33.4 19.9 
High Pulsatility 7392.0 ± 347.3 12.43 ± 1.42 12.7 19.9 
Low Pulsatility 5535.3 ± 48.9 9.28 ± 0.97 57.5 19.9 
CHOP235A BH 
Steady 1225.4 ± 36.8 2.42 ± 0.26 0 - 
Patient-Specific 756.3 ± 28.4 1.49 ± 0.17 31.9 23.1 
High Pulsatility 789.0 ± 17.6 1.45 ± 0.16 22.0 23.1 
Low Pulsatility 743.6 ± 108.6 1.48 ± 0.26 38.6 23.1 
 
Figure 6-6 shows the comparison of an instantaneous velocity magnitude profile 
from the CHOP11B BH High Pulsatility PIV acquisition at the 130mm plane, sampled in 
the IVC to a steady state analytical velocity profile with the same mass flow rate, and an 
apparent power loss assumed velocity profile. The blunted parabolic profile of the 
experimental data suggests Womersley-type flow characteristics within the IVC. This 
proves the existence of a fundamentally different flow profile existing between the steady 
state and pulsatile experimental conditions. The comparison of the experimental data to the 
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steady state analytical solution shows spatial velocity gradient differences that give rise to 
the change in the viscous dissipation term value from steady state to any of the pulsatile 
experimental conditions. The apparent power loss line is equal to the average velocity 
because 𝑄𝑄 = 𝑉𝑉� ∙ 𝐴𝐴, where 𝑄𝑄 is the volumetric flow rate, 𝑉𝑉�  is the average velocity, and 𝐴𝐴 is 
the cross-sectional area. It is clearly a different velocity profile than the measured profile. 
The apparent power loss profile will not change  
 
Figure 6-6: Velocity vector x-component versus normalized radius plotted for the CHOP235A patient-
specific BH condition, sampled from the IVC on the 89mm plane.  
6.6 Comparing Viscous Dissipation and Power Loss 
Careful consideration of the flow physics within the TCPC draws question toward this 
study’s calculation of a viscous dissipation term in addition to a power loss term. A 
thermodynamic perspective of the flow collision process occurring within the TCPC 
identifies viscous dissipation as the only source of lost energy (entropy). So, if calculated 
correctly, ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 and 𝜑𝜑 (as well as 𝑖𝑖𝑃𝑃𝑖𝑖 and 𝑖𝑖𝜑𝜑) should always show the same trend, making 
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a viscous dissipation term calculation redundant. In fact, this intuition is so strong that 
some studies have calculated a volume-integrated viscous dissipation rate instead of ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 
with the assumption they are equal [150–152]. However, ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 and 𝜑𝜑 (and 𝑖𝑖𝑃𝑃𝑖𝑖 and 𝑖𝑖𝜑𝜑) do 
not show the same trend due to respiration or pulsatility effects. A thorough derivation of 
both ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 and 𝜑𝜑 reveals the reasoning behind the trend discrepancy and highlights 
important issues related to these two terms in the Fontan hemodynamics research field. 
6.6.1 Control Volume Energy Analysis 
The apparent power loss term used in this study, ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎, comes from a control volume energy 
analysis of the TCPC. The derivation that follows closely aligns with Munson, Young, and 
Okiishi [153]. 
 The first law of thermodynamics for a system states that the time rate of increase 
of the total stored energy of the system is equal to the sum of the net time rate of energy 
addition by heat transfer into the system and the net time rate of energy addition by work 





+ � 𝜌𝜌𝜌𝜌 𝑈𝑈�⃑ ∙ 𝑛𝑛�⃑  𝑑𝑑𝐴𝐴
𝐶𝐶𝐶𝐶
= ?̇?𝑄𝑚𝑚𝑛𝑛 + ?̇?𝑊𝑚𝑚𝑛𝑛 (6-2) 
 
where 𝜌𝜌 is the intensive total energy, 𝑈𝑈�⃑  is the fluid velocity vector, 𝑛𝑛�⃑  is a unit vector normal 
(outward) to the control surface (cs), ?̇?𝑄𝑚𝑚𝑛𝑛 is the extensive heat rate added to the control 
volume, and ?̇?𝑊𝑚𝑚𝑛𝑛 is the extensive work rate added to the control volume. The intensive total 
energy, 𝜌𝜌, is related to the intensive internal energy, 𝑢𝑢� , the intensive kinetic energy, 𝑈𝑈2/2, 
and the intensive potential energy, 𝑔𝑔𝜕𝜕, by Equation (6-3): 
 







 The work term, ?̇?𝑊𝑚𝑚𝑛𝑛, is broken into several forms of work by Equation (6-4): 
 ?̇?𝑊𝑚𝑚𝑛𝑛 = ?̇?𝑊𝑚𝑚𝑛𝑛,𝑟𝑟ℎ𝑎𝑎𝑒𝑒𝑖𝑖 + ?̇?𝑊𝑚𝑚𝑛𝑛,𝑎𝑎𝑟𝑟𝑜𝑜𝑟𝑟𝑟𝑟 + ?̇?𝑊𝑚𝑚𝑛𝑛,𝑎𝑎𝑚𝑚𝑟𝑟𝑣𝑣𝑜𝑜𝑜𝑜𝑟𝑟 (6-4) 
 
where ?̇?𝑊𝑚𝑚𝑛𝑛,𝑟𝑟ℎ𝑎𝑎𝑒𝑒𝑖𝑖 is the net shaft work rate into the system (i.e. via turbine), ?̇?𝑊𝑚𝑚𝑛𝑛,𝑎𝑎𝑟𝑟𝑜𝑜𝑟𝑟𝑟𝑟 is the 
net pressure work into the system acting on all the control surfaces, and ?̇?𝑊𝑚𝑚𝑛𝑛,𝑎𝑎𝑚𝑚𝑟𝑟𝑣𝑣𝑜𝑜𝑜𝑜𝑟𝑟 is the 
net viscous work rate into the system due to stress tangential to the control surfaces. Both 
?̇?𝑊𝑚𝑚𝑛𝑛,𝑎𝑎𝑟𝑟𝑜𝑜𝑟𝑟𝑟𝑟 and ?̇?𝑊𝑚𝑚𝑛𝑛,𝑎𝑎𝑚𝑚𝑟𝑟𝑣𝑣𝑜𝑜𝑜𝑜𝑟𝑟 definitions are provided in Equation (6-5) and Equation (6-6), 
respectively: 
 









where 𝑝𝑝 is the hydrostatic fluid pressure and 𝜏𝜏 is the shear stress vector. 
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 The power (energy rate) lost during the TCPC flow process is equal to the sum of 
the time rate of internal energy change and the heat rate out of the control volume. Isolating 
these terms on the left-hand side of the energy balance results in Equation (6-8): 
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 ?̇?𝐸𝑜𝑜𝑜𝑜𝑟𝑟𝑟𝑟 = ?̇?𝑊𝑚𝑚𝑛𝑛,𝑟𝑟ℎ𝑎𝑎𝑒𝑒𝑖𝑖
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 Equation (6-8) is most general form of power loss, and is mathematically equal to 
the volume integral of the viscous dissipation rate. Yet, ?̇?𝐸𝑜𝑜𝑜𝑜𝑟𝑟𝑟𝑟 ≠ ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎, and this has led to 
several problems with power loss. 
6.6.2 Power Loss Problems 
One problem with power loss as a Fontan connection hemodynamic metric stems from the 
assumptions made to calculate a power loss term. Apparent power loss, ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎, was 
developed on simpler Fontan circulation models where most of these assumptions were 
valid. Subsequent Fontan circulation models, including the model in this study, include 
complexities that invalidate these assumptions, but ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 is still used because it relates to 
patient outcomes. This causes confusion as to the physical meaning of ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 and its 
comparison to viscous dissipation. 
 In order to arrive at ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 from ?̇?𝐸𝑜𝑜𝑜𝑜𝑟𝑟𝑟𝑟 the following assumptions are made: 
(1) No shaft work is present on the system control surface 
?̇?𝑊𝑚𝑚𝑛𝑛,𝑟𝑟ℎ𝑎𝑎𝑒𝑒𝑖𝑖 = 0 
(2) No viscous work is present in the system 
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(5) The velocity profile at the control surfaces is constant 




The validity of these assumptions varies depending on the complexity of the system 
under consideration. Assuming no shaft work is present is almost always perfectly valid. 
The question of negligible viscous work is more complex. Examination of Equation (6-6) 
shows negligible viscous work can exist when either (1) the shear stress vector is extremely 
small, (2) the velocity vector is extremely small, or (3) the shear stress vector and velocity 
vector are orthogonal to one another. Proper control volume selection can usually create a 
situation where any one of these 3 situations occurs. However, if the TCPC inflow and 
outflow control surfaces are not perfectly orthogonal to the TCPC inflow and outflow 
velocity field, respectively, then the viscous work cannot be considered zero. Non-
orthogonal control surfaces are most likely to occur at the outflows where the velocity 
fields is unknown prior to control surface definition. The third assumption, that the control 
volume does not change in time, is only valid for rigid wall studies, and is the first 
assumption that cannot be accounted for in an in vivo setting. The fourth assumption, that 
there is no change in elevation (or no gravity influence) between control surfaces is 
probably not representative of the patient’s lifestyle, but can be considered valid during an 
in vivo study, as patient-specific data is collected in the supine position. Similarly, as long 
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as the in vitro study or in silico simulation does not include gravity effects, this assumption 
is valid. The fifth, and final, assumption is never valid, as even a steady flow, rigid-walled, 
idealized anatomy Fontan circulation model system produces spatially-varying velocity 
profiles at the control surfaces. Spatially-varying profiles occur anytime the fluid domain 
includes a no-slip condition and flow. Each of these assumptions contributes to the 
confused physical meaning behind ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 as a power loss metric. 
Another issue with power loss is that it requires static pressure measurements for 
calculation. Static pressure values are not difficult to acquire for in vitro or in silico studies, 
but are not typically available for Fontan patients. Extensive catheterization is required to 
obtain pressure values at all of the TCPC inlets and outlets, and such invasive procedures 
are typically avoided. One particularly important limitation associated with the inability to 
acquire in vivo power loss values is the subsequent inability to verify in vitro and in silico 
power loss values against patient-specific in vivo data. Without verification, the knowledge 
from in vitro and in silico power loss correlations to patient outcomes will always be 
limited. 
Ultimately, though ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 loses physical meaning from assumptions and requires an 
invasive pressure measurement that restricts its calculation during in vivo studies, it is still 
valuable for its correlations to patient outcomes . For pure statistical purposes, ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 can be 
related to patient outcomes without any physical understanding; it is simply a number. So, 
any solution to the lost physical meaning and required static pressure power loss problems 
must maintain correlations to patient outcomes to be truly useful. 
The following analysis examines the viscous dissipation term acquired in this study 
as a solution to the previously stated power loss problems 
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6.6.3 Viscous Dissipation as a Solution to Power Loss Problems 
In order to act as a solution to the present power loss problems, viscous dissipation must 
meet three requirements: (1) maintain physical meaning by employing no invalid 
assumptions, (2) require only values measureable in the clinic, and (3) relate with current 
power loss values, ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎, to maintain correlations to patient outcomes. Analysis of viscous 
dissipation as a solution to the power loss problems begins with its derivation from a 
differential energy conservation analysis. 
6.6.3.1 Differential Energy Analysis 
The viscous dissipation term used in this study, 𝜑𝜑, comes from a differential energy 
conservation analysis. The first law of thermodynamics, restated from section 6.6.1, is that 
the time rate of increase of the total stored energy of the system is equal to the sum of the 
net time rate of energy addition by heat transfer into the system and the net time rate of 
energy addition by work transfer into the system. The differential work rate transferred into 
the system is broken into work done by pressure forces normal to the surface (Equation 
(6-9)), work done by shear forces tangential to the surface (Equation(6-10)) and body 
forces (Equation (6-11)). 
 𝑑𝑑?̇?𝑤𝑎𝑎 = �−𝑝𝑝𝐼𝐼 ∙ 𝑈𝑈�⃑ � 𝑑𝑑𝑉𝑉 (6-9) 
 𝑑𝑑?̇?𝑤𝑟𝑟 = ∇ ∙ �𝜏𝜏 ∙ 𝑈𝑈�⃑ � 𝑑𝑑𝑉𝑉 (6-10) 
 
𝑑𝑑?̇?𝑤𝑏𝑏 =  𝜌𝜌𝜋𝜋 ∙ 𝑈𝑈�⃑  𝑑𝑑𝑉𝑉 (6-11) 
where 𝑝𝑝 is the static pressure, 𝐼𝐼 is the identity vector, 𝑈𝑈�⃑  is the velocity vecotry, 𝜏𝜏 is the 
symmetric shear stress tensory, and 𝜋𝜋 is a body force (gravity) per unit mass. 
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 The differential heat rate transferred into the system is broken into volumetric 
heating (Equation (6-12)) and thermal conduction heating (Equation (6-13)) components. 
 𝑑𝑑?̇?𝑄𝑎𝑎 = 𝜌𝜌?̇?𝑞𝑎𝑎 𝑑𝑑𝑉𝑉 (6-12) 
 𝑑𝑑?̇?𝑄𝑣𝑣 = −(∇ ∙ ?̇?𝑞𝑣𝑣)𝑑𝑑𝑉𝑉 (6-13) 
 
where ?̇?𝑞𝑎𝑎 is a term representing heat added to the entire volume per unit mass (i.e. due to 
radiation or a chemical reaction), and ?̇?𝑞𝑣𝑣 is the conductive heat vector. 













where 𝜌𝜌 is the total energy, 𝑢𝑢�  is the intensive internal energy, and 𝑈𝑈
2
2
 is the intensive kinetic 
energy. The potential energy contribution for this analysis is considered as part of the body 
forces term (Equation (6-11)). 
 Constructing Equations (6-9) through (6-14) to meet the first law of 









= 𝜌𝜌?̇?𝑞𝑎𝑎 − (∇ ∙ ?̇?𝑞𝑣𝑣) − �𝑝𝑝𝐼𝐼 ∙ 𝑈𝑈�⃑ � + ∇ ∙ �𝜏𝜏 ∙ 𝑈𝑈�⃑ � + 𝜌𝜌𝜋𝜋 ∙ 𝑉𝑉�⃑  
(6-15) 
 
 Similar to section 6.6.1, the sum of the change in internal energy and the heat rate 
leaving the system are equal to the power lost. These terms are isolated on the left-hand 
side of Equation (6-15) by subtracting the differential kinetic energy rate (Equation (6-16)) 










� = −𝑈𝑈�⃑ ∙ ∇𝑝𝑝 + 𝑈𝑈�⃑ ∙ �∇ ∙ 𝜏𝜏� + 𝜌𝜌𝜋𝜋 ∙ 𝑉𝑉�⃑  (6-16) 
 
 Equation (6-17) results, and defines the differential power lost in the Fontan 
connection.  
 ?̇?𝜌𝑜𝑜𝑜𝑜𝑟𝑟𝑟𝑟 = −𝑝𝑝�∇ ∙ 𝑈𝑈�⃑ � + 𝜏𝜏:∇𝑈𝑈�⃑  (6-17) 
 
 Assuming the fluid in question is Newtonian allows for a relationship between the 





































































 Equation (6-18) is simplified by assuming incompressible flow , which leaves 
Equation (6-19): 
 











































 Thus we see that the product of the viscous dissipation term, 𝜑𝜑, and the dynamic 
viscosity is equal to the true power loss per unit volume. Integration of this product will 
result in ?̇?𝐸𝑜𝑜𝑜𝑜𝑟𝑟𝑟𝑟, the same quantity derived in section 6.6.1. The viscous dissipation term 
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derivation included no invalid assumptions, so it maintains its physical meaning and fulfills 
solution requirement (1). 
 The viscous dissipation term, 𝜑𝜑, found in Equation (6-19) is measureable in the 
clinic. Unlike apparent power loss, the viscous dissipation term does not require static 
pressure to be calculated. This avoids any need for invasive measurement, which is 
preferentially avoided for in vivo measurements. The only measurement that the viscous 
dissipation term requires is a time-resolved velocity field, the spatial gradients of which 
compose all terms in the viscous dissipation equation. Time-resolved blood velocity fields 
are potentially available via 4D MRI technology [154,155]. The research of 4D MRI 
technology to improve its accuracy and availability in the clinic is underway [152]. Thus, 
the viscous dissipation term, 𝜑𝜑, fulfills solution requirement (2) by being a clinically 
measureable quantity. 
6.6.3.2 Statistical Analysis 
An analysis of whether 𝜑𝜑 fulfills the final solution requirement of relating to apparent 
power loss, and thus relating to patient outcomes, was conducted through statistical 
comparison of 𝜑𝜑 and ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 values. Indexed power loss and the indexed viscous dissipation 
term were also compared, for completeness. The statistical comparison of 𝜑𝜑 to ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 and 𝜑𝜑 
to 𝑖𝑖𝑃𝑃𝑖𝑖 employed values calculated from two different methods, an in silico method and an 
in vitro method. The in silico method values were used to relate power loss and viscous 
dissipation values for a single condition across multiple patients, and used similar TCPC 
modeling techniques to that which exists in the current literature. The in vitro method 
values were used to relate power loss and viscous dissipation for two patients across 
multiple conditions, and used TCPC modeling techniques closer to physiological realities. 
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 The in silico methods for acquiring the viscous dissipation and power loss values 
provided time-resolved three-dimensional velocity fields and static pressure values through 
the use of ANSYS Fluent 17.0 (ANSYS, Inc. Canonsburg, PA). The coupled solver scheme 
was employed to solve to continuity and linearized momentum equations simultaneously. 
Temporal and spatial discretizations employed second-order schemes, and warped-face 
gradient correction was employed to improve gradient calculation accuracy. The 
simulation was conducted on polyhedral meshes, converted from an unstructured 
tetrahedral mesh. Mesh size was 0.05 𝜕𝜕 𝐻𝐻𝑎𝑎𝑜𝑜𝑟𝑟𝑟𝑟𝑜𝑜𝑜𝑜���������, where  𝐻𝐻𝑎𝑎𝑜𝑜𝑟𝑟𝑟𝑟𝑜𝑜𝑜𝑜��������� is the average diameter of 
all TCPC inlets and outlets. Boundary layer zones were created to improve numerical 
accuracy near the walls. The boundary layer zone was filled with three uniform prismatic 
boundary meshes equal to 1/3 the size of the surrounding elements. These mesh parameters 
were previously established as creating mesh-independent results [121]. Flow extensions 
equal to 10 times the vessel diameter in length were added to all inlets and outlets. User-
defined functions were used to apply fully-developed time-varying velocity profiles at the 
inlets. Time step size was set at 0.001 seconds to ensure the Flow Courant number was ~ 
0.1. The vessel walls were assumed rigid, and the fluid was assumed Newtonian with 
density equal to 1060 kg-m-3 and dynamic viscosity equal to 3.5x10-3 Pa-s. 
 The power loss (?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 and 𝑖𝑖𝑃𝑃𝑖𝑖) and viscous dissipation (𝜑𝜑 and 𝑖𝑖𝜑𝜑) terms were 
calculated from the CFD solution, and analyzed statistically. Table 6-9 summarizes the 
values used for the statistical comparison of 𝜑𝜑 to ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 and 𝑖𝑖𝜑𝜑 to 𝑖𝑖𝑃𝑃𝑖𝑖. The patient-specific 
data used in the CFD simulations were chosen from the Cardiovascular Fluid Mechanics 
Lab Fontan Database Patients were selected to include mean inflow and outflow (cardiac 
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output) values spanning the range of all patients within the data base. Patients with more 
than 2 inlets (IVC and SVC) or more than two outlets (LPA and RPA) were excluded. 
Table 6-9: Values used for multi-patient, single condition viscous dissipation and power loss 
relationship analysis. PS - patient-specific. 
Model Condition ?̇?𝑬𝒄𝒄𝒓𝒓𝒓𝒓 (mW) 𝒊𝒊𝑴𝑴𝒊𝒊 (x106) 𝝋𝝋 (1/s2) 𝒊𝒊𝝋𝝋 (x1012) 
202B 
BH PS 
11.00 41.82 54215.03 49.56 
89B 3.50 9.64 6749.47 3.14 
82B 5.15 21.03 27635.55 11.66 
39C 3.68 78.66 37593.52 49.64 
23B 2.60 28.02 11902.93 12.80 
21A 1.89 22.20 15862.29 12.05 
18A 0.55 4.99 8199.43 1.95 
128A 0.86 4.15 9312.65 2.45 
88B 4.61 26.58 23561.35 19.83 
33B 3.75 41.50 11642.50 17.68 
 
The data were analyzed for normality within each variable using the Shapiro-Wilk 
test within IBM SPSS Statistics (IBM, Inc., Armonk, NY). Indexed power loss and the 
viscous dissipation term were found to be normally distributed, but apparent power loss 
and indexed viscous dissipation were not. Accordingly, Spearman’s correlation test was 
used to explore the relationships between both the viscous dissipation term and apparent 
power loss, and indexed viscous dissipation and indexed power loss, respectively. 
 Both relationships showed a significant statistical correlation. The correlation 
coefficient for the apparent power loss and viscous dissipation term comparison was 𝑟𝑟 =
0.709 (𝑝𝑝 = 0.022). The indexed viscous dissipation and indexed power loss comparison 
results in an 𝑟𝑟 = 0.952 correlation coefficient (p<0.001). This result fulfills the third 
solution requirement (section 6.6.3). With all three requirements fulfilled, viscous 
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dissipation (the 𝑖𝑖𝜑𝜑 and 𝜑𝜑 terms) can be considered adequate solutions to the existing power 
loss problems.  
 The strong correlation between the power loss and viscous dissipation terms from 
the in silico methods is at least partially due to the CFD modelling assumptions. Of the 5 
assumptions made to arrive at ?̇?𝐸𝑎𝑎𝑎𝑎𝑎𝑎 listed in section 6.6.2, 3 of them were made in the in 
silico methods. The 3 assumptions made were: assumption (1): no shaft word was present 
in the system, assumption (3): the control volume did not change in time, and assumption 
(4): there was no change in elevation between control surfaces. To test the usefulness of 
viscous dissipation as a solution to the power loss problems under a more general system, 
power loss and viscous dissipation values were also collected and statistically analyzed 
under in vitro methods. 
 The in vitro methods employed to produce values for the in vitro statistical analysis 
were those described in section 4.2.2. The viscous dissipation terms calculations under 
these methods only assumed two of the 5 assumptions listed in section 6.6.2: assumption 
(1) that no shaft work was present in the system and assumption (4) that there was no 
elevation change between control surfaces. The major difference between the in vitro and 
in silico methods was the use of flexible walls for the in vitro analysis. Table 6-10 
summarizes the power loss and viscous dissipation values from the in vitro methods used 
for statistical analysis.  
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Table 6-10: Values used for multi-condition viscous dissipation and power loss relationship analysis. 
Puls - pulsatile; PS - patient-specific 
Model Condition ?̇?𝑬𝒄𝒄𝒓𝒓𝒓𝒓 (mW) 𝒊𝒊𝑴𝑴𝒊𝒊 (x106) 𝝋𝝋 (1/s2) 𝒊𝒊𝝋𝝋 (x1012) 
11B 
BH 
Low Puls 7.2 125.0 5535.3 9.28 
PS 16.3 290.3 6272.8 10.66 
High Puls 20.6 360.8 7392.0 12.43 
FB PS 55.6 418.6 5586.5 5.95 
EX Peak PS 278.5 329.4 33359.0 9.30 Half-Peak Puls 96.6 268.1 18850.3 9.26 
235A 
BH 
Low Puls 9.9 206.2 743.6 1.45 
PS 18.0 374.0 756.3 1.48 
High Puls 26.9 501.5 789.0 1.49 
FB PS 33.8 170.6 533.6 0.41 
EX Peak PS 97.9 170.6 807.9 0.31 Half-Peak Puls 71.5 185.3 742.4 0.37 
 
 The data used for the viscous dissipation and power loss relationship analysis did 
not include any steady state (0% pulsatility) values. The steady state condition was 
excluded because of the fundamentally different trend seen in the effect of pulsatility on 
viscous dissipation data (section 6.5).  
 The data were analyzed for normality within each variable using the Shapiro-Wilk 
test within IBM SPSS Statistics. Only indexed power loss was found to be normally 
distributed. Accordingly, Spearman’s correlation test was then used to explore the 
relationships between both the viscous dissipation term and apparent power loss, and 
indexed viscous dissipation and indexed power loss, respectively. 
 Neither relationship showed a significant statistical correlation, but the relationship 
between indexed viscous dissipation and indexed power loss showed a trend. The 
correlation coefficient for the apparent power loss and viscous dissipation term comparison 
is 𝑟𝑟 = 0.322, which is statistically insignificant (𝑝𝑝 = 0.308). The indexed viscous 
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dissipation and indexed power loss comparison results include an 𝑟𝑟 = 0.518 correlation 
coefficient that is trending toward statistical significance (𝑝𝑝 = 0.084). 
 The relationships between the power loss and viscous dissipation terms from the in 
vitro method are less strong as the relationships between the terms from the in silico 
methods for two reasons. First, the in vitro method viscous dissipation terms calculations 
does not include the rigid wall assumption, but the power loss calculations do. The 
influence of a moving wall weakens the correlation between the two metrics. Second, the 
in vitro method experimental conditions span two different patients and multiple 
physiological conditions per patient, but the in silico method relates metrics from multiple 
patients (n=10) at only one physiological condition. The indexed viscous dissipation and 
indexed power loss comparison shows a stronger relationship than the non-indexed viscous 
dissipation and apparent power loss comparison for both methods because indexing the 





7.1 In Vitro Fontan Circulation Model Verification 
The purpose of the in vitro Fontan circulation model verification aspects of this study are 
to characterize the model against in vivo patient-specific data. This verification is a 
relatively standard engineering process of defining what is known and what is uncertain 
when comparing data sets. Thus, there are no limitations in the verification method itself.  
 That being said, the in vitro Fontan circulation model itself is not without its 
limitations. The intent of the model is to reproduce Fontan connection hemodynamics both 
in the global circulatory system and in the local total cavopulmonary connection (TCPC). 
The most notable limitation is in the use of a bulk compliance metric to characterize the in 
vivo TCPC material properties. In reality, the in vivo TCPC is a mixture of heterogeneous 
living tissue types (arterial and venous) and artificial graft material for the IVC connection. 
Representing these vessels with a homogenous, linear elastic material with a single 
compliance value belies the complexity of the in vivo solid dynamics. Of course, these solid 
dynamics are in direct contact with, and affect the blood fluid dynamics creating different 
in vitro flow fields than those which may exist and are recorded in this study. Both the 
viscous dissipation and hepatic flow distribution metrics calculated in the study are directly 
based on the in vitro flow fields, so these metrics could be affected. However, the 
homogeneous flexible TCPC models used do still deform dynamically under pulsatile 
flows, and are the most physiologically accurate models used in this field of study, to date. 
 The in vitro Fontan circulation model is also limited in that it cannot replicate 
Fontan circulatory system remodeling or growth based on hemodynamic conditions. 
Though this limitation does not impact the influence of any of the effects of respiration, 
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exercise, or pulsatility on Fontan connection hemodynamics directly, the secondary effects 
of global circulation differences on Fontan connection hemodynamics are not considered. 
For example, increasing pulsatility consistently increases both apparent power loss and 
indexed power loss in this study. Research suggests that the presence of pulsatility in 
Fontan flows affects pulmonary system vasodilation. With larger pulmonary blood vessels, 
pulmonary vascular resistance drops, and an increase in single ventricle diastolic filling is 
implied. If the single ventricle fills more it will also eject more blood with every systolic 
stroke, increasing cardiac output. This increased cardiac output manifests itself at the 
Fontan connection as an increase in either IVC or SVC inflow, and a possible change in 
the IVC:SVC flow ratio. The in vivo circulatory system will iterate on this process until 
reaching homeostasis, but the in vitro model never replicates the change in pulmonary 
vascular resistance. This limitation is only applicable to the derived experimental 
conditions (high pulsatility, low pulsatility, and half-peak exercise), as the patient-specific 
physiological experimental conditions were set according to in vivo data that assumes the 
patient is in a homeostatic circulatory system condition. Ultimately, this effect is secondary 
and its changes to the Fontan connection are considered insignificant when compared to 
the primary effects. 
 Though it did not limit accuracy, the five step process used to verify the flexible 
TCPC model compliance (section 4.2.1.4.2) was tedious and time-consuming. In a sense, 
this process is limited in the number of models produced in a given amount of time. 
Technically, step 1 of the process could have been eliminated through the use of a more 
sophisticated finite element analysis (FEA) computational model. The information 
provided from step 1 is the compliance of an arbitrarily thick model given with the silicone 
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model material properties. A more advanced FEA model could have used the volume and 
pressure change information from the in vivo data available, combined with material 
properties from the silicone material, to estimate a desired wall thickness resulting in the 
patient-specific compliance. This methodological change should be considered if a larger 
number of compliance-matched flexible TCPC models are to be constructed. 
 The final limitation of the in vitro Fontan circulation model is concerning the use 
of the BH anatomical data as the baseline model shape. This selection assumes that the BH 
anatomical data holds the TCPC stress-free state, which is most acceptable when 
performing analyses only based on the BH condition. The pulsatility data collected in this 
study, for example, can validly use this assumption. However, it is possible that the 
introduction of respiration and/or a switch to exercise conditions introduced a different 
baseline, mean pressure in the chest cavity. This would mean that employing the BH model 
shape during those conditions eliminates its validity as a stress-free model. This could 
cause unpredictable changes to local wall deformations that may affect each of the metrics 
calculated. The use of condition-specific models rather than just patient-specific flexible 
TCPC models was not pursued due to time and cost. Future considerations of TCPC wall 
deformation (most probably in the case of CFD FSI analyses) should carefully consider 
and define the TCPC stress-free state for each patient-specific condition. 
7.2 PIV Velocity Field Analysis 
The most notable limitation related to the PIV velocity field analysis is due to the PIV 
acquisition method itself. Without the ability to collect volumetric particle image 
velocimetry data, stereoscopic PIV data at sparsely spaced planes is the next best 
acquisition technique. The limitations in analyzing the resultant volumetric velocity field 
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from the stereoscopic PIV data are housed in the volumetric and temporal interpolation 
necessary to fill in missing data. 
The linear temporal interpolation employed between the PIV-acquired time points 
may not be representative of the temporal velocity behavior. Fluid dynamics possesses 
inherently non-linear physics, so the potential exists that a non-linear temporal 
interpolation scheme may more accurately represent the temporal velocity field changes. 
This limitation affects the viscous dissipation and hepatic flow distribution metrics 
calculated from the transient velocity field data sets (pulsatile and patient-specific data 
sets), but only in so far as the absolute values of these metrics are concerned. Comparisons 
between these metrics should still hold, as the temporal interpolation method is kept the 
same for all transient experimental conditions. 
 The volumetric interpolation method employed a static TCPC unstructured mesh 
to resample the enclosed rectangular prism, and defines a 0 (zero) velocity value on the 
TCPC unstructured mesh surface. This resampling and 0 (zero) velocity boundary 
definition is necessary to define the TCPC model boundary location and use the location 
to interpolate velocity values not lying in the PIV-acquired planes. However, the TCPC 
unstructured mesh is static, which means it does not deform with the deforming planes. To 
guarantee that the static TCPC unstructured mesh never over-wrote velocity data in the 
PIV-acquired plane locations, the mesh was offset by 2 mm outward at every surface. This 
method most directly affects the velocity gradients near the wall, which then affects the 
viscous dissipation metrics most drastically. 
The hepatic flow distribution calculation, which is based on the PIV velocity fields, 
is calculated by seeding an IVC cross-sectional plane evenly with respect to space. This 
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even seeding distribution assumes that the hepatic factor, which originates upstream of the 
IVC in the liver, is perfectly well-mixed in the bloodstream by the time it reaches this 
seeding plane. A more accurate HFD calculation can be conducted if the anatomical model 
includes both the hepatic veins (hepatic factor input/source) and the IVC are included 
before their confluence. Unfortunately, including these vessels was not standard of care or 
part of the MRI data acquisition protocol used for the retrospective data set on which the 





The Fontan procedure is the standard palliative treatment for single ventricle congenital 
heart defects. Though early outcomes are successful, long-term complications exist. These 
complications and patient outcomes are related to Fontan connection local and global 
hemodynamics. The evidence for these relationships exist based on in vivo, in vitro, and 
computational studies, some of which assumed rigid-wall Fontan connection models. This 
study developed an in vivo compliance-verified Fontan connection model as the basis for 
a set of in vitro Fontan connection hemodynamics experiments exploring the effects of 
respiration, exercise, and pulsatility on Fontan hemodynamics. The hypothesis of the study 
is that respiration, exercise, and pulsatility each affect Fontan hemodynamic metrics related 
to patient outcomes. The conclusions from each of the study aspects are included in the 
following sections. 
8.1 Fontan Circulation In Vitro Modelling 
This study successfully developed an in vivo compliance-verified Fontan connection model 
for use in an in vitro Fontan circulation. Development included analysis of patient-specific 
MRI data to calculate the in vivo compliance, and iterative in vitro compliance testing using 
computational simulations to determine material properties. The completed in vitro Fontan 
circulation matched target in vivo flow conditions within an acceptable percentage, as 
quantified by two different error metrics. Both these patient-specific flow conditions based 
on MRI data and derived flow conditions were used as experiments from which bulk 
hemodynamic and local velocity fields were collected. The collected data was analyzed for 
the effect of respiration, exercise, and pulsatility on Fontan hemodynamic metrics related 
to patient outcomes. 
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8.2 Respiration and Fontan Hemodynamics 
The effect of respiration on Fontan hemodynamics was assessed for two different patient-
specific Fontan connection models. The respiration effect for each model was assessed by 
comparing and contrasting a patient-specific breath-held experimental condition to a 
patient-specific free-breathing experimental condition. Velocity fields were compared 
qualitatively, and the following quantitative metrics were also compared: apparent power 
loss, indexed power loss, a viscous dissipation term, indexed viscous dissipation, and 
hepatic flow distribution. 
 The results of the respiration comparison showed some consistent trends. Apparent 
power loss consistently increases with added respiration. Also, hepatic flow distribution 
consistently decreases with the added influence of respiration. Indexed power loss, the 
viscous dissipation term, and indexed viscous dissipation did not show consistent trends. 
All three of these metrics showed an increase in value when respiration effects were added 
for the first patient-specific model (CHOP11B), but then showed a decreased value for the 
second model (CHOP235A). 
 The trends found in this study are important to understand for Fontan patient well-
being. Though highly patient-specific and with some quantifiable error, trends showing a 
decrease in hepatic flow distribution when respiration effects are considered can affect 
clinical understanding surrounding pulmonary arteriovenous malformations. This shunting 
across the capillary bed coincides with, and is attributed to, uneven hepatic flow 
distribution in Fontan patients. Thus, depending on the MRI protocol used for HFD 
analysis, the results may be increased over the true patient’s flow distribution value. 
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 Regardless of trends, the use of free-breathing versus breath-held flow conditions 
affects all of the hemodynamic metrics calculated in this study. The importance of 
accurately modeling the patient-specific physiology with proper anatomy, flexibility, and 
FB versus BH flow boundary conditions cannot be understated.  
8.3 Exercise and Fontan Hemodynamics 
The effect of exercise on Fontan hemodynamics was assessed for two different patient-
specific Fontan connection models. The exercise effect for each model was assessed by 
comparing and contrasting a patient-specific free-breathing experimental condition to a 
derived half-peak exercise experimental condition and a patient-specific peak exercise 
experimental condition. Velocity fields were compared qualitatively, and the following 
quantitative metrics were also compared: apparent power loss, indexed power loss, a 
viscous dissipation term, indexed viscous dissipation, and hepatic flow distribution. 
 The results of the exercise comparison showed some consistent trends. Both 
apparent power loss and the viscous dissipation term increase consistently from the free-
breathing patient-specific condition to the derived half-peak exercise condition, and from 
the derived half-peak exercise condition to the patient-specific peak exercise condition. 
Indexed power loss, indexed viscous dissipation, and hepatic flow distribution did not show 
consistent trends.  
 The most notable Fontan patient outcome related to exercise is the finding that 
increased indexed power loss under resting conditions correlates with decreased exercise 
capacity [48]. There is no established correlation precedent between resting, free-breathing 
indexed power loss and peak exercise power loss. The results of this study contribute to 
this lack of correlation. Exercise intensity level undoubtedly has an influence on both 
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global and local Fontan hemodynamics, but the relationship is complicated. This is not 
surprising, as changing from resting, free-breathing to exercise conditions includes changes 
in mean inflow rate, IVC:SVC inflow ratio, LPA:RPA outflow ratio, waveform pulsatility, 
waveform frequency content, and likely several other parameters. With simultaneous 
changes to so many physiologic variables, it is not surprising  that the relationship with the 
output metrics is more complicated than can be currently determined. 
Regardless of trends, the use of different exercise flow conditions affects all of the 
hemodynamic metrics calculated in this study. The importance of accurately modeling the 
patient-specific exercise physiology with proper anatomy, flexibility, and flow boundary 
conditions cannot be understated. 
8.4 Pulsatility and Fontan Hemodynamics 
The effect of pulsatility on Fontan hemodynamics was assessed for two different patient-
specific Fontan connection models. The pulsatility effect for each model was assessed by 
comparing and contrasting a derived steady flow breath-held experimental condition to a 
derived low pulsatility breath-held experimental condition, a patient-specific breath-held 
experimental condition, and a derived high pulsatility breath-held experimental condition. 
Velocity fields were compared qualitatively, and the following quantitative metrics were 
also compared: apparent power loss, indexed power loss, a viscous dissipation term, 
indexed viscous dissipation, and hepatic flow distribution. 
 The results of the pulsatility comparison showed some consistent trends. Both 
apparent power loss and indexed power loss increase consistently with increasing 
pulsatility. The viscous dissipation term and indexed viscous dissipation also increase in 
value with increasing pulsatility, but only when the steady flow case (0% pulsatility) is not 
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considered. This complicated trend is attributed to the fundamental fluid dynamics 
difference between a steady flow velocity profile and the velocity profile of a pulsatile 
flow. Hepatic flow distribution showed no consistent trend with changing pulsatility. 
 These results help this study conclude that all Fontan connection hemodynamic 
assessments and calculations under pulsatile flow conditions with flexible model walls 
should be performed using pulsatile conditions. Time-averaged flow conditions are an 
inaccurate assessment of power loss, viscous dissipation, and hepatic flow distribution 
metrics under the model conditions used in this study. Previous Fontan hemodynamic 
models without the use of flexible walls concluded that the error introduced by assuming 
time-averaged conditions was small [147,148]. However, the relationship between the 
steady flow value and the pulsatile value for each of these metrics with a flexible wall 
model is too complicated and contains too much variability to base life-changing decisions 
on a steady flow assumption and account for pulsatile flow with a simple correlation. 
Regardless of trends, the use of different flow pulsatility conditions affects all of the 
hemodynamic metrics calculated in this study. The importance of accurately modeling the 
patient-specific physiology with proper anatomy, flexibility, and flow boundary conditions 
– including pulsatility – cannot be understated. 
8.5 Viscous Dissipation Relationship to Power Loss 
A comparison between viscous dissipation and power loss as hemodynamic metrics was 
conducted, exploring the problems power loss faces as an adequate metric for future 
studies.  
Viscous dissipation is an adequate solution to the problems present with the power 
loss as a hemodynamic metric because it maintains physical meaning, is calculable from 
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clinically-available data, and it is relatable to patient outcomes through statistical 
relationships to apparent power loss. The viscous dissipation term derivation from 
differential conservation of energy analysis showed that a volume-integrated viscous 
dissipation term was equal to the true power lost in the TCPC without any invalid 
assumptions. The viscous dissipation terms calculated in this study were derived from a 
time-resolved three-dimensional velocity fields, and do not require pressure measurements. 
Both the non-indexed and indexed viscous dissipation term are statistically relatable to 
apparent power loss and indexed power loss, respectively, for the in silico BH patient-
specific condition across multiple patients. Thus, the indexed viscous dissipation term from 




9 RECOMMENDATIONS AND FUTURE WORK 
9.1 Recommendations 
This study on the effects of respiration, exercise, and pulsatility on in vitro Fontan 
hemodynamics is by no means all-inclusive or final. It does not answer every question. In 
fact, quite the opposite is true. Regardless, there are some lessons learned from this study 
that are important toward the future directions of the field. 
 First, the study findings conclusively recommend the use of flexible-walled TCPC 
models when analyzing Fontan hemodynamics. Admittedly, the Fontan models used in this 
study were homogeneous, and the study results are not directly compared to results from 
rigid-walled models to determine its relative importance to other factors (anatomy, flow 
conditions, etc.). However, the ability to adequately model Fontan connection flows with 
acceptable error proves that flexible modelling is possible. The in vivo information 
undoubtedly states that flexible modelling is required. So, flexible modelling should be 
adopted. The next step along this vein is to account for the heterogeneous nature of the in 
vivo Fontan connection. The main obstacle in employing a heterogeneous model in this 
study was the optical access required for the PIV data collection. 
 Second, this study’s findings recommend careful attention be paid to the 
physiological condition behind all Fontan hemodynamic analyses. The tremendous 
variability in velocity fields produced by the different experimental conditions in this study 
result in large changes in patient-relevant outcomes. Though not always explicitly 
visualized, these velocity field variations will be present for any in vivo, in vitro, or in silico 
studies. Thus, all studies should note the general finding that small changes in Fontan 
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connection boundary conditions can have large effects on patient-relevant metrics, and take 
extra care in assigning and characterizing these conditions.  
 Third, this study advocates for the continued use of the viscous dissipation term as 
an important metric potentially relatable to patient outcomes. The apparent power loss 
metric established in the literature is a construct of the Bernoulli equation assuming steady 
flow and constant control surface boundary conditions. These assumptions break down in 
the presence of pulsatile flow (see section 6.5). Conducting future studies using only 
apparent power loss and indexed power loss as efficiency-related metrics may confound 
future findings and patient outcome relationships. As engineering procedures advance to 
include more complex patient-specific modeling the metrics to relate findings from these 
models and simulations to patient outcomes must include the effect of the modeling 
advancements, or else the extra effort to advance the model provides very little clinical 
impact. 
9.2 Future Work 
Future work examining Fontan hemodynamics relatable to patient outcomes should include 
efforts to overcome some of the limitations from this study.  
The first limitation to address is the simplified material properties this study used to 
characterize TCPC compliance. The most advanced work toward modelling the 
heterogeneous nature of the TCPC exists in a study from Long et al [45]. Without the 
optical access requirement of an in vitro study seeking velocity field information, Long et 
al was able to assign different material properties according to the computational mesh 
spatial location. Long et al then performed fluid structure interaction simulations and drew 
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conclusions on the influence of variable wall properties. What remains is verification of 
the Long et al model, both from a material property and fluid dynamics perspective.  
The second limitation to address is the inability to assess long-term Fontan circulation 
changes with the current in vitro model. This limitation also exists for the current 
computational and animal Fontan circulation models. Adding chronic outcomes to these 
models will require an extensive understanding of Fontan circulation growth and 
remodeling, which is currently not well understood. This understanding will, most likely, 
require an extensive, long-term clinical data collection study encompassing several years 
to decades. The most promising source of retrospective data may be The Australian and 
New Zealand Fontan Registry, an extensive database of thousands of Fontan patients 
spanning decades. 
The third limitation to address is the stereoscopic PIV and volumetric interpolation 
methods used to acquire the volumetric velocity fields. The post-acquisition plane 
alignment and interpolation introduce uncertainties which can possibly be decreased if a 
volumetric PIV method were followed instead. Tracking the TCPC wall motion to replace 
the static boundary used in the spatial and temporal interpolation method will also improve 
velocity field accuracy. 
The final limitation to be addressed by future work is to acquire PIV data which 
includes the hepatic veins. This eliminates the need to assume that the hepatic factor is 
evenly distributed at the seeding plane location for hepatic flow distribution calculations. 
Ultimately, Fontan circulation in vitro modeling needs to advance each of the above 
listed areas because of its pivotal role in addressing biomedical engineering issues related 
to patient outcomes. The advancement of medical technology, either through medical 
 
 176 
device development or medical procedural changes, is best accomplished through the 
multi-prong approach of in vivo, in vitro, computational, animal testing, and clinical trials. 
In vitro tests play a pivotal role in providing a middle ground between in vivo, animal 
testing, and clinical trials, which provide limited information about true physiology, and 
computational models, which provide almost boundless information about a modelled 
physiology. The middle ground consists of true physics (fluid dynamics, solid mechanics, 
etc.) of a modelled physiology useful for repeatable testing that provides more information 
(can be examined more invasively) than in vivo studies, but less information than 
computational studies. Thus, the key to every in vitro study and its effectiveness in 
furthering medical technology is in its modelling limitations. By identifying and 
eliminating these limitations, in vitro studies will continue to play a pivotal role in 
biomedical engineering. 
With as many modelling limitations overcome as possible, the next stage for Fontan 
patients in general is to transition from a palliative to a curative procedure. The underlying 
issue for all Fontan patients is their fundamentally different circulatory system. The lack 
of a pulmonary support pump leads to the numerous comorbidities and complications they 
endure [156]. One future avenue for eliminating these complications is to provide a 
mechanical pump. Mechanical pumps already exist as ventricular assist devices (VADs) 
for congestive heart failure patients, and studies exist examining some existing VAD 
designs for efficacy in the Fontan connection [104,157]. Significant obstacles regarding 
growth and remodeling, flow pulsatility, VAD preload requirements, and Fontan 
connection afterload remain before existing VADs can be used in Fontan patients. These 
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APPENDIX A: LABVIEW VIRTUAL INSTRUMENT 
The LabVIEW virtual instrument used to control the pulsatile piston pump, trigger imaging 
systems, and record pressure and flow measurements was composed of an active waveform 
display on the left-hand side and various control panels on the right with different display, 
calculations, calibration, and output settings. Figure 11-1 shows the panel with display 
settings. Figure 11-2 shows the panel with calculations settings. Figure 11-3 shows the 
panel with calibration settings. Figure 11-4 shows the panel with output settings. 
 
Figure 11-1: LabVIEW virtual instrument with plot display settings panel. The Plot 1 and Plot 2 curves 
settings are used to display different channels in the plots on the left. The two plots in the lower right 




Figure 11-2: LabVIEW virtual instrument with calculations settings panel. The Resistance Calculation 
Input and Mean/Pulsatility Channel boxes are used to specify the input channel number (0-15) for the 
calculations displayed below. The analysis period displays the time, in seconds, over which the 





Figure 11-3: LabVIEW virtual instrument with calibration settings panel. This panel is used to specify 
the linear relationship between the analog input signal (V) and its respective metric value (L/min or 
mmHg) using a gain (G) and offset (O) for each channel. The DO Force Null? button can be used to 






Figure 11-4: LabVIEW virtual instrument with output settings panel. The trigger and pump filepath 
boxes specify the custom waveform file location (.csv format) on the computer hard drive. The 
multiplier and period boxes (above and below) specify the custom waveform amplitude gain and time 
period, respectively. The input and output channels boxes specify the DAQ devices and channels used. 
The Input/Output Rate box specifiys the data sampling and created waveform frequency. The Samples 
to Read box specifies the number of samples (at the Input/Output Rate box frequency) to use when 




APPENDIX B: SEGMENT FLOW ANALYSIS 
The following content is chapter 22 from the Medviso Segment v1.9 user’s manual. This 
chapter addresses flow analysis and was used in the acquisition of patient-specific flow 
data. 
22 Flow Analysis 
This functionality may depend on your MRI scanner. Currently it has 
been tested using Siemens, Philips and GE scanners. 
When flow image stacks are displayed, the screen should now similar to 
what is shown in Figure 34. On the left image panel the magnitude image is 
shown and on the right image panel the phase image is shown. When a flow 
image stack is selected a white frame around both the magnitude image and 
phase image is drawn in the thumbnail preview area. This helps to keep track of 
which phase images belongs to which magnitude images. 
 
 
Figure 34: Example of main GUI in flow mode. 
22.1 Automatic segmentation of flow ROI’s 
The suggested method is to select the ROI tool . Then draw a rough 
outline of the vessel contour. Thereafter start the automated vessel tracking and 
refine. This is done by pressing Ctrl-T. 
Another method to automatically segment a vessel is to drag the center 
cursor (white +) to the approximate center of the desired vessel and press Ctrl-
G, or Auto delineate a vessel under the Segmentation→ROI and Flow Tools 
menu. The vessel is automatically delineated and you are asked for an 
appropriate label. Deleting, renaming, recoloring the region of interest is 
described in Chapter 17. If you are not satisfied with the ROI there are two 





Refine operation operates on the current time frame or all time frames 
depending on the single frame mode checkbox. Short key for the refine function 
is Ctrl-R. You need to have the ROI pen active when using the hot key. Refine 
on all time frames is particularly useful if the vessel is fairly round and not too 
close to other surrounding tissue. 
 
22.1.2 Refine and propagate 
Start at the first time frame of the time series. If pleased with the result simply use the right 
arrow key on the keyboard to proceed to next time frame. When you find a time frame 
where you are not pleased with the segmentation use the ROI pen to adjust the contour or 
use the refine option Ctrl-R with the single frame mode checkbox enabled. Continue by 
propagating the contour by pressing Ctrl-F. 
 
22.1.3 Shrink flow ROI 
If the RIO is outside the vessel then it might be advantageous to shrink 
the ROI followed by one or more refine operations. Shrink flow ROI is found 
under the Segmentation menu and the submenu ROI and Flow tools. 
 
22.2 Plotting the result of the flow analysis 
The flow plotting utility is started by using the icon  or by using the 
function Plot flow curves under the Flow menu. An example of the graphical 
user interface is shown in Figure 35. 
In the upper right area of the GUI you can select which parameter to plot. 
The volumes presented in Volume panel of the GUI represents flow integrated 
between the two vertical red bars. These bar can interactively be moved with the 
mouse to control the range of the integration. Forward volume is the volume of 
the flow integrated only over the time frames where the net flow is positive 
(forward). Backward volume is the volume of the flow integrated only over the 
time frames where the net flow is negative (back- ward). This should be 
contrasted to the flow parameter Forward/Backward that plots simultaneously 
the flow that goes forward and backward of the region of interest. Note that there 
can be significant backward flow in one time frame even though the net flow is 
forward in that very time frame. An example on the latter is shown in Figure 36. 






Figure 35: Example of flow plotting GUI. Plotting parameter can be 
selected in the upper right corner of the GUI. The flow integration is performed 
between the two red bars. 
 
It is also possible to plot the Velocity over time, and this is shown in 
Figure 37. The ’error bars’ denote the standard deviation of all pixels in the ROI 
of that particular time frame. 
Another possibility is to plot the max or min velocity in the ROI over 
time. It is also possible to plot the radius and diameter over time. The radius are 
calculated as; what diameter need a circular vessel have to have the same area as 
the area of the ROI. The option Signed Kinetic Energy calculates the kinetic 
energy in the blood assuming standard density of the blood. 
The final possibility is to plot a 3D profile of the velocity distribution 
of the vessel. This can be plotted for all time frames at once or only a single 
time frame that later can be stepped forward/backward in time. An example of 





Figure 36: Example of plotting of backwards and forward flow 
simultaneously. The sum of the two curves will be the net flow showed in Figure 
35. 
22.3 Compensating for eddy current effects 
To get accurate flow measurements it is important to compensate for 
concomitant field effects such as eddy currents, and Maxwell effects. Ideally 
Maxwell effects should be compensated for directly on the MRI scanner since 
it can be analytically calculated. Consult your MRI vendor for details about how 
this is implemented in your scanner. Note that when compensating for eddy 
current effects the image stack should not be cropped upon loading, since the 
algorithm need phase information of static tissue in the chest wall to function 
properly. 
The graphical user interface for compensating for eddy current effects 





Figure 37: Example of plotting of velocity over time. The ’error’ bars 
shown the standard deviation of the pixels within the ROI over time. 
 
 
Figure 38: Example of plotting of a 3D profile of the velocity distribution. 
 
 Figure 39: Example graphical user interface for compensating of concomitant field 
effects. In the left the identified static tissue is the displayed, and in the middle panel the 
corresponding phase for these pixels is shown, and in the right panel the resulting phase 
correction is shown. 
 
You can select model order, and clear the phase correction. When you are 
pleased with the phase correction press Apply to proceed. The function automatically finds 
stationary parts in the image by selecting a percentage of the pixels whose standard 
deviation of the phase over time is smallest. The fraction of pixels taken can be controlled 
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by the edit box Percentile. The image is divided into four quadrants and the algorithm to 
find stationary pixels is applied to each quadrant separately. This is done to ensure that 
there are about the same number of pixels from each quadrant. Pixels taken as stationary 
tissue are shown as red dots in the magnitude image. The Magnitude slider controls what 
magnitude the pixels need to have before being labeled as stationary. By selecting the mode 
of operation as Static tissue ROI then ROI's that are labeled Static tissue are taken as 
stationary areas. This is particularly useful when doing phantom experiments, since the 
automated identification of static areas fails in cases with stationary row. The mode of 
operation Phantom Experiment (GE-method) automatically finds a row image stacks that 
have the same scanning parameters this useful when a static tissue have been scanned in 
the same position as the patient as recommended by GE for eddy current compensation. 
For usage, see paper by Alex Chernobelsky et al. [10]. 
 
 22.4 Phase unwrapping 
In cases were the velocity in the blood is higher than the VENC the velocities can 
wrap around. Under certain conditions these phase wraps can be uncovered and phase 
unwrapping can be performed to retrieve the correct velocities. The graphical user interface 
for the phase unwrapping tool is shown in Figure 40 
The Show ROI pixels checkbox shows the pixels that are used in the ROI in a red color. 
This is useful when one want to know exactly what pixels are included in the ROI. The 
Use Magnitude Mask checkbox is used when one want to limit the automated phase 
unwrapping only in pixels that have a magnitude over a certain threshold. 
 
22.4.1 Automated Unwrapping 
The automated phase unwrapping algorithm works on a pixel by pixel basis and 
operates along the temporal dimension. It looks for pixels where the phase appears to have 
wrapped once up and once down. Therefore the algorithm will fail for a biphasic velocity 
profile if phase wrapping occurs at both phases. Furthermore, it only considers single wrap 





Figure 40: Example of the graphical user interface for phase unwrapping. The left 
image panel shows the original phase, and the right image panel shows the unwrapped 
phase. The long slider adjusts the current time frame. 
 
22.5 Creating angio and velocity magnitude images 
It is possible to create a so called angio image that is the magnitude image times the velocity 
magnitude. This is available under the Flow menu and Create Angio. If you have more than 
one velocity encoding direction it is possible to create a velocity magnitude image that is 
the square root of the sum of squares of all velocity directions (velocity magnitude). 
 
22.6 Coupling magnitude and flow images 
If magnitude and flow image stacks have been loaded into Segment without being coupled 
to each other, it is possible to couple them using the Couple Magnitude/Phase Flow Image 
Stacks from the Flow menu. Available magnitude and phase image stacks are then 





APPENDIX C: CUSTOM FFT MATLAB SCRIPT 
The following custom-built MATLAB script was used to determine the frequency content 







%% Frequency Analysis of Each Vessel Signal 
  
% pull in the individual vessel data to be analyzed 
data = rpa_ex;                              % data for specific vessel         
N = length(data);                           % number of discrete data 
points 
Dt = 0.02002004;                            % time step size (secs) USER 
INPUT! 
T = N*Dt ;                                  % total time 
ffreq = 2*pi/T ;                            % fundamental frequency 
t = linspace(0,T,N) ;                       % time vector 
f = (1/Dt)*(0:(N/2))/N';                    % frequncy domain 
k=0:(N/2-1);                                % frequency counter 
omega=k*ffreq;                              % in units of rads/sec 
  
% perform a single fft on the entire data 
ftilde = data;                              % re-cast the data 
ftilde(1) = (data(1)+data(end))/2 ; 
ftilde(end) = [] ; 
  
Fone = fft(ftilde,N) ;                      % perform fft 
  
P2tilde = abs(Fone/N);                      % 2-sided spectrum 
P1tilde = P2tilde(1:N/2+1); 
P1tilde(2:end-1) = 2*P1tilde(2:end-1);      % single-sided spectrum 
  
h(3) = figure(3); 
plot(f,P1tilde) 
  
% perform a BUNCH of ffts on data subsets, and we'll average the result 
num = 1000;                                 % number of ffts 
P1_sum = 0;                                 % initialize power spectrum 
vector 
Y_sum = 0;                                  % initialize Foureir 
coefficients vector 
fft_store = cell(2,num);     
  
% initialize fft store cells 
for i = 1:num 
    r = rand(); 
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    begin = floor(1+(N/2-1)*r);             % set random beginning between 
1 and N/2 
    data_subset = data(begin:end); 
     
    fhat = data_subset;                     % re-cast the data 
    fhat(1) = (data_subset(1)+data_subset(end))/2 ; 
    fhat(end) = [] ; 
     
    F = fft(fhat,N) ;                       % perform fft 
         
    P2 = abs(F/N);                          % 2-sided spectrum 
    P1 = P2(1:N/2+1); 
    P1(2:end-1) = 2*P1(2:end-1);            % single-sided spectrum 
         
    fft_store{1,i} = P1;                    % store power spectra 
    fft_store{2,i} = F;                     % store fft values 
      
    P1_sum = P1_sum + P1;                   % sum all of the power spectra 
vectors to get average later 
end 
  
P1_avg = P1_sum./num;                       % average power spectrum 
  
h(1) = figure(1); 
plot(f,P1_avg)                              % plot single sided amplitude 
spectrum 




% L = 10; 
% fapprox = A(1)*ones(size(t)); 
% for k=1:L 




% ask for user input 
in = input('Enter the TOTAL number of frequencies to be kept, NOT 
including the zero frequency: '); 
  
freqs = zeros(in,1); 
locs = zeros(in,1); 
  
for i = 1:in 
    h(1) = figure(1); 
    plot(f,P1_avg) 
    title('Single-Sided Amplitude Spectrum of X(t)') 
    xlabel('f (Hz)') 
    ylabel('|P1(f)|') 
     
    datacursormode on 
    dcm_obj = datacursormode(h(1)); 
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    display('Click peak to save frequency, then press Return.') 
    pause                                   % Wait while the user does 
this. 
     
    c_info = getCursorInfo(dcm_obj); 
    freqs(i) = c_info.Position(1);          % store frequencies to be 
kept 
    locs(i) = find(freqs(i) == f,1);        % store index location of 
these frequencies in the frequency vector 
end 
  
% Use the coefficients from the SINGLE fft calc rather than the averaged 
% The averaged power spectrum from the multiple FFTs was used simpley to 
% see the frequency content easier. Averaging out all the Fourier 
% coefficients in this case will ruin our reconstruction of the data, so 
we 
% must only use the single fft calculation when reconstructing. 
  
A = 2*real(Fone)/N;                        % cosine coefficients 
A(1)= A(1)/2 ; 
B =-2*imag(Fone)/N;                        % sine coefficients 
  
fapprox = A(1)*ones(size(t)); 
for l=1:length(locs) 
    k = locs(l); 
    fapprox = fapprox + A(k)*cos(omega(k)*t) + B(k)*sin(omega(k)*t); 
end 
  







APPENDIX D: VESSEL FREQUENCY CONTENT 
This appendix includes tables of the coefficients and frequencies extracted from MRI flow 
data that serve as filtered patient-specific waveforms to which the in vitro Fontan 
circulation model was verified. Relate to section 4.2.1.2. 
Table 11-1: CHOP11B BH patient-specific pulsatility frequency content 
CHOP11B BH 
n An (cos terms) Bn (sin terms) ωn = 2πfn fn (Hz) 
0 37.837 0 0 0 
1 2.304 -2.497 6.088 0.969 
2 -7.924 0.477 12.177 1.938 
3 0.627 0.819 18.265 2.907 
4 -0.822 1.172 24.353 3.876 
5 -2.062 2.238 30.442 4.845 
6 -1.480 2.872 36.530 5.814 
7 -0.344 3.352 42.619 6.783 
8 0.246 2.915 48.707 7.752 
9 0.954 2.706 54.795 8.721 
10 1.454 2.581 60.884 9.690 
11 2.096 2.197 66.972 10.659 
12 2.550 1.736 73.060 11.628 
13 2.691 1.149 79.149 12.597 




Table 11-2: CHOP11B FB patient-specific pulsatility frequency content 
CHOP11B FB 
n An (cos terms) Bn (sin terms) ωn = 2πfn fn (Hz) 
0 50.375 0 0 0 
1 -4.813 -4.400 0.316 0.050 
2 2.677 1.383 0.631 0.100 
3 3.504 4.249 0.947 0.151 
4 14.725 -1.822 1.263 0.201 
5 6.551 -16.413 1.579 0.251 
6 2.128 13.751 1.894 0.301 
7 -15.924 8.483 2.210 0.352 
8 -10.958 0.580 2.526 0.402 
9 3.678 0.118 2.841 0.452 
10 -6.173 -5.486 3.157 0.502 
12 -1.710 -7.448 3.788 0.603 
14 3.439 5.029 4.420 0.703 
15 -4.146 4.101 4.736 0.754 
17 1.726 0.813 5.367 0.854 
18 -5.982 2.089 5.683 0.904 
19 -0.832 -8.075 5.998 0.955 
20 -2.278 -4.941 6.314 1.005 




Table 11-3: CHOP11B EX patient-specific pulsatility frequency content 
CHOP11B EX 
n An (cos terms) Bn (sin terms) ωn = 2πfn fn (Hz) 
0 113.674 0 0 0 
1 1.727 3.643 0.628 0.100 
2 6.386 1.914 1.255 0.200 
3 5.828 -0.630 1.883 0.300 
4 15.475 -0.305 2.511 0.400 
5 -5.059 -3.756 3.138 0.499 
6 -0.411 6.525 3.766 0.599 
7 -6.485 8.694 4.394 0.699 
9 5.267 -8.727 5.649 0.899 
10 -9.308 7.242 6.277 0.999 
16 3.191 -12.134 10.043 1.598 
18 -2.898 -1.988 11.298 1.798 
20 2.863 -9.624 12.554 1.998 
21 8.266 -4.831 13.181 2.098 
23 2.001 -5.120 14.437 2.298 
28 1.231 -4.773 17.575 2.797 
29 -3.975 8.856 18.203 2.897 
30 3.734 -3.922 18.831 2.997 
31 -6.584 -2.595 19.458 3.097 
38 4.615 3.482 23.852 3.796 
39 1.084 -14.482 24.480 3.896 
45 9.331 -13.327 28.246 4.495 
46 9.824 -3.824 28.874 4.595 
47 15.164 6.212 29.501 4.695 
48 -16.751 23.731 30.129 4.795 
49 17.739 -6.014 30.757 4.895 
50 -2.113 -8.036 31.384 4.995 
51 0.899 -10.293 32.012 5.095 




Table 11-4: CHOP235A BH patient-specific pulsatility frequency content 
CHOP235A BH 
n An (cos terms) Bn (sin terms) ωn = 2πfn fn (Hz) 
0 38.984 0.000 0.000 0.000 
1 4.351 5.884 8.231 1.310 
2 -1.425 4.381 16.462 2.620 
3 -3.603 -2.625 24.693 3.930 
4 -2.619 -0.965 32.924 5.240 
5 -0.509 0.421 41.154 6.550 
6 -0.440 -0.621 49.385 7.860 
7 -0.292 0.064 57.616 9.170 
8 -0.628 0.523 65.847 10.480 
9 -0.489 0.074 74.078 11.790 
10 -0.396 0.539 82.309 13.100 
11 -0.578 0.698 90.540 14.410 
12 -0.647 0.480 98.771 15.720 
13 -0.462 0.601 107.001 17.030 
14 -0.494 0.733 115.232 18.340 
15 -0.493 0.599 123.463 19.650 
16 -0.344 0.666 131.694 20.960 
17 -0.292 0.803 139.925 22.270 
18 -0.367 0.750 148.156 23.580 
19 -0.238 0.788 156.387 24.890 
20 -0.210 0.844 164.618 26.200 
21 -0.238 0.807 172.849 27.510 
22 -0.181 0.896 181.079 28.820 
23 -0.112 0.863 189.310 30.130 
24 -0.084 0.784 197.541 31.440 
25 -0.001 0.812 205.772 32.750 
26 0.056 0.825 214.003 34.060 
27 0.110 0.818 222.234 35.370 
28 0.156 0.822 230.465 36.680 
29 0.160 0.794 238.696 37.990 
30 0.236 0.779 246.927 39.300 
31 0.331 0.752 255.157 40.610 
32 0.349 0.717 263.388 41.920 
33 0.412 0.708 271.619 43.230 
34 0.457 0.701 279.850 44.540 
35 0.486 0.650 288.081 45.850 
36 0.548 0.634 296.312 47.159 
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37 0.580 0.612 304.543 48.469 
38 0.601 0.568 312.774 49.779 
39 0.645 0.526 321.004 51.089 
40 0.681 0.492 329.235 52.399 
41 0.696 0.442 337.466 53.709 
42 0.730 0.395 345.697 55.019 
43 0.766 0.367 353.928 56.329 
44 0.762 0.313 362.159 57.639 
45 0.783 0.250 370.390 58.949 
46 0.805 0.210 378.621 60.259 
47 0.804 0.164 386.852 61.569 
48 0.825 0.118 395.082 62.879 




Table 11-5: CHOP235A FB patient-specific pulsatility frequency content 
CHOP235A FB 
n An (cos terms) Bn (sin terms) ωn = 2πfn fn (Hz) 
0 36.608 0.000 0.000 0.000 
1 5.728 -0.053 0.316 0.050 
2 3.087 -0.866 0.632 0.101 
3 4.376 2.969 0.949 0.151 
4 2.224 -0.825 1.265 0.201 
5 20.811 -2.485 1.581 0.252 
6 5.354 0.788 1.897 0.302 
7 1.617 3.956 2.213 0.352 
8 -1.709 4.807 2.530 0.403 
9 -4.188 2.118 2.846 0.453 
10 9.423 -0.191 3.162 0.503 
11 0.474 0.706 3.478 0.554 
12 -2.738 1.448 3.794 0.604 
13 -3.801 0.440 4.111 0.654 
14 -3.950 -3.431 4.427 0.705 
15 0.109 -1.452 4.743 0.755 
16 -0.743 -2.669 5.376 0.856 
17 -0.201 -2.125 5.692 0.906 
18 -1.282 -6.756 6.008 0.956 
19 -7.525 -0.333 6.324 1.007 
20 0.362 2.960 6.640 1.057 
21 -0.746 2.745 6.957 1.107 
22 4.086 1.236 7.273 1.157 
23 2.552 -1.052 7.589 1.208 
24 -2.413 -0.192 8.538 1.359 
25 0.496 -2.150 10.119 1.610 
26 -3.135 -2.063 12.332 1.963 
27 -0.545 2.687 12.648 2.013 
28 0.985 2.785 28.142 4.479 
29 2.198 0.843 28.459 4.529 




Table 11-6: CHOP235A EX patient-specific pulsatility frequency content 
CHOP235A EX 
n An (cos terms) Bn (sin terms) ωn = 2πfn fn (Hz) 
0 77.981 0.000 0.000 0.000 
1 -13.317 6.851 0.624 0.099 
2 -6.536 0.440 1.247 0.199 
3 -12.169 6.102 1.871 0.298 
4 17.338 -7.174 2.495 0.397 
5 -29.383 -2.079 3.119 0.496 
6 29.857 23.892 3.742 0.596 
7 2.262 24.937 4.366 0.695 
8 12.264 0.184 4.990 0.794 
9 10.817 -7.215 5.613 0.893 
10 10.168 0.211 6.861 1.092 
11 -18.086 -2.376 8.108 1.290 
12 2.268 -13.457 18.087 2.879 





APPENDIX E: COMPREHENSIVE EXPERIMENTAL CONDITIONS 
The following table, Table 11-7, provides a comprehensive list of metrics describing the 
experimental conditions conducted in this study. These metrics are derived from the 
hemodynamic results. 















Steady 3.28 73.9 46.9 0 
Patient-
Specific 3.2 75.1 45.9 33.4 
Low 
Pulsatility 3.22 73.8 46.9 12.7 
High 
Pulsatility 3.21 74.1 45.9 57.5 
FB 
Steady 3.9 75.8 47.4 0 
Patient-
Specific 4.04 76.3 56.4 84.8 
EX 
Peak 




7.90 79.3 43.1 101.1 
Half-Peak 
Steady 6.08 78.5 47.0 0 
Half-Peak 
Pulsatile 5.95 77.8 46.1 93.4 
CHOP235A 
BH 
Steady 3.10 79.0 23.5 0 
Patient-
Specific 3.10 76.8 23.0 31.9 
Low 
Pulsatility 3.09 77.0 18.6 22.0 
High 
Pulsatility 3.21 77.3 23.1 38.6 
FB 
Steady 4.96 43.9 25.1 0 
Patient-
Specific 4.96 43.8 25.3 115.2 
EX 
Peak 




7.08 48.2 25.3 126.4 
Half-Peak 
Steady 6.22 47.3 26.8 0 
Half-Peak 




APPENDIX F: PIV ACQUISITION IMAGE CONVERSION STUDY 
The purpose of this short study was to determine the number of images required to insure 
velocity field convergence of PIV data. The velocity field data is acquired over a transient 
flow profile at specific time points (see Figure 4-10 for example), and then ensemble 
averaged over several flow profile cycles. The number of cycles (with one image pair per 
cycle) required to converge the ensemble average velocity field is the quantity in question. 
If an adequate number of images is not acquired, the resulting ensemble velocity field data 
is inaccurate. However, acquiring an excessive number of cycles increases acquisition time 
and required data storage space. 
 The number of cycles over which to acquire images for each time point was 
determined by collecting a large number of images for a representative time point and 
iteratively processing an increasing number of these images until changes in the ensemble 
average velocity field became increasingly small. The processing method conducted for 
this convergence study was the same as for all PIV processed images, as outlined in section 
4.2.2.2.4. The representative time point chosen was from the CHOP11B Peak Exercise 
condition during maximum IVC inflow. This point was chosen because it was the 
maximum Reynolds number across all data acquisition conditions, and thus possessed the 
most potential for time-dependent inconsistencies. Convergence analysis was conducted 
by collecting 200 image pairs at this time point, and subtracting the processed velocity field 
of the 200 image pairs from an increasing number of processed image pairs in 25 image 
increments. The resulting velocity field then included a velocity difference at each spatial 




Figure 11-5: PIV image convergence study example calculation of velocity difference 
The ensemble average velocity field was considered converged when the velocity 
difference equaled zero. Figure 11-6 displays the total velocity difference value for each 
number of image pairs calculated, for each image sampling plane of the model. 
 
Figure 11-6: Total velocity difference value for each convergence study calculation 
 The results of the convergence study show that each PIV measurement plane 
possesses ensemble average velocity field convergence at 125 image pairs. Thus, the PIV 




APPENDIX G: PIV VELOCITY FIELD ANALYSIS STATE 
MACHINES AND SCRIPTS 
G.1 Plane Alignment 
The plane alignment ParaView state machine used for PIV velocity field analysis methods 
in section 4.2.2.2.5.1 was copied and saved for each condition analyzed. A screen shot of 
the state machine in use for the CHOP11B BH patient-specific pulsatility condition is 
shown in Figure 11-7. 
 
Figure 11-7: AlignPlanes.pvsm screenshot showing the mechanism for aligning the planes of an 
acquisition in space 
G.2 Concatenate Points 
The following custom MATLAB script takes the velocity data points on each plane and 
the TCPC model and concatenates them together into a single data set. 
% Concatenate Planes and TCPC 
% This script takes the aligned experimental planes and TCPC surface and 








%% User Input 
  
FolderLoc = 'Z:\PIV\11B\BH_EX_PK\BH_Puls_High_PostProcessing\saves\'; 
LastFileNum = 44; 




TCPCfilename = 'tcpc.0.csv'; 
  
WriteNamePrefix = 'AllPoints_'; 
WriteNamePostfix = '.csv'; 
  
%% 
for i = 1:LastFileNum+1 
    AllPoints = []; 
    FileNum = i-1; 
    for j = 1:length(PlaneNames); 
        PlaneName = PlaneNames{j}; 
        FileName = 
strcat(PlaneName,filenameMid,num2str(FileNum,'%d'),filenamePostfix); 
        CSV = csvread(FileName,1,3); 
        AllPoints = [AllPoints; CSV]; 
    end 
    % Add TCPC to each time step and make sure that the matrix saved has 
    % unique rows 
    AllPointsTime = AllPoints; 
    TCPCfile = strcat(FolderLoc,TCPCfilename); 
    TCPCCSV = csvread(TCPCfile,1,6); 
    AllPointsTime = [AllPointsTime; TCPCCSV]; 
    AllPointsTime = unique(AllPointsTime, 'Rows'); 
     
    % allocate names for table 
    Vx = AllPointsTime(:,1); 
    Vy = AllPointsTime(:,2); 
    Vz = AllPointsTime(:,3); 
    Mag = AllPointsTime(:,4); 
    PointsX = AllPointsTime(:,5); 
    PointsY = AllPointsTime(:,6); 
    PointsZ = AllPointsTime(:,7); 
        
    % Create a table from the saved arrays 
    T = table(Vx, Vy, Vz, Mag, PointsX, PointsY, PointsZ); 
     
    % Save the table as a CSV file for import into Paraview 
    SaveName = 
strcat(FolderLoc,WriteNamePrefix,num2str(FileNum,'%d'),WriteNamePostfix
); 
    writetable(T,SaveName);  
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    % display time step just finished 
    TimeStep = i-1 
end 
G.3 Spatial and Temporal Interpolation 
The spatial and temporal interpolation ParaView state machine used for PIV velocity field 
analysis methods in section 4.2.2.2.5.1 was copied and saved for each condition analyzed. 
A screen shot of the state machine in use for the CHOP11B BH patient-specific pulsatility 
condition is shown in Figure 11-8. 
 
Figure 11-8: Interpolate.pvsm screenshot showing the spatial interpolation filter properties 
G.4 Spatial Interpolation Verification 
The spatial interpolation scheme described in section 4.2.2.2.5.2 was verified for accuracy 
using a virtual data set. The virtual data set consisted of computational fluid dynamics 
(CFD) results of an idealized TCPC anatomy. The CFD results included velocity and 
pressure values dispersed on a 3-dimensional mesh. Velocity magnitude was selected as 
the comparison metric. The verification process consisted of sampling the virtual data set 
with 6 slices normal to the z-direction. These slices then underwent the same spatial 
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interpolation scheme described in section 4.2.2.2.5.2, as if they were the experimentally-
collected PIV slices. The true virtual data set and the interpolated virtual data set were then 
sampled at a z-normal plane not equal to any of the 6 z-normal planes used in the 
interpolation. 
 Qualitative comparison of the true and interpolated data sets shows excellent fluid 
flow structure agreement, as seen in Figure 11-9. 
 
Figure 11-9: Qualitative comparison on true and interpolated data for spatial interpolation verification 
G.5 Hepatic Flow Distribution Calculation 
Hepatic flow distribution was calculated in a ParaView state machine employing the PIV 
velocity field analysis methods in section 4.2.2.2.5.1, and was copied and saved for each 
condition analyzed. A screen shot of the state machine in use for the CHOP11B BH patient-
specific pulsatility condition is shown in Figure 11-11. Figure 11-10 shows a quantitative 
comparison of the two data, which was determined by subtracting the velocity magnitude 





Figure 11-10: Quantitative comparison of true and interpolated data toward verification of the spatial 
interpolation scheme used. 
 Summing the velocity magnitude difference between each data set resulted in an 







Figure 11-11: HFD.pvsm screenshot showing the particle tracer filter properties 
G.6 Viscous Dissipation Term Calculation 
The viscous dissipation rate term was calculated in a ParaView state machine employing 
the PIV velocity field analysis methods in section 4.2.2.2.5.1, and was copied and saved 
for each condition analyzed. A screen shot of the state machine in use for the CHOP11B 








APPENDIX H: PIV UNCERTAINTY DETAILS 
PIV measurement uncertainty was quantified following the method outlined by Raffel, et 
al [142]. Error measurements were taken from the steady flow versions of the patient-
specific conditions for each model. The total measurement uncertainty was divided into 3 
error forms: particle lag error, 𝜀𝜀𝑎𝑎, bias error, 𝜀𝜀𝑏𝑏, and random error, 𝜀𝜀𝑟𝑟. These individual 
error were calculated for a 95% confidence interval, and combined into a total error, 𝜀𝜀𝑇𝑇, 
using the same RSS method found in Equation (4-11). All errors were calculated for each 
velocity component (𝑉𝑉𝑚𝑚, 𝑉𝑉𝑦𝑦, and 𝑉𝑉𝑧𝑧), as both a velocity value and a percentage of the 
maximum velocity. 
 Particle lag error considers the tracer particle relaxation time, 𝜏𝜏𝑟𝑟, compared to the 
velocity field characteristic time, 𝜏𝜏𝑒𝑒 . The particle relaxation time is estimated in [142], and 





  (11-1) 
 
where 𝑑𝑑 is the particle diameter and 𝜐𝜐 is the fluid kinematic viscosity. When compared to 
the velocity field characteristic time (calculated from the smallest physical diameter and 
the maximum velocity for each model over all conditions), the 𝜏𝜏𝑒𝑒: 𝜏𝜏𝑟𝑟 ratio is on the order 
of 1𝜕𝜕10−10. Physically, there is this order of time delay between when the fluid changes 
and when the particle is affected by these changes. Thus, the particle lag error is considered 
negligible. Particle lag error is considered equal to 0 for all total error calculations. 
 Bias error was determined by plotting the probability density function of the 
instantaneous velocity data. By binning the velocity distributions in varying size, the 
maximum pixel fraction where peak locking effects may exist was recorded, and equated 
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to the direction-specific bias error. Random error was evaluated as ten percent of the 
particle image diameter (in pixels), again, according to [142]. 
 Table 11-8 and Table 11-9 summarize the PIV error calculations for CHOP11B. 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































APPENDIX I: COMPREHENSIVE RESULTS SUMMARY 
Table 11-12 includes a summary of all experimental conditions and results collected for all 
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